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ABSTRACT
Inflammation is a physiological, innate, normally beneficial response to tissue injury
and infection. If the inflammatory response occurs in an uncontrolled manner or
fails to resolve, pathological consequences may include excessive tissue injury,
chronic inflammation and scarring. Neutrophilic and eosinophilic granulocytes are
key effector cells of the inflammatory response which contain proteases and have the
ability to generate inflammatory mediators. If these potentially histotoxic contents
are released indiscriminately excessive tissue damage may result. Apoptosis in
granulocytes is now thought to represent a key process in the normal control and
resolution of inflammation. It leads to shut-down of granulocyte secretory processes
and removal of the intact senescent cell by macrophages which utilise a novel
phagocytic recognition mechanism that fails to trigger macrophage mediator release.
Few factors present at inflammatory foci have been demonstrated to accelerate
granulocyte apoptosis; most inhibit the process, adding to the longevity of these
cells. The purpose of these studies was to examine the role of different classes of
inflammatory mediators in the induction of granulocyte apoptosis and investigate the
possible mechanisms involved.
We have shown that the majority of pro-inflammatory cytokines inhibit the process
of apoptosis in granulocytes. The anti-inflammatory cytokine IL-10 had no effect on
granulocyte apoptosis, but in neutrophils, it inhibited the survival effects of LPS.
TGF-p, inhibited granulocyte apoptosis but potentiated the pro-apoptotic effects of
TNF-a, at early timepoints in neutrophils. Eicosanoids also exert differential effects
on granulocyte apoptosis, however prostaglandins of the J series proved to be potent
inducers of apoptosis in both cell types. The use of receptor agonists demonstrated
that these pro-apoptotic effects may be mediated via a class of intracellular
peroxisome proliferator activated receptors (PPARs), for which these prostanoids are
ligands.
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Both TGF-(3 and PPARs can inhibit the transcription factor nuclear factor-kappa B
(NF-kB). Further examination of the role of this transcription factor in granulocyte
apoptosis illustrated that it exerts potent survival effects in both neutrophils and
eosinophils, and that inhibition of its activation synergistically enhanced the pro-
apoptotic response of TNF-a in neutrophils, and induced eosinophils to respond to
the pro-apoptotic effects of this cytokine.
The data presented strongly support the hypothesis that NF-kB activation is
necessary for the survival of granulocytes, and that certain physiological mediators,
such as TNF-a, prostaglandins of the J series and the cytokine TGF-P may be
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1.1 The Inflammatory Response
The inflammatory response occurs as a consequence of tissue injury, trauma or
infection, and consists of a series of reactions to limit ongoing tissue damage, isolate
and destroy the infective organism and activate the repair processes needed for
healing and gain of normal function (Baumann & Gauldie, 1994). The body reacts to
inflammatory stimuli by increasing blood flow and capillary permeability in the
affected site to help amplify the migration of cells into the area. The cell types seen
in different inflammatory loci vary according to the stimulus, its persistence and the
type of immune reaction it elicits; for example, neutrophils are common in sites of
acute inflammation, while eosinophils accumulate in allergic reactions. An
inflammatory response can be either beneficial or detrimental to the host. If the
inflammatory stimulus is removed, resolution of the damage allows healing to begin,
but if the stimulus persists or the inflammatory response goes awry, chronic
inflammation may result.
1.2 Neutrophils
Neutrophils develop from the myeloid line and have a limited life span in the
circulation with a half-life of 4 - 6 hours (Bicknell et al., 1994). They have a mean
diameter of 7 pm, a multi-lobed nucleus and a large number of granules. Neutrophils
are peripheral blood cells, and must migrate to inflammatory foci during the acute
immune response. During the first stage, cells respond to chemotaxins and adhere to
endothelial cells. Initial adhesion is dependent on the interaction of neutrophil and
endothelial cell selectins with their ligands. Selectin-mediated adhesion is relatively
weak, allowing neutrophils to roll on the endothelium. Firmer adhesion
(margination) is achieved through the engagement of neutrophil CD11/CD18 P2
integrins with endothelial cell ligands such as intercellular adhesion molecule-1
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(ICAM-1) (Carlos & Harlan, 1994, Springer, 1994). Margination allows a large
number of cells to be available when needed to increase the circulating neutrophil
pool. An important site of neutrophil margination is the lung, because of the large
lung capillary surface area (approximately 60 m2) available for endothelial cell
contact, and because the relative diameter of the lung capillaries (5 pM), means that
deformation of the neutrophil must occur for the cell to pass through the capillary
(Hogg, 1987). Neutrophils accumulate at the site of tissue injury or infection by
responding to chemotaxins released from the inflammatory locus. This involves
diapedisis of neutrophils between the cells of the endothelium and migration along a
chemotactic gradient.
The major role of these cells is the phagocytosis and killing of bacterial and fungal
pathogens, in which granule contents play a part. Human neutrophils contain a large
number of granules which are morphologically, biochemically and functionally
distinct and contain more than 20 enzymes (for a recent review see Borregaard &
Cowland, 1997). The two main types are azurophil and specific granules. Azurophil
granules are peroxidase positive, containing myeloperoxidase, which is involved in
the generation of toxic reactive oxygen species in the phagolysosome. These
granules also contain cationic proteins involved in antimicrobial activity such as
bacterial/permeability-inducing protein (BP1), which is active intracellularly and
defensins which are released extracellularly when neutrophils degranulate. Other
granule constituents with antibacterial activity include cathepsin G, and lysozyme.
Neutrophil specific granules contain glycoproteins, lysozyme, lactoferrin and vitamin
Bj2. However, the physiological functions of many granule constituents are poorly
understood (Borregaard & Cowland, 1997).
Activated neutrophils also have the capacity to release a large variety of other
products at inflammatory sites; these include oxygen radicals and lipid mediators
(Malech & Gallin, 1987). Arachidonic acid (AA) is cleaved from plasma membrane
phospholipids and immediately metabolised to generate one or more biologically
active eicosanoids (Section 1.9) (Samuelsson, 1983). Thromboxanes and
prostaglandins are primarily generated by platelets, while leukotrienes are the
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products of neutrophil arachidonic acid metabolism. Phospholipase A2 can release
arachidonate from the sn-2 position of phospholipids, which can then be
enzymatically converted via acetyltransferase to platelet-activating factor (PAF), an
an important mediator with diverse biological activity (Hanahan, 1986). The
oxidative burst and degranulation in human neutrophils are stimulated by a variety of
agonists. Activation of neutrophils can produce a release of superoxide anions (O2")
and hydrogen peroxide (H2O2) within seconds (Lehrer et al., 1988). Further reduction
of these radicals produces more toxic oxygen radicals such as the hydroxyl radical
( OH), through a reaction involving the reduction of ferrous to ferric iron, and
hypochlorous acid (HOC1), through the catalytic effect of myeloperoxidase (Lehrer
et ah, 1988). Cytokines produced by other inflammatory cells can act synergistically
with agonists to produce a potentiated oxidative burst (referred to as priming).
In the course of eliminating the invading pathogen, neutrophils can directly injure
healthy tissue. In adult respiratory distress syndrome (ARDS), neutrophils may
damage tissue through H2O2 generation (McGuire et ah, 1982). Neutrophil
infiltration, in myocardial infarction in humans and animals (Lucchesi & Mullane,
1986) can exacerbate ischemia-induced myocardial damage, increasing the area of
myocardial necrosis (Simpson et al., 1990). This is also evident in reperfusion-
induced injury of other tissues including the central nervous system and
gastrointestinal tract (Simpson et al., 1990). Neutrophil oxidants are also implicated
in glomerulonephritis (Johnson et al., 1988), while proteases released during
degranulation of neutrophils including elastase, collagenase, and gelatinase, can
cause tissue injury in ARDS, rheumatoid arthritis, cystic fibrosis, and emphysema
(Wong & Travis, 1980, Lee et al., 1981, Janoff, 1985, Bruce et al., 1992).
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1.3 Eosinophils
Eosinophils, like neutrophils, are derived from the myeloid line and are important in
immunological defence against parasites (Butterworth et ah, 1975, Gleich &
Adolphson, 1986). They are predominantly tissue cells and large numbers can be
found in the epithelial lining of the gastrointestinal and respiratory tracts even when
blood eosinophil counts are low, suggesting that eosinophils may have a prolonged
life span in the tissues (Weller, 1991). In the blood, the half-life of human
eosinophils is 18 ± 2.1 h (Steinbach et ah, 1979); healthy non-allergic subjects have
eosinophil counts of less than 0.4 x 109/1 of blood. The cells circulate for an
estimated 3 to 8 h after which they diapedese and migrate into the tissues. The
process of extravasion appears to be random, and bears no relation to the time the
cells have already spent in the circulation (Spry, 1993). Eosinophils, like
neutrophils, marginate and diapedese into tissues similarly through post-capillary
venules where slow blood flow allows adhesion to the endothelium. Eosinophil
adherence is partially mediated through VLA-4 and VCAM-1 (Weller et ah, 1994).
After attachment the cells migrate between endothelial cells into the connective
tissue surrounding the vessels, where they are most prominent in disease (Weller,
1994). Survival time in the tissues is unknown, but eosinophil survival may be
extended in vitro by adding growth factors such as GM-CSF, IL-3 and IL-5 (Spry,
1993).
Eosinophils have a diameter of 8 pm, with a bi-lobed nucleus and characteristic
granules (Sokol et ah, 1987, 1991). The granules of mature eosinophils are ovoid,
cytoplasmic membrane-bound organelles, 0.15 to 1.5 pm in length, which contain
major basic protein (MBP) and eosinophil cationic protein (EPC) (Gleich et ah,
1976, Egesten et ah, 1986, Peters et ah, 1986, Gleich 1990) as well as peroxidase,
aryl sulphatase, and hydrolytic lysosomal enzymes (Bainton & Farquhar, 1970). The
peroxidase of eosinophilic granules differs from the myeloperoxidase of neutrophils
in substrate specificity and sensitivity to a variety of inhibitors (Bolscher et al.,
1991). In addition to the specific granules, mature eosinophils possess some smaller
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granules (0.1 to 0.5 jam) which contain aryl sulphatase and acid phosphatase
(Parmley & Spicer, 1974). Eosinophils also generate oxidative products, hypohalous
acids, lipid mediators (for example, LTC4 and PAF), ribonucleases, cytokines and
chemokines (Spry 1993, Bruijnzeel 1994, Thomas 1995). Several cytokines have
been shown to be transcribed, or released by eosinophils including TGF-a (Wong et
al., 1990), IL-la, (Weller et al„ 1993), IL-3, (Kita et al„ 1991, Fujisawa et al„ 1994),
IL-4 (Moqbel et al., 1995, Nonaka et al., 1995), IL-5 (Broide et al., 1992, Dubucquoi
et al., 1994), IL-6 (Hamid et al., 1992, Melani et al., 1993), IL-8 (Braun et al., 1993,
Kita et al., 1995), GM-CSF (Weller et al., 1993), TNF-a (Costa et al., 1993), TGF-p,
(Wong et al., 1991, Ohno et al., 1992) and RANTES (Lim et al., 1995).
Although these products play a part in host defence, they may also cause damage to
the host (particularly granule proteases) in chronic inflammatory diseases such as
asthma, causing increased airway reactivity, epithelial damage and inflammation of
the airway tissue (Gleich & Adolphson, 1986). MBP is toxic to many mammalian
cells, including human lung epithelium, where it produces pathologic changes similar
to those observed in asthma (Gleich et al., 1979, Motojima et al., 1989, Sedgwick
1995).
Asthma is a bronchial inflammatory disease characterised by a leukocyte mucosal
infdtration which is predominantly eosinophilic (Bousquet et al., 1990, Djukanovic
et al., 1990). The cells are recruited from the circulation following inhalation of
asthmogens such as allergen in sensitised subjects. Cytokines and chemotactic
factors are released by resident cells, such as mast cells and lymphocytes (Barnes,
1989a, b). These mediators increase chemotaxis, the expression of adhesion
molecules on bronchial endothelial cells, and lead to increased expression of their
ligands on eosinophils (Silberstein & David, 1987, Resnick & Weller, 1993). In the
bronchial mucosa, eosinophils are activated and release mediators and cytokines,
amplifying the inflammatory process and increasing bronchial responsiveness to
cause asthma symptoms (Gleich, 1990, Smith 1992). Repeated provocation results
in chronic inflammation in the airways and a marked hyperresponsiveness to
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constrictor mediators which correlates with the numbers of eosinophils present in the
lung (Bousquet et ah, 1990, Bradley et ah, 1991).
Eosinophils can also be involved in a range of pathologies ranging from allergic (for
example, rhinitis) and inflammatory (such as inflammatory bowel disease and
eosinophilic gastroenteritis) to malignant disorders such as Hodgkins's diseases and
certain leukaemias (Seminario & Gleich, 1994). In such conditions, increased levels
of eosinophils are often found in the circulation and tissues.
In inflamed tissues there is a close spatial and temporal association between
eosinophils and recirculating T lymphocytes (Spry, 1971a, b). Increasing evidence
suggests that the late phase reaction, including eosinophilia and IgE production, are
orchestrated by T-lymphocytes, particularly T helper cells of the Th2 subset.
Following specific recognition of an antigen, Th2 cells elaborate cytokines, such as
IL-4, which favour the synthesis of IgE by B-lymphocytes, or IL-5 (Basten &
Beeson, 1970, Sanderson et al., 1985, Campbell et al., 1988), which is an important
differentiation, growth and survival factor for eosinophils (Sanderson, 1992).
Eosinophils have receptors for IgE, which play a central role in anti-parasitic defence
(Capron et al., 1984, Gounni et al., 1994), but which also cause sensitisation to
allergens, the first stage in allergic reactions. Human eosinophil IgE receptors are
increased in atopic conditions such as allergen-induced atopic asthma (Barata et al.,
1997, Sihra et al., 1997, Rajakulasingam et al., 1998, Ying et al., 1998). Activated
Th lymphocytes are present in bronchoalveolar lavage fluid (BAL), bronchial
biopsies and peripheral blood from atopic subjects, their numbers correlating with
that of circulating eosinophils (Azzawi et al., 1990). Cytokines produced by Th
lymphocytes in response to antigen stimulation include IL-3 and GM-CSF, which
support the proliferation of granulocyte and macrophage precursors, and increase
eosinophil longevity (Alam et al., 1994a). Studies have correlated the concentration
of IL-5 in biological fluids with the number of T-cells and eosinophils in BAL and
serum from patients with allergic rhinitis (Sedgwick et al., 1991) and bronchial
asthma (Corrigan et al., 1993).
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1.4 Clearance of Inflammatory Cells
As part of the process of resolution, excess inflammatory cells must be removed.
Neutrophils and eosinophils do not re-enter the circulation after extravasion (Spry,
1993). Since tissue damage does not normally result from resolution, it follows that
these cells must be removed from an inflammatory foci without discharging
inflammatory mediators or intracellular contents, which would cause recruitment of
more cells to the site (Spry 1993). Therefore the fate of ageing granulocytes in the
tissues has been the focus ofmany relatively recent studies.
The inflammatory role of granulocytes is terminated by apoptosis, which is
associated with attenuation of cytotoxic responses and recognition and phagocytosis
by macrophages (Savill et al., 1989a, Savill 1992, Whyte et al., 1993a). This process
limits tissue injury and allows for removal of these cells without the liberation of
their cytotoxic contents. In vitro studies have shown that there is a direct relationship
between the amount of apoptosis in samples of aged neutrophils and their recognition
and phagocytosis by macrophages and that freshly isolated peripheral blood
neutrophils, are not recognised by monocyte-derived macrophages (Savill et al.,
1989a). However, during an inflammatory response in vivo, the process of apoptosis
may be delayed in granulocytes which have been exposed to various inflammatory
mediators (Squier et al., 1995, Chilvers et al., 1998).
The ingestion of apoptotic cells by macrophages causes no significant increase in
granule enzyme release or the secretion of thromboxane B2, an important
inflammatory mediator (Meagher et al., 1992). Therefore this mode of clearance may
be crucial in resolving the inflammatory process (Haslett et al., 1989), and has been
proposed as an important mechanism for the removal of granulocytes from sites of
inflammation (Savill et al., 1989a, 1990a, Haslett et al., 1994). This is supported by
in vivo studies demonstrating the removal of apoptotic neutrophils in endotoxin-
induced experimental lung injury (Cox et al., 1995), the neonatal respiratory distress
syndrome (Grigg et al., 1991) and experimental glomerulonephritis (Savill et al.,
1992a).
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Why ingestion of apoptotic cells, in contrast to that of bacteria or opsonised particles,
does not produce activation of phagocytic cells is currently unknown. Several
mechanisms appear to play a role in recognition. For example, the vitronectin
receptor avP3 integrin (Savill et al., 1990b), CD36 (Savill et al., 1992b), the class A
scavenger receptor (Piatt et al., 1996) the ATP-binding cassette transporter ABC-1
(Luciani & Chimini, 1996), the phosphatidyl serine receptor (Fadok et al., 1992), and
the CD 14 receptor (Devitt et al., 1998) have all been demonstrated to be involved in
this process. Interestingly, CD14 is the receptor, which also binds LPS to trigger
inflammatory responses; it is not clear why one ligand (LPS) should cause activation
and another (an apoptotic cell), should not.
1.5 Apoptosis
Cell death occurs in two different forms (Wyllie & Morris 1982). Necrosis refers to
processes occurring when cells die from severe injury such as physical or chemical
trauma and apoptosis or programmed cell death (PCD) which is a physiological
process. In necrosis there are early changes in mitochondrial shape and function, and
the cell rapidly becomes unable to maintain homeostasis. If the plasma membrane is
damaged, the cell loses its ability to regulate osmotic pressure and the cell swells and
ruptures. Intracellular contents spill into the surrounding tissue space and provoke an
inflammatory response (Cohen 1993).
Apoptosis refers to a series of morphological changes that differ from those seen in
necrosis. They occur in response to physiological stimuli such as growth factor
withdrawal and are similar in all cell types (Wyllie & Morris 1982). The plasma
membrane becomes ruffled and blebbed, the cell shrinks through fluid loss, but the
organelles appear normal, apart from the nucleus in which chromatin condenses.
This is accompanied by the fragmentation of DNA first into large (50 to 300 kb) and
subsequently into small oligonucleosomal fragments (Wyllie et al., 1980, Arends et
al., 1990, Roy et al., 1992). The cell membrane does not become permeable to vital
dyes at this stage. The cell may ultimately break up into apoptotic bodies, which are
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sealed and maintain their osmotic gradients, avoiding the release of intracellular
contents (Arends & Wyllie 1991, Cohen 1993). Granulocytes do not normally form
apoptotic bodies, but remain as an intact apoptotic cell until ingested by macrophages
(Savill et al., 1989a, Rossi & Haslett, 1997)
Apoptosis occurs in different cell types in response to different stimuli (Wyllie et al.,
1981). During cell culture, eosinophils and neutrophils undergo spontaneous
apoptosis in contrast to thymocytes that require treatment with UV radiation or
glucocorticoids (Wyllie & Morris 1982). This process can be detected by various
methods, such as nuclear changes (chromatin condensation or DNA laddering),
changes in dye binding to nuclear material (acridine orange or PI staining) (Nicoletti
et al., 1991), or by measuring surface changes, for example, using 3G8 antibody to
measure CD16 shedding (Dransfield et al., 1994), or Annexin V binding to exposed
phosphatidyl serine as the cells become apoptotic (Homburg et al., 1994).
1.6 Control ofApoptosis
The study of apoptosis and its control is complicated by the fact that diverse stimuli
are responsible for inducing PCD in different cell types. A stimulus that produces
apoptosis in a specific cell type may have differing or negligible effects on other
cells. For example, glucocorticoids will inhibit apoptosis in neutrophils but induce
apoptosis in thymocytes and eosinophils (Wyllie & Morris 1982, Cox 1995, Meagher
et al., 1996). In vivo, cells will interact with other cell types, cell products such as
cytokines, and with environmental factors which will influence signalling systems
and ultimately affect the fate of a given cell. However, because granulocytes are
known to undergo apoptosis in situ at an inflammatory focus to allow inflammation
to resolve, it is possible that inflammatory mediators, such as eicosanoids or
cytokines can induce programmed cell death in these cells. However, little is known
of the physiological processes that drive apoptosis enabling the process of resolution
to begin. Most of the inflammatory mediators which have been investigated prolong
the longevity of inflammatory cells (Colotta et al., 1992, Lee et al., 1993, Alam et al.,
1994a).
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Early studies indicated that the transcription and translation of specific genes were
required to induce apoptosis. This was based on the effects of cycloheximide and
actinomycin D in preventing thymocyte apoptosis triggered by irradiation,
glucocorticoid hormones and calcium ionophore (Cohen and Duke, 1984, Wyllie et
al, 1984, Kizaki et al, 1989). However, the protein synthesis inhibitor cycloheximide,
can either block the induction of apoptosis, promote it, or have no effect, depending
on the cell type studied (Cohen et al, 1992). When protein synthesis inhibitors
trigger apoptosis, it is possible that programmed cell death is held in check by
survival proteins that are not produced when protein synthesis is blocked. This would
also suggest that apoptotic effector molecules are constitutively present in most
mammalian cells (Raff et al., 1993). Cells without a nucleus can undergo the
characteristic cytoplasmic changes of apoptosis, while in contrast, isolated nuclei can
exhibit chromatin condensation and DNA fragmentation in a cell-free system
(Lazebnik et al., 1993, Newmeyer et al., 1994), implying that different cellular
compartments have considerable autonomy in undergoing structural changes during
apoptosis.
To try to understand the physiological factors that control apoptosis and resolution in
vivo, we examined different classes of mediators involved in the inflammatory
response and their effects on the constitutive rates of apoptosis in both neutrophils
and eosinophils. These included glucocorticoids, which have an anti-inflammatory
action, chemokines, various classes of eicosanoids (leukotrienes, 5-oxo-ETE and
prostaglandins) and pro- and anti-inflammatory cytokines.
1.7 Glucocorticoids
Glucocorticoids are steroid hormones with anti-inflammatory capabilities.
Clinically, treatment of hypereosinophilia in a range of diseases is by administration
of glucocorticoids, yet the mechanism(s) by which they exert their effects in vivo are
poorly understood (Barnes 1989b, 1990, Barnes & Adcock, 1993, Goulding &
Guyre, 1993). Glucocorticoids reduce both the numbers of eosinophils and the
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number of hypodense (activated) eosinophils in the circulation of asthmatics
(Baigelman et al., 1983, O'Connor et al., 1991), and reduce the secretion of IL-3, IL-
5 and GM-CSF from CD4 T cells (Corrigan et al., 1995). They bind directly to
cytosolic glucocorticoid receptors (GRs), which, when activated, exhibit DNA-
binding ability and interact with a wide range of nuclear targets. GRs are present
within the cell both in the cytoplasm and nucleus and undergo a conformational
change after ligand-binding to yield an active form of the receptor (Beato, 1989).
The activated receptor can recognise and bind to specific DNA sequences and bring
about activation or repression of transcription initiation of a nearby target gene.
Therefore glucocorticoids can both increase or decrease the expression of specific
proteins (Maroder et al., 1993).
1.8 Chemokines
Cell extravasion involves selectins, integrins and chemokines (chemoattractant
cytokines) and their receptors (Schall & Bacon, 1994, Ben-Baruch et al., 1995).
Chemokines are a family of secreted 8-10 kDa proteins (Baggiolini et al., 1994),
which induce cell migration and activation (Murphy 1994). They are usually divided
into three subgroups: C, C-X-C (where X is any amino acid) and C-C, according to
variation in a shared cysteine motif (Schall & Bacon, 1994). Most C-X-C
chemokines are chemoattractants for neutrophils, whereas C-C chemokines usually
act on eosinophils (Miller & Krangel, 1992, Schall & Bacon, 1994, Premack &
Schall, 1996). For example, IL-8, a member of the C-X-C family of chemokines
(Murphy et al., 1994), is a neutrophil chemoattractant which is produced by
monocytes, alveolar macrophages, endothelial cells, fibroblasts and epithelial cells
after stimulation with IL-1, TNF-a or LPS (Baggiolini et al., 1989, Oppenheim et al.,
1989).
Eotaxin is a specific C-C eosinophil chemokine secreted by eosinophils (Griffiths-
Johnson et al, 1993, Ponath et al, 1996), which has no activity on mononuclear cells
or neutrophils (Lim et al., 1995, Garcia-Zepeda et al., 1996). This chemokine was
isolated from an animal model of asthma with increased expression in the lungs
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within three hours of antigen challenge (Jose et al., 1994a, b, Rothenberg et ah,
1994). Eotaxin may be constitutively produced (Bartels et al., 1996), but it is
markedly upregulated in some human inflammatory diseases. The pro-inflammatory
cytokines TNF-a, and IL-1 a induce eotaxin mRNA expression in endothelial and
epithelial cells (Garcia-Zepeda et al., 1996). It is also produced by fibroblasts
(Bartels et al., 1996), macrophages, ciliated and non-ciliated bronchial epithelial cells
(Ponath et al., 1996, Li et al., 1997), and chondrocytes (Li et al., 1997).
RANTES (Regulated and Normal T-cell Expressed and Secreted) is another C-C
chemokine which acts on eosinophils both in vitro and in vivo (Kameyoshi et al.,
1992, Rot et al, 1992, Meurer et al., 1993, Ebisawa et al., 1994, Schroder et al, 1994).
This chemokine induces mild activation of eosinophils in vitro (as measured by
eosinophil cationic protein release, superoxide anion production, and induction of
hypodensity) (Kameyoshi et al., 1992, Rot et 1992, Alam et al., 1993, al., Schweizer
et al., 1994). Bronchial epithelial cells produce RANTES in vitro (Stellato et al.,
1995), and expression of this chemokine is enhanced in the bronchial epithelium,
alveolar macrophages and smooth muscle cells of asthmatic patients (Alam et al.,
1994b). In bronchial epithelial cells chemokine production can be modulated by
glucocorticoids (Stellato et al., 1995).
Some chemokines can bind to more than one receptor subtype. For example,
RANTES can bind to CCR1, CCR3, CCR4 and CCR5, while eotaxin binds to CCR3
(Premack & Schall, 1996). The MIP-la/RANTES receptor can bind several of the C-
C chemokines (Neote et al, 1993). This means that chemokines may have differential
effects on cells depending on the type and number of receptor or concentration of
chemokine present. For example, RANTES stimulates chemotaxis at low
concentrations in T cells, but at higher concentrations it produces a spectrum of
responses, including cytokine production and proliferation, which are normally
associated with T-cell activation (Bacon et al., 1995). Chemokine receptors are
functionally linked to phospholipases via heterotrimeric G proteins, with downstream
generation of inositol triphosphate, resulting in intracellular calcium release, calcium
channel opening and protein kinase C activation (Murphy, 1994, Bokoch 1995).
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Various chemokines have been shown to influence inflammatory cell activation.
However few studies have considered the effects of classical chemokines on cell
survival. Therefore, we examined whether such mediators could inhibit or increase
the constitutive rate of neutrophil and eosinophil apoptosis.
1.9 Eicosanoids
Eicosanoids are a group of substances formed from the C20 polyunsaturated fatty
acid, arachidonic acid (5,8,11,14-eicosatetraenoic acid) (AA). AA is liberated from
membrane phopholipids through activation of phospholipases (Scott et al., 1980).
There are two main pathways of arachidonate metabolism, the linear pathway which
leads to the formation of leukotrienes and hydroperoxyeicosantetraenoic acids
(HPETEs) and the cyclic pathway which leads to the formation of prostaglandins,
prostacyclins and thromboxanes (Scott et al., 1980). Such metabolites are important
modulators of inflammatory responses (Davis et al., 1984). The specific products
produced by this pathway depend on the tissue involved. The formation of
metabolites ofA A is shown in Figure 1.1.
1.9.1 The 5-lipoxygenase Products
One major pathway for AA metabolism in human neutrophils is initiated by the
action of 5-lipoxygenase, which is possibly regulated by 5-lipoxygenase activating
protein (FLAP) (Borgeat et al., 1976, Borgeat & Samuelsson 1979a, Ford-
Hutchinson, 1994). The initial product of this reaction is 5-hydroperoxy-6,8,11,14-
eicosatetraenoic acid which is either converted to LTA4 (Borgeat & Samuelsson
1979b) by the same enzyme (Rouzer et al., 1986) or reduced to the hydroxy
compound, 5-hydroxy-6, 8,11,14-eicosatetraenoic acid (5-HETE), by a peroxidase
(Borgeat et al., 1976). 5-HETE can also be oxidified by a highly specific microsomal
dehydrogenase in neutrophils to 5-oxo-6, 8,11,14-eicosatetraenoic acid (5-oxo-ETE)
(Powell et al., 1992), which can also be produced by eosinophils (Powell et al, 1995);
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this eicosanoid is a potent stimulator of both cell types (O'Flaherty et ah, 1993,
Powell et ah, 1993, 1995, Schwenk & Schroder, 1995). 5-oxo-ETE is up to 100-fold
more active than 5-HETE in causing PMN calcium transients and chemotaxis and in
promoting the degranulation responses of PMN challenged with PAF or TNF-
(O'Flaherty et ah, 1993, Powell et ah, 1993).
LTA4 is quite unstable and is rapidly converted by LTA4 hydrolase to the
proinflammatory compound LTB4; a potent activator of neutrophils causing
chemotaxis, homotypic and heterotypic adhesion, diapedisis, and reactive oxygen
generation (Ford-Ehitchinson et ah, 1980, Samuelsson et ah, 1987, Chatila et al.,
1989, Borgeat & Naccache, 1990, Lewis et al., 1990, O'Flaherty et al., 1991, 1994,
Elenderson, 1994). LTB4 is known to inhibit neutrophil apoptosis (Hebert et al,
1996). However, eosinophils are relatively unresponsive to LTB4 (Richards et al,
1991, Powell etal, 1995).
1.9.2 Prostaglandins
Prostaglandins are a group of C20 carboxylic acids containing a cyclopentane ring.
They have wide-ranging effects in the body and are important mediators of
inflammation. As shown in Figure 1.1 cyclooxygenase (COX) plays a key role in
prostaglandin synthesis. This enzyme occurs in both constitutive (COX-1) and
inducible (COX-2) isoforms (Kujubu et al., 1991, Xie et al., 1991). COX-1 is
postulated to provide cytoprotective effects (Mitchell et al., 1993), whereas COX-2 is
the major isoform in inflammatory cells (DeWitt & Meade, 1993). The main
mechanism of action of most non-steroidal anti-inflammatory drugs such as aspirin
(acetylsalicylic acid), is the inhibition of cyclooxygenases also known as
prostaglandin H2 synthases (PGHS) (Vane & Botting, 1987, Loll et al., 1995).
Cyclooxygenase oxygenates arachidonate converting it to PGG2; PGG2 is then
released from the cyclooxygenase active site and travels to the peroxidase site of the
enzyme where PGG2 is reduced to PGH2 (Eling et al., 1991). PGH2 is converted via
distinct synthases to PGD2, PGE2, PGF2a, PGI2 or thromboxane A2 (Pierce et al.,
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1995, Smith & DeWitt, 1996). PGD2 can be further metabolised to form 9-deoxy A9-
PGD2 (PGJ2) (Fukushima et al., 1982a), A12-PGJ2 (Kikawa et al., 1984) and 15-
deoxy-A12,A14"PGJ2. PGE2 can be also be metabolised to form PGA2 (Ohno et al.,
1986). Prostaglandins formed in the endoplasmic reticulum through the action of
COX-1 exit cells and function through cell surface receptors. COX-2 is normally
absent from cells but is expressed transiently in response to growth factors and
cytokines such as IL-1 and TNF-a (Lee et al., 1992, O'Sullivan et al., 1992, Riese, et
al., 1994). COX-2 expression can be inhibited by anti-inflammatory glucocorticoids
such as dexamethasone (Lee et al., 1992, O'Bannion et al., 1992, Herschman 1996).
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1.9.3 Prostanoid Receptors
The classification of prostanoid receptor subtypes was based upon the activities of
natural and synthetic agonists (Kennedy et al., 1982, Coleman et ah, 1984). This
classification has been verified by cloning data and the use of specific receptor
antagonists (Hirata et al., 1991, Abramovitz et al., 1994, Boie et al., 1994, Coleman
et al., 1994, Katsuyama et al., 1994, Lake et al., 1994, Nakagawa et al., 1994, Pierce
et al., 1995a). The receptors have been categorised into 5 groups, DP, EP, IP, FP and
TP, based on the binding characteristics of the five main prostanoids, PGD2, PGE2,
PGI2, PGF2 and thromboxane A2 respectively (Coleman et al., 1994). Four subtypes
of EP receptors, EPj - 4 have also been cloned (An et al., 1993, Funk et al., 1993,
Adam et al., 1994, Bastien et al., 1994, Regan et al., 1994a, b).
DP receptors are expressed on eosinophils (Butchers & Vardey, 1990), but there is
no evidence for the presence of IP, FP or TP receptors on these cells (Giembycz et
al., 1990). There are both EP2 and DP receptors on human neutrophils (Rossi &
O'Flaherty, 1989, Ney & Schror, 1991, Wheeldon & Varday, 1993, Darius et al.,
1994). Activation of the TP receptor in immature thymocytes has been shown to
induce apoptosis (Ushikubi et al., 1993). Occupation of EP2, or DP prostanoid
receptors inhibits certain neutrophil functions, including the respiratory burst,
homotypic aggregation and secretion (Rossi & O'Flaherty, 1989, Wheeldon &
Vardey, 1993, Wise & Jones, 1994, Talpain et al., 1995). These receptors appear to
inhibit neutrophil function via elevation of cAMP (Coleman et al., 1994). Activation
2~Pof other receptor types has been shown to affect Ca levels (Table 1.1).
2+
Interestingly, increases in Ca and cAMP have been demonstrated to modulate the
rate of constitutive apoptosis in neutrophils and eosinophils (Rossi et al., 1995,
Cousin et al., 1997). The receptor types, ligands and effects on the two main cellular
signalling pathways, cAMP and calcium are shown in Table 1.1.
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Receptor Ligands Effect on cAMP and Cai+
DP pgd2, pgj2 T cAMP (1,2) T Ca2+ (14)
EP, PGE2,PGEi, PGF2a, PGD2 T Cai+(3, 4, 5, 6) cAMP no effect (5)
ep2 pge2 T cAMP (7)
ep3 PGE, 4- cAMP (8) T Cai+ (8)
ep4 PGE2,PGEi tcAMP (12,13)
FP PGF2a, PGD2, PGE2 TCa'+ (9, 10)
ip PGI2, PGEi, PGE2, PGD2,
pgf2cc
tcAMP (11)
tp txa2, pgd2, pgf2 T Ca2+(10)
TABLE 1.1 Cell Surface Prostaglandin Receptors, Ligands and Intracellular
Effects
Table based on Coleman et al., 1994 and references as follows - 1. Ito et al., 1990, 2.
Bundy et al., 1983, 3. Creese & Denborough, 1981, 4. Coleman & Kennedy, 1985, 5.
Watabe et al., 1993, 6. Funk et al., 1993, 7. Jumblatt & Peterson, 1991, 8. Reeves et
al., 1988, 9. Behrman et al., 1985, 10. Nakano et al., 1993, 11. Ito et al., 1992, 12.
Nishigaki et al., 1998, 13. Kiriyama et al., 1997, 14. Raible et al., 1992.
As shown in Table 1.1 prostaglandin receptors are promiscuous and the effects of
prostaglandins on inflammatory cells could be mediated through several receptor
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types. The prostaglandin metabolites PGA2, A -pgj2, and 15dPGJ2 have been
shown to bind to intracellular, rather than cell surface receptors (Narumiya et al.,
1987). One such receptor family demonstrated to bind some of these metabolites is
the peroxisome proliferator-activated receptors (PPARs). PPARs are transducer
proteins belonging to the steroid/thyroid/retinoid receptor superfamily (Lemberger et
al, 1996). These are nuclear hormone receptors that regulate gene transcription in
response to peroxisome proliferators and fatty acids and are predominantly expressed
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in adipose tissue, adrenal gland and spleen (Kliewer et al., 1994, Tontonoz et al.,
1994, Lemberger et al., 1996). There are multiple subtypes of PPAR called a, 5 or y
in mammals and these subtypes are differentially activated by various agents (Dreyer
et al., 1992, Schmidt et al., 1992, Chen et al., 1993, Zhu et al., 1993, Kliewer et al.,
1994). PPAR-y is expressed in the immune system, by human monocytes, several
myeloid cell lines and bone-marrow precursors (Greene et al., 1995).
There has been much research on the influence of eicosanoids on the activation and
functional behaviour of inflammatory cells. Because pro-inflammatory cytokines
such as TNF-a can upregulate COX-2 activity, increased expression of eicosanoids
would be expected at an inflammatory site. However, the effects of only a few of
these mediators on granulocyte apoptosis have been examined formerly, and
therefore, several eicosanoids were chosen for study in this work.
1.10 Cytokines
Cytokines are involved in co-ordinating the immune system, where they control the
amplitude and duration of the response by regulating the growth, differentiation and
functional activities of immune and inflammatory cells (Karnitz & Abraham 1995).
They generally act in an autocrine or paracrine manner by binding to high affinity
cell receptors on target cells, which may be specific for each cytokine or cytokines of
a related group (Balkwill 1989).
Cytokines often regulate cell growth and some exhibit growth inhibitory or cytotoxic
actions. They have multiple, overlapping and sometimes contradictory functions
depending on local concentration, cell type and other environmental influences to
which the cell is exposed. Cytokines form part of a complex network where
production of one cytokine influences the production of, or the response to other
cytokines. For example, IL-3 or IL-5 stimulates eosinophils to express GM-CSF
(Moqbel et al., 1991). Cytokine-binding and culture conditions may change the
pattern of cellular behaviour by altering DNA, RNA and protein synthesis in cells
(Baumann & Gauldie 1994); for instance, freshly isolated eosinophils constitutively
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express mRNAs for IL-4, TGF-(51 and RANTES; in culture, the cells also produce
mRNA for IL-8 and GM-CSF. If cultured with IL-5 the cells produce IL-10, but
culture with TNF-a causes the production of IL-3 and TNF-a (Nakajima et al. 1996).
The effect of many pro-inflammatory cytokines on granulocyte apoptosis has been
examined. However, in an in vivo situation, cells in an inflammatory foci will be
affected by a plethora of cytokines, both pro- and anti-inflammatory, as well as
chemokines and eicosanoids. Cytokines may have antagonistic or synergistic actions
depending on the presence of other factors. Therefore this thesis examines the
effects of pro- and anti-inflammatory cytokines and their interactions with other
factors likely to be present during an inflammatory response, on granulocyte
apoptosis.
1.10.1 Pro-inflammatory Cytokines
Pro-inflammatory cytokines are those which activate or prime immune effector cells
which are associated with inflammatory conditions. Many cytokines can be
considered as pro-inflammatory although this definition is loosely defined since
cytokine action will depend on concentration and cell type studied. We elected to
study two main cytokines, granulocyte-macrophage colony-stimulating factor (GM-
CSF) and tumour necrosis factor-a (TNF-a). GM-CSF was chosen for study because
of the prior demonstration of its actions in inhibiting apoptosis in neutrophils and
eosinophils (Lee et al., 1993, Alam et al., 1994a). TNF-a has been demonstrated to
have both pro-and anti-apoptotic effects on neutrophils (Murray et al., 1997), but its
effect on eosinophil apoptosis is unknown.
1.10.2 Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)
Human GM-CSF is a 22 kDa glycoprotein named for its ability to stimulate bone
marrow progenitors to proliferate and differentiate into granulocytes and
macrophages (Clark & Kamen, 1987). Recombinant human GM-CSF affects the
activity of both neutrophils and eosinophils, for example increasing both antibody-
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dependent cytotoxicity and phagocytosis. It is known to activate the neutrophil
respiratory burst and enhance the action of other activators such as phorbol-myristate
acetate (Dispersio et ah, 1986). Recombinant GM-CSF is chemotactic for
neutrophils, but does not promote adhesion to endothelial cells. There is a single
class of high affinity receptors expressed at low levels on human neutrophils (200 -
800 per cell) (Dipersio et ah, 1988). GM-CSF signalling shares some signalling
components with IL-3 and IL-5, which also inhibit apoptosis in neutrophils and/or
eosinophils. The receptors for these three cytokines consist of 2 subunits: an a
subunit that is specific to each cytokine, but the (3 subunit is identical (Dower, 1993).
Dimerisation/oligomerisation of the p subunit is essential for signal transduction.
Although none of these receptor subunits has intrinsic kinase activity, these
cytokines induce tyrosine phosphorylation (Yousefi et ah, 1994), activation of Ras,
Raf-1 and mitogen activated protein (MAP) kinase and transcriptionally activate
nuclear protooncogenes such as c-myc, c-fos and c-jun (Dower, 1993) (Section
1.14.2). The P subunit is also associated with a novel family of receptor-coupled
protein tyrosine kinases, termed JAK kinases (Janus kinases or the 'just another
kinase' family) and a set of downstream signalling pathways which appear to be
highly conserved (Briscoe et ah, 1994, Karnitz & Abraham 1995). When JAKs are
phosphorylated on tyrosine residues their enzymatic activity increases (Briscoe et al.,
1994). Signal transduction is thought to be dependent on association of the
receptor's cytoplasmic domains with specific JAKs, although this interaction is not
fully understood (Ihle, et al., 1994, Karnitz & Abraham 1995). For example, the
JAK2 kinase constitutively associates with the IL-3/IL-5/GM-CSF receptor P subunit
in eosinophils and is activated after stimulation with these cytokines (Quelle et al.,
1994).
JAK phosphorylation causes activation of a family of transcription factors termed
STATs (signal transducers and activators of transcription) which are present as latent
monomers in unstimulated cells, but can be activated by phosphorylation of a
conserved tyrosine (Briscoe et al., 1994, Ihle et al., 1994, Karnitz & Abraham 1995).
This causes the formation of STAT protein dimers that translocate to the nucleus
where they function as sequence-specific activators of gene transcription. The array
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of STAT factors, which are phosphorylated and activated by each cytokine, is
determined by the availability of various STAT proteins in the target cell, and by the
affinities of these proteins for the stimulated receptor-JAK complex (Karnitz &
Abraham 1995). For example, IL-5 induces STAT1 activation in eosinophils
(Pazdrak et al., 1995). Other signal transduction pathways that are activated in the
cell will also influence the expression of genes that are induced (Pawson 1995).
1.10.3 Tumour Necrosis Factor-a (TNF-a)
TNF-a plays a central role in immunity and inflammation and regulates the functions
ofmany cell types. It was first named and isolated in 1975 (Carswell et al., 1975) and
cloned in 1984 (Gray et al., 1984) and is a primary mediator of endotoxin-induced
septic shock, cachexia, and inflammation (Beutler & Cerami 1988, 1989). TNF-a is
expressed on a wide range of cells as a 26 kDa integral transmembrane precursor
protein from which a 17 kDa homotrimeric soluble form is released after proteolytic
cleavage (Kriegler et al., 1988). This cell surface form can kill target cells by cell-
cell contact and induce apoptosis (Perez et al., 1990, Monastra et al., 1996). Mature
TNF-a in solution is a compact trimer of 52 kDa (Wingfield et al., 1987), which is
composed of the secreted 17 kDa protein and the 26 kDa pre-peptide which
spontaneously trimerise to form the mature protein (Smith & Baglioni, 1987).
The mammalian TNFR gene family consists of at least 12 different members that
interact with a corresponding TNF-related ligand family (Smith et al., 1994).
TNF/NGF receptor family consists of TNFR1, TNFR2, TNFRIII, Fas, CD40, CD30,
CD27, p75 NGF, OX-40, 4-1BB and DR3. Most are type I transmembrane proteins
with a characteristic cysteine-rich pseudorepeat in the extracellular region. This
family is involved in a wide range of biological effects including acute phase
responses, cell growth and apoptosis and lymphocyte activation (Smith et al., 1994).
Ligand-dependent activation of the TNFR superfamily depends on receptor
trimerisation (Banner et al., 1993, Bigda et al., 1994); each trimeric complex contains
three receptors bound to one ligand trimer.
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TNF-a interacts with cells through two types of receptor; the p55 receptor (TNFR1)
and the p75 receptor (TNFR2) (Hohmann et ah, 1989, Brockhaus et ah, 1990,
Loetscher et ah, 1990, Schall et ah, 1990). It binds to both receptors with high
affinity and independently. The membrane-bound form of TNF is biologically active
on both receptor subtypes (Perez et ah, 1990, Decoster et ah, 1995). TNFRs occur
on almost all nucleated cell types except unstimulated lymphocytes (Vandenabeele et
ah, 1995). The number of receptors varies from about 200 to 10,000 per cell, but
there is no correlation between the number of receptors and the magnitude of
response (Fiers et ah, 1987, Brockhaus et ah, 1990). After binding the ligand-
receptor complexes are internalised by clathrin-coated pits (Brockhaus et ah, 1990,
Porteu & Hieblot, 1994); the internalised receptor is subsequently degraded in
lysosomes (Mosselmans et ah, 1988). Unlike TNFR1, TNFR2 contains no tyrosine
residues in its intracellular domain and therefore, lacks a consensus sequence for
rapid cellular internalisation through coated pits (Collawn et ah, 1990).
Soluble TNF-binding proteins have been discovered (Seckinger et ah, 1988,
Engelmann et ah, 1989, Gatanaga et ah, 1990). These are truncated forms of the
extracellular domain of TNFR1 and TNFR2 and appear to arise by proteolytic
cleavage from surface-bound TNF receptors (Englemann et ah, 1990, Lantz et ah,
1990). A major source of these binding proteins may be neutrophils, which
reportedly shed 50 % of TNF receptors within two minutes in response to many
physiological and pharmacological agents (Porteu & Nathan, 1990). These soluble
proteins modulate the availability of biologically active TNF.
The cytoplasmic domains of the TNFR superfamily members are relatively short and
contain no known catalytic motif. They also lack significant sequence homology
among themselves except for a domain of approximately 80 amino acids long
referred to as the death domain (DD), which is involved in TNF-mediated cell killing
and is found in both TNFRI and Fas (Itoh & Nagata, 1993, Tartaglia et ah, 1993).
The use of yeast-two hybrid screens led to identification of the receptor associated
molecules, TRADD, FADD/MORT1, TRAF2, 1-TRAF, RIP, FAN, TRAP1, 55.11,
FLICE/MACH, and sentrin which associate with TNFRI and TRAF1, TRAF2, c-
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IAP-1, and c-IAP-2, which associate with TNFR2 (Figure 1.2- Section 1.12) (Darnay
& Aggarwal, 1997).
Many TNF signals are mediated via TNFR1, but signalling through TNFR2 is
controversial. For example, TNFR2 lacks a death domain, but it is implicated in
TNF-dependent cell killing (Heller et al., 1992, Higuchi & Aggarwal, 1993, Murray
et al., 1997). The development of TNF muteins which allow binding to either
TNFR1 or TNFR2, were used to determine the specific effects of each receptor
(Loetscher et al., 1993, Van Ostade et al., 1993, Barbara et al., 1994). These muteins
demonstrated that both NF-kB activation and cytotoxicity is mediated through
TNFR1 in some cells (Chainy et al., 1996). Other reports show activation ofNF-kB
and apoptosis mediated via TNFR2 (Tartaglia et al., 1993, Laegreid et al., 1994,
Rothe et al., 1994, Zheng et al., 1995). In other cells each receptor is able to induce
cytotoxicity and apoptosis on its own, and additive effects are observed when both
receptors are triggered together (Grell et al., 1993). The analysis of TNF actions on
various tumour cell lines revealed that TNF-induced cytotoxicity occurred in cells
expressing TNFR1 regardless of expression of TNFR2, while apoptosis was induced
by TNF in cells which expressed both receptors (Higuchi & Aggarwal, 1994). A
TNFR2-associated kinase that phosphorylates both receptors has been found, and
may provide a link between signals from both receptors (Darnay et al., 1994). Cell
death induction by both TNF and Fas receptors involves a critical function of
protease(s) related to ICE (Enari et al., 1995, Los et al., 1995, Tewari & Dixit, 1995)
(Section 1.14.1), and both can be suppressed in a cell-type manner by Bcl-2 (Hennet
et al., 1993, Itoh et al., 1993).
1.10.4 Anti-inflammatory Cytokines
Although many cytokines have been shown to be involved in cell activation, few
have been demonstrated to downregulate the production of pro-inflammatory
cytokines or inflammatory mediators from immune cells. Of these few, we chose
interleukin 10 (IL-10) and transforming growth factor-p (TGF-P) for study.
Disruption of IL-10 or TGF-P expression in mice is correlated with a non-resolving
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inflammatory state (Schull et al., 1992, Khun et al, 1993,) which suggests that these
cytokines may play a role in inflammatory resolution.
1.10.5 Interleukin 10 (IL-10)
Human IL-10, a member of the four a-helix family of cytokines (Vieira et al., 1991),
is an 18.5 kDa protein of 160 amino acids, containing two intramolecular disulphide
bonds (Moore et al, 1993, Windsor et al, 1993). It is acid labile and appears in
soluble form as a homodimer of 39 kDa (de Waal Malefyt, 1992). The gene
encoding IL-10 is located on chromosome 1 in both mouse and man and includes
possible binding sites for the transcription factors NF-kB and AP-1 (Kim et al.,
1992). IL-10 is produced by subsets of T cells as well as by monocytes,
macrophages and B cells (Fiorentino et al., 1989, Moore et al., 1990, de Waal
Malefyt et al., 1991, Vieira et al., 1991).
The IL-10 receptor is a transmembrane glycoprotein approximately 111 kDa in size
which closely resembles that for INF-y (Ho et al., 1993, Lui et al., 1994). The
receptor is a member of the type II cytokine receptor family (Bazan, 1990), and is
expressed in low numbers on responsive cells, however, cytokine-receptor binding is
of high affinity with a Kj of 200 pM (Ho et al., 1993, Lui et al., 1994).
IL-10 was first discovered as a novel factor produced by murine Th2 helper cells
which inhibits INF-y synthesis by murine Thl cells (Fiorentino et ah, 1989, 1991).
Mouse Th clones can be divided into two types based on the pattern of cytokines
secreted in response to antigen or lectin stimulation. Thl clones secrete IL-2, INF-y
and lymphotoxin, whereas Th2 express IL-4, IL-5, IL-6 and IL-10 (Fiorentino et al.,
1989). Both types of clone secrete IL-3, GM-CSF and TNF-a. Human IL-10 is also
produced by Th cell clones: however production is not restricted to Th2 cells, since
most ThO and Thl clones are also able to produce considerable levels of IL-10 (de
Waal Malefyt et al., 1992).
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Because macrophages and T cells both produce and respond to IL-10, it has been
proposed that IL-10 may provide a mechanism whereby these cells limit their own
participation and that of other immune-reactive cells in antigen-driven reactions (de
Waal Malefyt et ah, 1991, Rennick et ah, 1995). IL-10 is expressed later than other
cytokines released by activation of T cells and macrophages, which may reflect its
role in inhibiting the activation of these cells (de Waal Malefyt et ah, 1991,
Florentino et ah, 1991). Human monocytes activated by LPS produce high levels of
IL-10, but production is relatively late when compared with other cytokines with
maximal production at 24 - 28 h, while early cytokines such as TNF-a and GM-CSF
are produced by 4 h (de Waal Malefyt et al., 1991).
In humans, IL-10 inhibits IL-5 synthesis by resting CD4+ T cells and by
differentiated ThO or Th2 clones (Del Prete et al., 1993, Schandene et al., 1994). In
the context of allergic inflammation, inhibition of IL-5 generation may limit
eosinophil recruitment (Section 1.3). Mast cells can regulate a variety of eosinophil
functions via the production of cytokines that can be down regulated by IL-10
(Arock et al., 1996).
The inhibitory action of IL-10 on most cell-mediated immune responses in vitro
suggested that recombinant IL-10 might prove useful for the prevention and
treatment of certain inflammatory processes in vivo. Phase III trials to investigate the
efficacy of intravenous IL-10 administration in humans with inflammatory bowel
disease have been undertaken (Van Deventer et al., 1997). In a randomised,
controlled trial of IL-10 in humans there were no adverse signs after a single
intravenous injection of IL-10, which had inhibitory effects on T cells and
suppressed the production of TNF-a and IL-ip by whole blood stimulated ex vivo
with LPS (Chernoff et al., 1995, Huhn et al., 1996). Because of its ability to inhibit
production of these cytokines, which are involved in acute and chronic inflammatory
processes, IL-10 may be useful in a number of conditions such as sepsis, chronic
arthritis, and inflammatory bowel disease. Humans with inflammatory bowel disease
have been shown to have low levels of circulating IL-10 (Ishida 1993). In a recent
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study, 50% of patients with steroid-refractory Crohn's disease, achieved remission in
symptoms with IL-10 treatment (Van Deventer et ah, 1997).
Since eosinophils and neutrophils are pro-inflammatory cells, it is possible that IL-10
could be involved in the control of apoptosis and hence clearance from inflammatory
foci. IL-10 could act directly on these cells or indirectly by influencing the secretion
of cytokines or inflammatory mediators from other immune cells, alternatively it
may act in concert with other modulators of apoptosis.
1.10.6 Transforming Growth Factor-P (TGF-P)
TGF-P is a member of the TGF-P superfamily. These proteins are dimeric secreted
signalling molecules and include TGF-Ps, activins, Mullerian inhibitory substance
and bone morphogenetic proteins (Kingsley, 1994, Massague, et al., 1994) which
regulate proliferation, differentiation, migration and apoptosis of many cell types
(Ten Dijke, et al., 1996). These cytokines are also involved in immunomodulation,
inflammation, and bone and cartilage formation. Mammalian species express three
distinct isoforms of TGF-p, 1, 2 and 3 which are encoded by specific genes and are
expressed in unique patterns in vivo (Sporn et al., 1987, Derynck et al., 1988, Ten
Duke et al., 1988, Kondaiah et al., 1989, Millan et al., 1991). The expression of both
TGF-P2 and 3 is developmentally and hormonally regulated (Roberts & Sporn,
1992). Two other isoforms have been cloned; P4 has only been detected in chick
embryo chondrocytes (Jakowlew, et al., 1988), and P5 in Xenopus embryos and adult
tissues (Kondaiah et al., 1990). In vitro studies have demonstrated that leukocytes
principally express the type I isoform which exerts profound suppressive effects on
immune cell function (Wahl, 1994), therefore type I was chosen for these studies.
Mature TGF-pi is a 25 kDa disulphide-linked dimer of 112 amino acids which is
produced by platelets, lymphocytes, macrophages and various other cells (Assoian et
al., 1983, 1987, Kehrl et al., 1986). It has bifunctional actions in many cells,
stimulating or inhibiting growth depending on culture conditions and the presence of
other growth factors (Tucker et al., 1984, Roberts et al., 1985, Anzano et al., 1986).
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TGF-pl controls many functions in cells such as cell cycle progression,
differentiation, adhesion, migration and extracellular matrix production (Lyons &
Moses, 1990, Massague, 1990). It is mainly a growth inhibitor (Roberts et ah, 1986,
Moses et ah, 1990), but also affects the expression of a number of genes for
structural and metabolic proteins (Keski-Oja et ah, 1987, Massague, 1987). TGF-p
enhances normal wound healing via stimulation of chemotaxis, angiogenesis,
extracellular matrix accumulation and control of the production of cytokines and
other inflammatory mediators (Kehrl et al., 1986, Roberts et ah, 1986, Tsunawaki et
ah, 1988, Wahl et ah, 1987, Gold et ah, 1990). It stimulates the synthesis of
individual matrix components including fibronectin, tenascin, collagens and
proteoglycans (Ignotz & Massague, 1986, Roberts et ah, 1986, Balza et ah, 1988,
Bassols & Massague, 1988). It also blocks matrix degradation by decreasing the
synthesis of proteases and increasing the levels of protease inhibitors (Edwards et ah,
1987, Laiho et ah, 1987). TGF-P 1 is the only isoform of TGF-p found in a-granules
of platelets, and its release from degranulating platelets may be critical to the
initiation of repair responses (Assoian et ah, 1983). Expression of TGF-pl is
induced by its own ligand which serves to enhance and extend its expression,
throughout the course of the healing process (van Obherghen-Schilling et ah, 1988,
Kim et ah, 1990). However, this may also cause scarring and fibrosis that can
develop into chronic, progressive conditions that may adversely affect tissue
structure; this cytokine has been implicated in acute glomerulonephritis (Border et
ah, 1990, Okuda et ah, 1990, Yamaguchi et ah, 1990), diabetic nephropathy (Mauer
et ah, 1984, Velasquez et ah, 1990), idiopathic fibrosis of the lung (Brockelmann et
ah, 1991), pulmonary fibrosis (Raghow et ah, 1989), liver cirrhosis (Castilla et ah,
1991) and postoperative adhesions (Williams et ah, 1992).
The most widely distributed TGF-p receptors are type I (53 kDa) and type II (70
kDa) (Cheifetz et ah, 1987, 1990, Segarini et ah, 1989). Two other receptors are
known; the type III receptor (betaglycan), and endoglin. Betaglycan is a membrane
proteoglycan that binds TGF-P through a 100 kDa core protein, but has no obvious
signalling motif (Cheifetz et ah, 1987, Segarini & Seyedin, 1988, Andres et ah, 1989,
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Lopez-Casillas et al., 1991, Wang et al., 1991). Endoglin is a disulphide-linked
protein homodimer, structurally related to betaglycan and present at high levels in
vascular endothelial cells (Gougos & Letarte, 1988, Cheifetz et al., 1992). Type I, II
and betaglycan bind all three TGF-P isoforms: endoglin does not bind P2 (Cheifetz et
al., 1987, 1992, Bellon et al., 1993). Betaglycan and endoglin may function to
capture the soluble ligand and then present it to signalling receptors (Massague et al.,
1994), since the expression of betaglycan correlates with elevated binding of TGF-P
to receptor II. However, betaglycan is expressed at low levels on haematopoetic
cells (Wang et al., 1991) and among immune cells, only activated monocytes and
tissue macrophages express endoglin (Lastres et al., 1992, O'Connel et al., 1992).
TGF-P transduces signals via two different types of serine/threonine kinases, type I
(Attisano et al., 1993, Ebner et al., 1993, Bassing et al., 1994, Ten Dijke et al., 1994)
and type II receptors (Lin et al., 1992, Moustakas et al, 1993). The structures of these
receptors are similar and consist of small cysteine-rich extracellular regions, a
transmembrane region, and intracellular parts containing serine/threonine kinase
domains (Massague, et al., 1994, Kingsley, 1994). Type II receptors, have carboxyl-
terminal extensions of variable length that are rich in threonine and serine residues,
while type I receptors have, in their intracellular juxtamembrane region, a stretch of
residues rich in serine and glycine (Kingsley, 1994, Massague, et al., 1994). These
receptors are the only signalling receptors identified for TGF~p. TGF-P induces the
formation of a hetero-oligomeric complex, thought to be a heterotetramer consisting
of two molecules each of type I and II (Yamashita et al., 1994, 1995, Ten Dijke et al.,
1996, Weiss-Garcia & Massague, 1996). The type II receptor is a constitutively
active kinase, the autophosphorylation of which is not upregulated upon ligand
binding (Wrana et al., 1994). After binding of TGF-P to type II, type I is recruited
into a stable complex and is phosphorylated, by type II on its serine and threonine
residues (Wrana et al., 1994). Phosphorylation of type I is important for signal
transduction, (Wrana et al., 1992, Carcamo et al., 1994, Wieser et al., 1995).
Activated type I does not autophosphorylate or phosphorylate type II (Wrana et al.,
1994, Wieser et al., 1995). Thus, type I functions as a substrate for type II; its
phosphorylation and activation by type II is essential and sufficient for most TGF-p
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mediated signalling. However, both receptors are required for signalling; whereas
type II receptors can bind ligand by themselves, type I receptors cannot (Wrana et al.,
1992).
An early effect of TGF-P treatment is the transcription of jun B and c-jun
protooncogene mRNA and the mRNA for IkB-oc, an inhibitor of the transcription
factor NF-kB and a downregulation of c-Myc (Pertovaara et ah, 1989, Pientenpol et
ah, 1990, Arsura et ah, 1996, Iavarone and Massague, 1997). However, the
intracellular signalling pathways of this cytokine are still unclear, but recent research
has uncovered various proteins that seem to be involved in signal transduction.
TRIP-1 (TGF-p-receptor interacting protein-1) specifically associates with the type II
receptor in a kinase-dependent way and is phosphorylated on serine and threonine by
the receptor kinase, suggesting that it plays a role in receptor signalling (Chen et ah,
1995a). TRIP-1 may be a substrate of the Type II receptor in vivo (Chen et ah,
1995a). Other elements in the pathway appear to be TAK1, a TGF-p activated
MAPKKK (Section 1.12.2)(Yamaguchi et ah, 1995).
Inactivation of the type II receptor has been detected in some tumour types,
suggesting that this receptor may function as a tumour suppressor (Garrigue-Antar et
ah, 1995, Markowitz et ah, 1995, Parsons et ah, 1995, Pierce et ah, 1995b). Studies
on this role of the cytokine uncovered more signalling molecules that may be
involved in signal transduction. The retinoblastoma gene products (Rb) and pl5'nk4B
have been identified as tumour suppressor genes and are implicated in TGF-P
signalling (Alexandrow & Moses, 1995). TGF-P inhibits expression and activation
of cyclins (Howe et ah, 1991, Geng & Weinberg, 1993) and cyclin-dependent
kinases (Ewen et ah, 1993) and induces cyclin-dependent kinase inhibitors including
pi5 (Harmon & Beach, 1994), p21 (Datto et ah, 1995) and p27 (Polyak et ah, 1994).
It inhibits phosphorylation of Rb and the induction of c-myc (Moses et ah, 1990,
Alexandrow & Moses, 1995).
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A novel suppressor gene, DPC4, (deleted in pancreatic cancer), (Hahn et al., 1996),
is also involved in TGF-P signalling. DPC4 or Smad4 belongs to the SMAD family
of proteins (Derynck et al., 1996, Massague, 1996), which are phosphorylated by
activated TGF-P receptors, and propagate the signal through homo- and hetero-
oligomeric interactions (Eppert et al., 1996, Lagna et al., 1996, Zhang et al., 1996,
Attisano & Wrana, 1998). Smad4/DPC4 plays a central role as it is the shared
hetero-oligomerization partner of the other specific SMADs that can be activated by
other TGF-P family members.
TGF-P receptor activation induces phosphorylation of Smad2 and Smad3 (Eppert et
al., 1996, Lagna et al., 1996, Macias-Silva et al., 1996, Zhang et al., 1996, Nakao et
al., 1997a). These, in turn, form hetero-oligomeric complexes with Smad4/DPC4
(Lagna et al., 1996, Kretzschmar et al., 1997, Shi et al., 1997, Wu et al., 1997), and
translocate to the nucleus (Eppert et al., 1996, Macias-Silva et al., 1996, Nakao et al.,
1997a, Zhang et al., 1997), where they regulate transcriptional responses (Chen et al.,
1996a).
SMAD proteins are also involved in curtailing TGF-P signals. Smad7, is a TGF-P-
inducible antagonist of TGF-P signalling (Nakao et al., 1997b). Smad 7 associates
stably with the TGF-P receptor complex, but is not phosphorylated upon TGF-P
stimulation (Nakao et al., 1997b); it appears to inhibit TGF-P-mediated
phosphorylation of Smad2 and Smad3 (Hayashi et al., 1997, Nakao et al., 1997b).
TGF-P rapidly induces expression of Smad7 mRNA suggesting that Smad7 may
participate in a negative feedback loop to control TGF-P-mediated responses (Nakao
et al., 1997b). Smad6 forms stable associations with the type I receptor and
interferes with the phosphorylation of Smad 2 and the subsequent heteromerisation
with Smad4 signalling (Imamura et al., 1997). Smad6 is therefore likely to be
another inhibitor of TGF-p . However other pathways have been implicated in TGF-
P signalling (Alevizopoulos & Mermod, 1997) therefore inhibitory SMADs may
only target this specific pathway.
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1.11 Interactions Between Cytokines and Other Inflammatory Mediators
There are many obvious overlaps between the biological processes evoked by
cytokine and lipid mediator networks. Cytokines influence the production and
actions of lipid mediators at several broad levels. They can stimulate de novo
synthesis of lipid mediators, induce the enzymes that regulate lipid mediator
biosynthesis, cause degradation of or upregulation of receptor expression, and act
synergistically with a given lipid mediator to exert biological effects. Likewise,
certain lipid mediators can affect the biosynthesis and actions of cytokines.
AA can be liberated directly from phopholipids by the action of phospholipase A2
(PLA2) (Peplow, 1996). Cytokines such as IL-1 and TNF-a induce increased
expression of group II secretory PLA2 in a variety of cells (Coyne et al., 1992).
Group II sPLA2 plays a role in mediating arachidonic acid release and prostaglandin
production (Barbour et al, 1993). The 85 kDa cytosolic PLA2 (CPLA2) was the first
arachidonic acid-selective PLA2 identified, and is now recognised as an important
enzyme for mediating agonist-induced arachidonic acid release (Clark et al, 1995).
CPLA2 is regulated by both transcriptional and post-translational mechanisms. IL-1
and TNF-a each induce an increase in the synthesis of PLA2 and COX-2, whereas
TGF-P has inhibitory effects (Clark et al., 1995, Pruzanski et al., 1998). Therefore
the signals and effects which can be produced by a specific cytokine or eicosanoid
are complex and may, depending on the timepoint chosen for study, reflect
synergistic, additive or antagonistic effects of other mediators activated or produced
by the original stimulus.
1.12 TNF Signalling Pathways
Cytokines can have differential effects on specific cells because of variation in
receptor expression and through interactions with other factors. Flowever, signalling
can become complex because cytokines can trigger more than one intracellular
pathway and recent work has shown that many of these pathways can interact. This
complexity can be illustrated by means of the three main TNF-a signalling
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pathways; caspase, mitogen-activated protein (MAP) kinase and NF-kB activation.
(Figure 1.2). Since this cytokine has both anti- and pro-apoptotic effects it therefore
influences both survival and death pathways. Why some cells are susceptible to the
pro-apoptotic effects of TNF-a while others are resistant is currently unknown.
However, study of the intracellular inducers of the biological effects of TNF-a are
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1.12.1 The Caspase-Cascade Pathway
Apoptosis is regulated by a series of biochemical events; a common feature ofwhich
is the activation of caspases (cytosolic aspartate-specific cysteine proteases)
(Alnemri et ah, 1996). Caspases are inactive until a signal initiates activation of one,
which in turn will proteolytically activate the next protease in the pathway. The
activation of this cascade and the subsequent proteolytic cleavage of specific
substrates is thought to lead to the structural changes of apoptosis and the activation
of other effectors critical for death (Martin & Green, 1995).
Caspase substrates are rapidly being identified but the general assumption is that
caspases recognise a limited set of cellular proteins (Nicholson & Thornberry, 1997).
In human cells, several substrates for these proteases have been defined, including
enzymes functioning in DNA repair [e. g. PARP and DNA-PKCS (Casciola-Rosen et
al., 1995)], and structural proteins such as lamins A and B (Lazebnik et al., 1995,
Neamati et al., 1995, Orth et al., 1996) and fodrin (Martin et al., 1995). Mature
neutrophils have been shown to contain precursors of caspases 1, 3 and 7, but not
PARP or DNA-PKCS (Sanghavi et al., 1998).
Much of the current knowledge of proteases involved in the caspase-cascade was
derived from genetic studies in the nematode Caenorhabditis elegans (Ellis et al.,
1991, Hengartner & Horvitz, 1994). The C. elegans gene ced-3 encodes a protein
that is similar to the family of cysteine proteases, which includes interleukin-l-|3-
converting enzyme (ICE) (Cerreti et al., 1992, Thornberry et al., 1992, Yuan et al.,
1993) and the 32 kDa putative cysteine protease (CPP32) (Fernandes-Alnemri et al.,
1994). At least 5 proteases in the ICE family are expressed in mammalian cells, and
the activity of some of these enzymes appears to be required for apoptosis to occur
(Martin & Green 1995). Inappropriate expression of intracellular proteases including
ICE has been shown to drive cells into the apoptotic programme. Conversely,
specific ICE family protease inhibitors such as the viral protein crmA (Miura et al.,
1993) can prevent normal apoptosis.
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TNF-a activates the caspase pathway when TNF-induced trimerisation of TNFR1
triggers an association with TNFR1 -associated death domain protein (TRADD),
which recruits Fas-associated death domain protein (FADD) also known as MORT1
(Chinnaiyan et al., 1995, Hsu et ah, 1996). This interaction with TRADD and
FADD/MORT1 allows activation of the caspase cascade (Boldin et ah, 1996, Muzio
et al., 1996), when FADD/MORT1 recruits pro-caspase 8 to the receptor complex
(Darney & Aggarwal, 1997). When pro-caspase 8 is activated, the resulting cascade
of caspase activation causes cleavage of cytosolic, cytoskeletal, and nuclear proteins
leads to apoptosis (Patel et al., 1996). As shown in Figure 1.2, the TNF receptor
complex also interacts via TRADD with RIP (Receptor Interacting Protein) and
TRAF2 (TNFR associated factor) proteins which are involved in the activation of
stress-activated protein kinases (SAPK), c-Jun N-terminal kinases (JNK) and NF-kB
(Hsu et al., 1996, Lui et al., 1996). Another protein RAIDD, can associate with RIP
and can cause the recruitment and activation of caspase 2 (ICH-1) (Duan & Dixit,
1997).
1.12.2 The MAP Kinase Pathway
As shown in Figure 1.2, TNF-a also activates the MAP kinase pathway. MAP kinase
cascades are ubiquitous components of various signal transduction pathways
(Robinson & Cobb, 1997). They generally consist of a MAP kinase kinase kinase
kinase (MAPKKKK) which activates through phosphorylation, a MAP kinase kinase
kinase (MAPKKK), which phosphorylates and thereby activates a MAP kinase
kinase, (MAPKK), which in turn phosphorylates and activates the corresponding
MAP kinase (MAPK) (Illustrated in Figure 1.2). There are three different types of
MAP kinases: the p42 and p44 extracellular signal-regulated kinases (ERKs),
(Avruch et al., 1994), the JNKs/SAPKs (Derijard et al., 1994, Kyriakis et al., 1994)
and p38 kinases (Han et al., 1994).
ERKs are most efficiently stimulated by growth factors and phorbol esters (Davis,
1994, Kyriakis et al., 1994, Minden et al., 1994, Cobb & Goldsmith, 1995), The Raf-
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Mek-Erk cascade can be activated through FAN, a protein that binds to TNFR1 and
activates neutral sphingomyelinase (Adam-Klages et ah, 1996) (Figure 1.2).
JNK/SAPKs and p38 play a crucial role in the responses stimulated by pro¬
inflammatory cytokines, environmental stresses and apoptotic agents (Derijard et ah,
1994, Han et al., 1994, Kyriakis et al., 1994, Kyriakis & Avruch, 1996a, b). These
kinases can be activated by small GTP-binding proteins that include Cdc42 and Racl
(Coso et al., 1995, Minden et al., 1995). JNK and p38 can be activated by
phosphorylation of Tyr and Thr residues by the upstream kinase MKK7 (Tournier et
al., 1997) or by MKK4/SEK-1 (Lange-Carter et al., 1993, Sanchez et al., 1994,
Derijard et ah, 1995, Lin et al., 1995a), which is phosphorylated and activated by
MEKK1 (Han et al., 1994, Sanchez et al., 1994). MEKK1, can in turn, be activated
by p21-activated protein kinase (PAK) (Bagrodia et al., 1995). Similarly, p38
kinases are activated by MKK3 and MKK6/SAPKK3 (Cuenda et al., 1996,
Raingeaud et al., 1996).
As shown in Figure 1.2 TRAF2 mediates activation of NF-kB, and JNK and p38
kinases in response to TNF-a. Recent studies (Lui et al., 1996, Natoli et al., 1997,
Reinhard et al., 1997) have shown that TRAF2-mediated activation of JNK, but not
NF-kB can be inhibited by an inactive mutant of MEKK1, indicating that JNK and
NF-kB signalling diverge downstream of TRAF2. MEKK1 has been implicated in
TNF-induced JNK/SAPK activation as has ASK1, a kinase which is TNF-inducible,
and also activates p38 (Ichijo et al., 1997). MKK7 has also been found to be
activated in response to TNF-a (Foltz et al., 1998).
Stress stimuli can induce apoptosis in a variety of cell types; therefore JNK/SAPK
and p38 have been implicated as part of the apoptotic mechanism in response to
these stimuli (Xia et al., 1995, Verheij et al., 1996, Zanke et al., 1996). For example,
in Jurkat cells, JNK and p38 MAP kinase activation have been coupled to Fas-
induced apoptosis, and it appears that this coupling requires the activation of
caspases (Juo et al., 1997), while ASK1 activation, can also cause apoptosis (Ichijo et
al., 1997, Malinin et al., 1997). Because TNF-a is known to activate both JNK and
p38, these kinases may play a role in either TNF-a-induced survival, or cell death.
However the role of the stress-activated kinases during apoptosis induced by various
stimuli is controversial. Inhibition of early TNF-induced JNK and p38 kinase by
expression of dominant negative mutants of MKK4, MKK6 or the p38 inhibitor
SB203580 increased TNF-induced apoptosis, whereas expression of wild type
MKK4 and MKK6 enhanced cell survival in the presence of TNF (Roulston et al.,
1998), suggesting that JNK and p38 activation may mediate cell survival signals in
response to TNF-a. Recently JNKs/SAPK and the p38 kinases, have also been
shown to be activated by hematopoietic growth factors such as IL-3, GM-CSF and
G-CSF (Foltz et al., 1998), which are known to enhance survival in granulocytes
(Lee et al., 1993, Alam et al., 1994a).
1.12.3 Activation of NF-kB
The third major pathway in TNF-a signalling causes activation ofNF-kB. NF-kB is
an inducible transcription factor that is usually found in the cytoplasm of
unstimulated cells, bound to an inhibitor subunit known as Ik-B. This factor is
activated when Ik-B is phosphorylated, ubiquitinated, and degraded via the
proteasome, thus exposing the nuclear localisation sequence (NLS) which allows
activated NF-kB to enter the nucleus and bind to DNA (Baeuerle & Henkel,
1994).(Section 1.15)
As shown in Figure 1.2, TRAF2 binds directly to TNFR2 (Darney and Aggarwal,
1997). The NF-kb-inducing kinase (NIK) is a MAPKKK-related kinase that binds
TRAF2 and activates NF-kB when overexpressed (Malinin et al., 1997). TRAF2
appears to be the bifurcation point of two kinase cascades leading to activation of
NF-kB and JNK, respectively (Song et al., 1997). Therefore, stimuli that induce NF-
kB, such as TNF-a, also activate the JNK cascade, and the two pathways may be
interlinked. Transfection ofMEKK1 can induce IkB degradation and activate NF-kB
reporter genes (Hirano et al., 1996, Meyer et al., 1996). This activation of NF-kB
occurs through site-specific phosphorylation of IkB at Ser-32 and 36 (Lee et al.,
52
1997a). MEKK-1 can also induce the site-specific phosphorylation of IkB in vivo
and activates the IkB kinase in vitro (Lee et al., 1997a, Mercurio et al. 1997).
MEKK1 is therefore a critical component of both the c-Jun and NF-kB stress
response pathways.
1.12,4 Other Signalling Pathways Involved in TNF-a Signalling
TNF-a signalling also involves activation of a phosphatidylcholine-specific
phospholipase C, which generates 1,2-diacylglycerol (DAG), in response to ligand.
DAG, as well as directly activating protein kinase C, may in turn initiate a signalling
cascade that involves the activation of acidic sphingomyelinases, the generation of
ceramide and ceramide-dependent activation of serine-threonine kinases (Siebenlist
et ah, 1994).
A role for ceramide produced by the sphingomyelin cycle was proposed as a second
messenger of TNF-a mediated cellular responses including the induction of
apoptosis (Obeid et ah, 1993, Jarvis et ah, 1994), and the activation of NF-kB
(Schutze et ah, 1992). In contrast there are also several reports that demonstrate that
ceramides are not involved in the signal transduction of TNF-a (Dbaido et ah, 1993,
Betts et ah, 1994). Neutral sphingomyelinase hydrolyses sphingomyelin in the outer
leaflet of the plasma membrane, while an acidic sphingomyelinase produces
ceramide in the endosomal/lysosomal compartments (Hannun et ah, 1993).
However, ceramides do not mimic TNF-a-induced apoptosis (Murray, 1998),
although inhibition of acidic sphingomyelinase inhibits TNF-induced apoptosis, but
does not inhibit NF-kB activation (Higuchi et ah, 1996). Therefore although TNF-a
activates NF-kB, ceramide does not (Higuchi et ah, 1996).
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1.13 Transcription Factors
The primary control of eukaryotic gene expression occurs at the level of transcription
where genes may be regulated in response to a specific signal or in a particular tissue
type (Darnell, 1982). Transcriptional control of gene expression involves the binding
of regulatory proteins or transcription factors to short, c/s-acting DNA sequence
elements located within and near the promoter of a gene. There are several types of
DNA sequences to which transcription factors will bind. These include promoter,
regulatory and enhancer/repressor elements. The transcription factors that bind to
regulatory and enhancer/repressor sites will increase or decrease the rate of
transcription but are not essential for basal activity (Wildeman et al., 1986, Zenk et
al., 1986).
Two major signal transduction systems utilise cAMP and diacylglycerol (DAG) as
secondary messengers (Nishizuka, 1986). Each of these pathways is also
characterised by the mobilisation of a specific protein kinase, protein kinase A and
protein kinase C, respectively. Intracellular levels of cAMP are regulated primarily
by adenylate cyclase. cAMP, in turn, binds co-operatively to two sites on the
regulatory subunit of protein kinase A (PKA), releasing the active catalytic subunit
(Roesler et al, 1988, Lalli & Sassone-Corsi, 1994). The activated catalytic subunit is
released from cytoplasmic and Golgi complex anchoring sites and used to
phosphorylate a number of cytoplasmic and nuclear proteins on serines in the context
X-Arg-Arg-X-Ser-X (where X is any amino acid) (McKnight et al, 1988, Roesler et
al, 1988). In the nucleus, PKA-mediated phosphorylation ultimately influences the
transcriptional regulation of various genes through distinct, cAMP-inducible
promoter responsive sites (Ziff, 1990, Borrelli et al, 1992).
Exposure of cells to TNF-a results in activation of at least two transcription factors,
activator protein-1 (AP-1) (Brenner et al., 1989) and NF-kB (Osborn et al., 1989).




AP-1 is a sequence-specific transcriptional activator composed of members of the
Jun and Fos families which associate to form a variety of homo-and heterodimers
that bind to a common site (Angel & Karin, 1991). AP-1 activity can be induced by
an increase in AP-1 components or by phosphorylation at specific sites which can
enhance the transactivating potential of several AP-1 proteins, including c-Jun and c-
Fos (Smeal, et al., 1991, Suzuki et al., 1991, Deng & Karin, 1994). Most of the
genes that encode AP-1 components behave as "immediate-early" genes, i.e. genes
whose transcription is rapidly induced independently of de novo protein synthesis,
following cell stimulation. Among these, the regulation of c-fos and c-jun
transcription is best understood.
All three MAPK families contribute to induction of AP-1 activity in response to a
diverse array of extracellular stimuli; each affecting AP-1 through phosphorylation
of a different substrate. The most relevant MAPKs that contribute to AP-1 activation
appear to be the JNK and p38 kinases (Karin, 1995, Karin et al., 1997) which
activate various transcription factors. For example, both c-Jun (Devary et al., 1992),
activating transcription factor 2 (ATF2) (Gupta et al., 1995), induce the c-jun and c-
fos genes. Another part of the increase in AP-1 activity is due to c-Jun
phosphorylation. Phosphorylation of c-Jun potentiates its ability to activate
transcription as either a homodimer (Pulverer et al., 1991, Smeal et al., 1991) or as a
heterodimer with c-Fos (Deng & Karin, 1994). AP-1 is typically upregulated in
proliferative processes and can be activated by phorbol esters via the protein kinase
C signal transduction pathway.
1.15 NF-kB
NF-kB was first identified as a nuclear factor that binds the decameric DNA
sequence 5-GGGACTTTCC-3" within the intronic immunoglobulin kappa light
chain enhancer in mature B cells (Sen & Baltimore, 1986). Many inflammatory
mediators regulate gene expression in target cells through transcription factors such
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as NF-kB. NF-kB is activated rapidly in response to many pathogenic signals,
participates in cytoplasmic/nuclear signalling, and potently activates transcription of
a variety of genes encoding cytokines such as IL-1, IL-2, IL-6, IL-8, TNF, and GM-
CSF (Baeuerle & Henkel, 1994).
NF-kB is formed from members of the Rel family of proteins that comprises two
groups classified on the basis of their structure, function and mode of synthesis.
Group 1 includes p50 and p52, which are synthesised as precursor proteins of 105
(pl05) and 100 (plOO) kDa respectively (Ghosh et al., 1990, Kieran et al., 1990,
Schmid et al., 1991). These precursors are able to dimerise with other family
members (Mercurio et al., 1993, Naumann et al., 1993, Rice et al., 1993, Scheinman
et al., 1993). In such heterodimers, the long C-terminal portion of the precursor
blocks the NLS of each subunit, resulting in cytoplasmic localisation (Blank et al.,
1992, Henkel et al., 1992, Matthews et al., 1993). However, both precursors can be
processed to provide active DNA-binding NF-kB dimers (Fan & Maniatis, 1991,
Mercurio et al., 1993). Group II comprises p65/RelA, c-Rel, RelB and the
Drosophila proteins Dorsal and Dif (Sen & Packer, 1996). Rel proteins are
characterised by the presence of a Rel homology domain, which is about 300 amino
acids in length and includes a DNA binding domain and an NLS. Rel/NF-kb
proteins can form homo- or heterodimers (Baeuerle & Henkel, 1994, Thanos &
Maniatis, 1995).
The most common form of NF-kB is a heterodimer of p50 and RelA/p65 proteins
(Ghosh et al., 1990, Kieran et al., 1990, Nolan et al., 1991, Ruben et al., 1991). Rel B
readily associates with p50 and p52, forming potent transcriptional activators, but no
RelB homodimers or heterodimers with RelA (p65) and c-Rel have been observed in
vitro or in vivo (Bours et al., 1990, Ryseck et al., 1992, Dobrzanski et al., 1993).
Combinations of p50 with p65 or c-Rel are transcriptionally active as are p65
homodimers and whereas p52 and p50 homodimers are transcriptionally inactive and
can repress KB-dependent transcription (Ballard et al., 1992, Lernbecher et al., 1993,
Brown et al., 1994).
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NF-kB dimers are sequestered in the cytoplasm by physical association with
inhibitor proteins referred to as IkB (Henkel et ah, 1993). Treatment of cells with
various inducers leads to the dissolution of this cytoplasmic complex and the
translocation of free NF-kB to the nucleus (Baeuerle et ah, 1988).
Currently the IkB family consists of IkB-cx, IkB-P, IkB-y, IkB-s and Bcl-3 (Ohno et
al., 1990, Bhatia et al., 1991, Haskill et al., 1991, Davis et al., 1991, Franzoso et al.,
1992, Hatada et al., 1992, Inoue et al., 1992a, b, Liou et al., 1992, Tewari et al.,
1992), the most predominant being the a and p subunits. These inhibitors have 5-7
conserved domains known as ankyrin repeats (Schmitz et al., 1991, Blank et al.,
1992, Nolan & Baltimore, 1992), which interact with NF-kB subunits thus masking
the nuclear localisation signals and preventing activation ofNF-kB and its transport
to the nucleus (Siebenlist et al., 1994, Baldwin, 1996). They also contain a carboxy-
terminal protein destabilising sequence rich in proline, glutamate/aspartate and
serine/threonine, also known as the PEST sequence, which facilitates proteolytic
degradation of IkB proteins (Baeuerle & Henkel, 1994, Thanos & Maniatis, 1995).
IkBoc is capable of binding to most dimers, thereby blocking their nuclear
localisation signals (Zabel & Baeuerle, 1990, Beg et al., 1992, Ganchi et al., 1992,
Kumar & Gelinas, 1993, Zabel et al., 1993,). Like ficBa, IkBP also binds to many
dimers and undergoes phosphorylation and degradation upon stimulation (Thompson
et al., 1995). IkBs is induced by phorbol esters and acts as a potent inhibitor of kB
dependent gene expression (Baeuerle & Baltimore, 1996). An alternately spliced
form of pi05, IxBy, which consists solely of the long C-terminal ankyrin repeat-
containing domain, has been seen in some cells. IkBy is able to bind various dimers
and retain them in the cytoplasm (Inoue et al., 1992c).
With the exception of Bcl-3, the IkBs inhibit NF-kB activity (Baeuerle & Baltimore,
1988a,b, Inoue et al., 1992b, Zabel et al., 1993). Bcl-3 appears to interact
specifically with only p50 and p52 homodimers and can form a nuclear complex.
Bcl-3 has been reported to both inhibit these homodimers and cause transcriptional
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activation (Franzoso et al., 1992, Inoue et al., 1993, Zhang et al., 1994). Bcl-3 may
prevent inactive p50 homodimers from binding to DNA thus allowing the binding of
a transcriptionally active NF-kB complex to the same site (Franzoso et al., 1993).
Different isoforms of IkB appear to target different combinations of Rel proteins, for
example ficBa and IkB-{3 associate predominantly with p50/RelA and p50/c-Rel
heterodimers (Davis et al, 1991, Haskill et al., 1991, Kerr et al., 1991), IkB-s binds
to p65 and c-Rel homodimers (Whiteside et al., 1997) and Bcl-3 interacts with p50
and p52 homodimers (Franzoso et al. 1992, Nolan et al., 1993). The precursor
proteins pi05 and pi00, can also be considered IkB proteins because they bind p50,
c-Rel and RelA and inhibit their DNA binding and nuclear translocation (Mercurio et
al., 1993, Naumann et al., 1993, Rice et al., 1993).
The activation of NF-kB results in the rapid degradation of IkB causing release of
NF-kB from its cytosolic inhibitor (Beg et al., 1993, Beg & Baldwin 1993, Brown et
al., 1993, Henkel et al., 1993, Scott et al 1993, Sun et al., 1993). Upon stimulation,
specific kinases phosphorylate IkB leading to its ubiqitination (DiDonato et al.,
1996), and degradation by the proteasome complex (Chen et al., 1995b). All known
inducers ofNF-kB cause degradation of IicB-a. By contrast, IkB-$ is only affected
by a subset of inducers (e.g. LPS and IL-1), which cause a persistent activation of
NF-kB that varies in magnitude in a cell-type-specific manner (McKinsey et al.,
1996, Meyer et al., 1996).
Stimuli that activate NF-kB act by means of proteins kinases that phosphorylate IkB.
A specific NF-kb-inducing kinase (NIK) has been characterised which activates an
IkB-oc kinase previously known as CHUK (Regnier et al., 1997), while a cytokine-
responsive IkB kinase (IKK) has been described which specifically phosphorylates
IkB-cc, resulting in activation of NF-kB in response to pro-inflammatory cytokines
(DiDonato et al., 1997). Casein kinase II also phosphorylates IicB-a (Janosch et al.,
1996), while a multi-subunit complex in HeLa cell cytoplasmic extracts that can
phosphorylate IxB-a at Ser-32 and 36 has been isolated (Chen et al., 1996b). A
novel property of this kinase is that it can be activated in vitro by ubiquitination.
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NF-kB activation is regulated at various levels. The IkBci gene has a kB recognition
sequence in its promoter region and its constitutive expression is strongly enhanced
by NF-kB activating stimuli (Haskill et ah, 1991, Brown et al., 1993, Sun et ah,
1993). Free IkB-oc can enter the nucleus (Morin & Gilmore, 1992, Zabel et al.,
1993), and can dissociate the NF-kB-DNA complex (Zabel & Baeuerle, 1990). This
causes passage of NF-kB to the cytoplasm, thereby terminating gene activation
(Arenza-Seisdedos et al., 1995). This type of feedback loop causes transient
expression ofNF-kB responsive genes.
The genes encoding pi05, pi00, c-Rel and Bcl-3 also contain kB binding sites in
their promoter regions, and stimulation of cells leads to increased synthesis of these
proteins (Bours et al., 1990, Hannick & Temin, 1990, Ohno et al., 1990, Ten et al.,
1992, Cogswell et al., 1993, Brown et al., 1993, Cheng et al., 1994, Chiao et al.,
1994, Liptay et al., 1994, Nolan et al., 1993).
While ubiquitination of IkBcc leads to its complete degradation, ubiquitination of
pl05 results in an increase in the rate at which pl05 is processed to p50 (Beg et al.,
1993). P50 homodimers bind to kB sites, but inhibit rather than trigger transcription
(Franzoso et al., 1993, Baeuerle & Henkel, 1994, Baldwin, 1996). The RelA gene, is
ubiquitously expressed at very low levels (Ruben et al., 1991, Costello et al., 1993),
but synthesis of p65/RelA is not upregulated by Rel/NF-kB dimers (Ueberla et al.,
1993). All the genes encoding negative regulators of RelA activity seem to be under
positive transcriptional regulation by RelA-containing complexes. This imposes a
tight negative control on RelA, the strongest transactivating subunit of the NF-kB
system. Therefore, after activation, there may be a shift in the composition of NF-
kB. Upregulation of p50 homodimers could inactivate transcription of some genes
while the change in dimers complexes could activate different gene profiles, since
dimer composition may determine the DNA-binding specificity of a given NF-kB
complex (Urban et al., 1991, Urban & Baeuerle, 1991, Kunsch et al., 1992).
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1.16 Interactions Between Transcription Factors
Accumulating evidence indicates that a relatively small number of transcription
factors have a critical role in controlling the complex gene expression involved in the
immune response. These include the NF-kB, NFIL-6, CREB/ATF, AP-1, STAT and
NF-AT families of transcription factors (Akira & Kishimoto, 1997).
NF-kB has been shown to synergise with a number of different transcriptional
activator proteins, including Ets, ATF-2/c-Jun and NF-IL6. This synergy is a
consequence of direct interactions between NF-kB and these proteins and co¬
operative binding to adjacent binding sites. The interacting transcription factors can
be present constitutively or co-induced with NF-kB. Several inducers of NF-kB
activate JNK, which in turn phosphorylates ATF-2 and c-Jun both of which synergise
with NF-kB (Gupta et al., 1995). NF-kB also to interacts with AP-1 (Stein et al.,
1993a), SP1 (Perkins et al., 1992), and C/EBPp (Stein et al., 1993b). Interaction of
NF-kB and AP-1 results in the synergistic activation of both kB and AP-1 response
elements, while interaction of NF-kB and the transcription factor C/EBPp results in
the enhancement ofC/EBPP and the repression of kB response element function.
The interplay between transcription factors means that the end result of a stimulus
will be dependent on the end products of a variety of signalling pathways. This
situation is further complicated by links between these pathways such as already
discussed for MEKK-1. Therefore the dissection of cause and effect with regard to a
specific stimulus is difficult and complex.
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1.17 Aims of Thesis
The aims of this thesis were to investigate the regulation of granulocyte apoptosis by
physiological, pro- and anti-inflammatory mediators. In view of the role of apoptosis
in inflammatory resolution, we were most interested those which would drive the
process of apoptosis in granulocytes, and in particular, any mediators which appeared
to have specific effects on either neutrophil or eosinophil apoptosis. Therefore, the
main body of this work involved an investigation into the effects of various classes
of mediators including cytokines, chemokines, prostaglandins, and leukotrienes on
the constitutive rates of both neutrophil and eosinophil apoptosis. Further to such
results, we wished to examine the mechanisms involved in enhancing both
granulocyte survival and programmed cell death and to investigate the signalling





2.1.1 Isolation of Human Peripheral Blood Granulocytes
Human neutrophils and eosinophils were purified by previously described methods
(Haslett et ah, 1985, Savill et ah, 1989a, Stern et ah, 1992). In the case of eosinophil
donors, those with a history of atopy were asymptomatic at the time of the study and
none were undergoing glucocorticoid treatment. Cell isolation was performed under
sterile conditions using LPS-free reagents and plastic ware (Flacon, Oxford, UK).
Venous blood (36 ml) was collected into 50 ml polypropylene tubes, each containing
4 ml of sterile 3.8% sodium citrate solution to prevent coagulation. The citrate and
blood were mixed by gentle invertion of the tubes several times to minimise cell
activation, before centrifugation at 370g for 20 min at room temperature. This gives
two layers, an upper layer containing plasma and platelets, and lower layer
containing a leukocyte/erythrocyte pellet.
The platelet-rich plasma (PRP) was aspirated without disturbing the lower pellet.
This erythrocyte/leukocyte layer was sedimented by the addition of 5 ml of 6%
dextran (T500) (2.5 ml dextran per 10 ml cell pellet), and the volume made up to 50
ml with sterile 0.9% saline. Both these reagents had been warmed to 37 °C in a
water bath for 30 min, since the efficiency of dextran sedimentation depends upon
temperature. The cells were allowed to sediment at room temperature for 30 min,




Neutrophil isolation was performed at room temperature and under sterile conditions.
The leukocyte-rich layer was aspirated from the sedimented red cells, centrifuged
(235g, 6 min) and resuspended in 2.5 ml of 55% isotonic Percoll (9:1 v/v PercolklO
2~b 2~F
x PBS) in 1 x PBS without Ca /Mg . Discontinous Percoll gradients were prepared
by overlaying 2.5 ml of 70% iostonic Percoll onto 2.5 ml of 81% isotonic Percoll in a
15 ml Falcon tube, and the resuspened cell fraction overlayed to form the final layer
of the gradient.
These gradients were centrifuged at 720g for 20 min at room temperature.
Neutrophils were harvested from the 70%/81 % interface (monocytes can be
harvested from the 70%/55% interface). Cells were sequentially washed twice in
PBS without divalent cations and PBS with divalent cations (235g, 6 min) with yield
assessed before the final wash. Although, density gradient centrifugation does not
separate neutrophils from eosinophils or basophils, neutrophils were generally > 98%
pure, with basophils rarely seen and preparations containing > 5% eosinophils
discarded or purified for eosinophil studies. Typical neutrophil yield was approx 100
x 106/40 mis of whole blood.
2.1.3 Eosinophil Isolation
Eosinophils isolation was performed using a two stage procedure based on a
modification of a previously described method involving a combination of dextran
sedimentation and centrifugation through six isotonic discontinuous plasma-Percoll
gradients to produce cell fractions which partially separate neutrophils and
eosinophils (Haslett et al., 1985), followed by a negative selection step (Bach et ah,
1990) using immunomagnetic separation to purify eosinophils from contaminating
neutrophils. This stage was performed using the murine anti-neutrophil ab 3G8
(anti-CD 16)-coated sheep anti-mouse IgG-Dynabeads.
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Eosinophils were prepared as described for neutrophils (Section 2.1.2). The
leukocyte-rich layer was aspirated from the sedimented red cells, centrifuged (530g,
6 min) and resuspended in 2 ml autologous platelet-poor plasma (PPP) (Section
2.1.7). Percoll-plasma gradients (60 -77% Percoll) were prepared by diluting stock
Percoll (9:1 v/v Percoll: 10 X PBS) in 1 x PBS without divalent cations and
overlaying 2 ml of each gradient in a 15 ml Falcon tube, with the leukocyte
suspension as the final layer. The gradients were centrifuged (570g, 40 min) at room
temperature, with the brake and accelerator off. Eosinophilic and neutrophilic
granulocytes were harvested from the 74/77% interface and washed sequentially in
PPP (370g, 5 min), followed by PBS without divalent cations (260g, 5 min) before
suspension in PBS without divalent cations containing 0.1% gelatin. The cell yield
was assessed and the percentage of neutrophil contamination in each fraction was
quantified either by flow cytometry analysis involving antibody detection of cells
expressing surface CD 16 or morphologically by examination of cytocentrifuge
preparations. CD16-Dynabeads were prepared under sterile conditions by combining
3G8 cell supematants with dynal M450 sheep anti-mouse dynabeads (10 ml supt:700
p.1 dynabeads), in a 15 ml falcon tube. The antibody/bead mixture was rotated at 4
°C overnight to allow maximal coating of beads. Coated beads were washed three
times in HBSS without divalent cations containing 0.1% gelatin and the beads
retrieved by stationary contact (5 min) using a magnet (Dynal Magnetic Particle
Concentrator, MPC-1). Harvested granulocytes were incubated with washed 3G8-
Dynabeads at a bead:neutrophil ratio of 3:2 on a rotary mixer at 4 °C for 20 min, and
the beads with attached neutrophils were magnetically separated by stationary
contact (3 min) with a magnet. This procedure was repeated once. Purified
eosinophils (>99% pure with neutrophils as the major contaminant) were washed
twice in 8 ml of PBS without divalent cations containing 0.1% gelatin by
centrifugation (235g, 5 min) and final yield of purified cells was assessed. Cell yield
was typically 30 x 106 cells per 240 ml of blood, but this varied with donor.
Alternatively, eosinophils were isolated using the neutrophil separation method
followed by extraction of the contaminating neutrophils using the murine anti-
neutrophil ab 3G8 (anti-CD16)-coated sheep anti-mouse IgG-Dynabeads as already
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described. This method allowed higher yields of eosinophil (approximately 10 -20
%) without affecting cell purity or viability.
2.1.4 Cell Culture ofNeutrophils
Purified neutrophils were routinely suspended at a density of 5 x 106 in Iscoves's
DMEM supplemented with 10 % autologous serum and 50 U/ml penicillin and 50
U/ml streptomycin. Cells were cultured in flat-bottomed 96 well Falcon flexiwell
plates (Becton-Dickenson, UK), in a final volume of 150 pi, at 37 °C in a humidified
5% CO2 atmosphere for the time periods indicated. Reagents to be examined in this
assay system were diluted to 10 x the final concentration required in Iscove's
DMEM, before the addition of 15 pi of each reagent to be investigated.
2.1.5 Cell Culture of Eosinophils
Purified eosinophils were suspended at a density of 2.0 x 106/ml in Iscove's DMEM
supplemented with 10 % autologous serum and 50 U/ml penicillin and 50 U/ml
streptomycin. Eosinophils were cultured in flat-bottomed 96 well Falcon flexiwell
plates, in a final volume of 150 pi, at 37 °C in a humidified 5% CO2 atmosphere for
the time periods indicated. Reagents to be examined in this assay system were
diluted to 10 x the final concentration required in Iscove's DMEM, before the
addition of 15 pi of each reagent to be investigated.
2.1.6 Preparation of Autologous Serum
PRP (15 ml) was added to a sterile glass tube and 330 pi of CaCE at a final
concentration of 20 pM. This was incubated for approximately 45 min at 37 °C to
allow clotting of plasma components, forming autologous serum.
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2.1.7 Preparation of Platlet Poor Plasma (PPP)
PRP was placed in a 15 ml Falcon tube and centrifuged at 2400g for 20 min causing
platelets to pellet. The PPP was decanted off and the pelleted platelets were
discarded.
2.1.8 Assessment of Apoptosis
2.1.8.1 Morphological Criteria
Cells were removed from culture at various times, as indicated in the Results for
assessment of morphology according to the method of Savill et al (1989a).
Cytocentrifuge preparations of cell samples in each experiment were prepared in a
Shandon Cytospin II (Shandon, UK), air dried, fixed in methanol, and stained with
Diff-Quik™. Cells were examined under oil immersion light microscopy (x 1250
magnification), and apoptotic cells were defined as those containing one or more
darkly stained pyknotic nuclei (See Chapter 5, Figure 5.4 and 5.5). For each
condition examined, slides were prepared from duplicate or triplicate incubations and
a total of at least 500 cells were counted over five fields of view, with the observer
blinded to the assay conditions.
2.1.8.2 Annexin V Binding
Assessment of apoptosis was also performed by flow cytometry using FITC-labelled
recombinant human annexin V that binds to phosphatidylserine exposed on the
surface of apoptotic cells. Stock annexin V was diluted 1:200 with binding buffer
and then added (25 pi) to 75 pi of the recovered cell samples. Following a 10 min
incubation at 4 °C, these samples were fixed by the addition of 100 pi of 3%
paraformaldehyde before analysis using an EPICS Profile II (Coulter Electronics,
Luton, U.K.).
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2.1.8.3 Chromatin fragmentation assay
DNA was extracted as described previously by the method of Dignam et al., (1983).
Neutrophils (2 x 106) were taken after the indicated treatment and lysed in 500 pi of
lysis buffer (6 M guanidine hydrochloride, 50 mM Tris-CL, pH 8.0, and 0.1 % N-
lauroyl sarcosine) at 4 ° C and the nucleic acids extracted by the addition of an equal
volume of 10 mM Tris-Cl pH 8.0 saturated phenol:chloroform mixture (50:50 v/v).
The resulting emulsion was centrifuged at 1,200 g for 10 min at room temperature
and the aqueous phase removed and precipitated with 0.6 volumes isopropanol at
room temperature. The precipitated nucleic acids were then pelleted by
centrifugation at 1,000 g for 5 min and re-dissolved in 50 pi TE buffer (10 mM
Trizma base, 10 mM boric acid and 1 mM EDTA, pH 8.0) containing 50 pg/ml
Rnase A. The fragmented DNA was separated by agarose gel electrophoresis on a
1.4 % (w/v) agarose, 0.5 x TBE (10 mM Trizma base, 10 mM boric acid and 1 mM
EDTA, pH 8.3) gel. The gel was run for 2 h at 75 V and stained using ethidium
bromide (0.5 pg/ml).
2.1.9 Cell viability and recovery
Cell viability was determined as the ability to exclude trypan blue dye (10 pi of
cells:40 pi of trypan blue) using microscopic examination of treated cells. Cell
recovery was determined by counting the number of granulocytes occupying 25
squares of the haemocytometer. From this value the percentage of cells retrieved
after the experiment, compared with the number of cells added to each well initially
was estimated. Thus, at an initial cell concentration of 2 x 106/ml, cell recovery was
calculated using the following formula: Recovery = No of cell in 25 squares/200.
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2.1.10 Assessment of Cell Membrane Integrity
Samples of treated cells (150 ml cells at 2 x 106/ml) were centrifuged and
resuspended in 150 pi of propidium iodide solution (33 pg/ml propidium iodide in
PBS containing 1.67 pg/ml Rnase). Cells were incubated for 5 min before analysis
using an EPICS Profile II (Coulter Electronics, Luton, U.K.). Heat-treated (necrotic
cells) from the same samples were used as controls (See Chapter 5, Figure 5.8).
2.1.11 Elecromobility Shift Assay
EMSAs were carried out as described by the manufacturer (Promega Corp,
Southampton). Nuclear extracts were prepared from 5 x 106 cells using a
modification of the method of Dignam et al., (1983). Pelleted cells were
resuspended in 200 pi hypotonic buffer (buffer A; 10 mM Tris-HCl, pH 7.8, 1.5 mM
NaEDTA, 10 mM KC1, 0.5 mM dithiothreitol, 1 pg/ml aprotinin, leupeptin, and
pepstatin A, 1 pM 4-(2-aminoethyl)benzenesulfonyl fluroride, 1 mM sodium
orthovanadate, 0.5 mM benzamidine and 2 mM levamisole) and placed on ice for 10
min. Following the addition of 0.1 volumes of 10 % NP-40 (v/v) the cells were
vortexed briefly and centrifuged at 12,000 g for 2 min at 4 °C. The supernatant was
discarded and the pellet washed in 100 pi buffer A minus NP-40 and recentrifuged.
The pelleted nuclei were then resuspended in 50 pi hypertonic buffer (20 mM Tris-
HCl, pH 7.8, 150 mM NaCl, 50 mM KC1, 1.5 mM EDTA, 5 mM dithiothreitol, 1
pg/ml aprotinin, leupeptin and pepstatin A, 1 mM 4-(2-aminoethyl(benzenesulfonyl
fluoride, 1 mM sodium orthovanadate, 0.5 mM benzamidine and 2 mM levamisole)
and stored at -80 °C until use
Nuclear extracts (approximately 2 pg protein, 7 x 105 cell equivalent in 7 pi) were
incubated in binding buffer (4 % glycerol, 1 mM MgCB, 0.5 mM EDTA, 0.5 mM
dithiothreitol, 50 mM NaCl, 10 mM Tris-HCl, pH 7.5, with 50 pg/ml
poly(dI.dC)(dI.dC) with 0.017 pM of y32P-labelled double stranded oligonucleotide
containing the decameric kB binding site at room temperature for 20 min prior to
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addition of 5 pi loading buffer (0.01 % bromophenol blue, 20 % Ficoll 400 (w/v) and
1 mM EDTA). Samples were loaded onto an 8 % native acrylamide gel in 0.5 x TBE
buffer and run at 250 V for 2 h. The gel was then dried using 3M Whatman paper
and exposed to BioMax MS-1 X-ray film. Processed films were analysed using
Grablt and GelPlate software.
2.1.12 Statistical Analysis
All data are presented as mean +/- SEM of the indicated number of experiments.
Data were analysed by the student's t-test and where appropriate by one way analysis




Reagents were obtained from the following suppliers:-
Affinity, (Exeter, UK); AI2PGJ2 (dissolved in DMSO at 10 mM and stored at -20
°C), 15-deoxy12PGJ2 (dissolved in DMSO at 10 mM and stored at -20 °C), SN50
(dissolved in H20 at 10 mg/ml and stored at -20 °C), and SN50M (dissolved in H20
at 10 mg/ml and stored at -20 °C).
Alexis Corporation, (Nottingham UK); GEA 3162 (dissolved in H20 at 30 mM
and stored at 4 °C).
Amersham, (Buckinghamshire, UK); [y-32P]ATP (3,000 Ci/mM) and Igepal-C630.
Bachem, (Saffron Walden, UK); ZVAD-fmk (dissolved in DMSO at 100 mM and
stored at -20 °C).
Baxter Healthcare Ltd, (Ballieston, Glasgow, Scotland, UK); Diff-Quik™ stain
Solution I (Eosin G in phosphate buffer, pEl 6.0), Solution II (Thiazine blue in
phosphate buffer, pEl 6.0), saline solution, 0.9% (sterile).
Bender MedSystems, (Vienna, Austria); Fluorescein isothianate (FITC)-labelled
recombinant human Annexin V.
Calbiochem-Novabiochem Ltd (Beeston, Nottingham, UK); Ro31-8220 was
dissolved in DMSO at 1 mM and stored at 4 °C
Cascade Biochem Ltd (Reading, Berkshire, UK); prostaglandin D2 (PGD2)
(dissolved in ethanol at 2.84 mM and stored at -20 °C), 11-deoxy prostaglandin Ei
(PGEi) (dissolved in ethanol at 2.95 mM and stored at -20 °C), prostaglandin F2a
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(PG F2a) (dissolved in ethanol at 2.83 mM and stored at -20 °C) and leukotriene B4
(dissolved in ethanol at 3 mM and stored at -20 °C).
Dako Corporation, (Buckinghamshire, UK); FITC-conjugated F(ab')2 fragments
of rabbit anti-mouse immunoglobulin (Ig).
David Ball Laboratories, (Warwick, UK); dexamethasone (stored at 4 °C at a stock
concentration of 8.3 mM.
Dynal (UK) Ltd, (Wirral, UK); dynabeads M-450 sheep anti-mouse IgG (supplied
as 4 x 108 beads/ml in PBS pFI 7.4 with 0.1% human serum albumin and 0.2 %
sodium azide.
Genzyme Diagnostics, (Kent, UK); recombinant human granulocyte-macrophage
colony-stimulating factor (GM-CSF) (dissolved in PBS without divalent cations at
1000 U/ml and stored at -70 °C).
Gibco Life Technologies, (Paisley, Scotland, UK); Flanks balanced salt solutions
(HBSS), pH 7.4, HBSS with 1.2 mM Ca2+ and 0.8 mM Mg2+, pH 7.4 (HBSS with
divalent cations), Iscove's Dulbecco's modified Eagles medium without supplement
with L-glutamine (Iscove's DMEM) and culture supplements, penicillin (50 U/ml),
and streptomycin (50 U/ml), and phenol.
Marindale Pharmaceuticals, (Romford, UK); calcium chloride.
Peprotech, Inc (Rocky Hill, N. J., USA); eotaxin (stored at 0.1 mg/ml at -80 °C).
Pharmacia Fine Chemicals, (Uppsala, Sweden); percoll, and poly(dI.dc)(dI. dc).
Phoenix Pharmaceuticals, (Gloucestershire, UK); sterile 3.8% sodium citrate
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R&D Systems Europe Ltd, (Oxon, UK); TNF-a (dissolved in PBS at 10 pg/ml
and stored at - 80 °C), IL-10 (dissolved in PBS at 1 pg/ml and stored at - 80 °C) and
RANTES (dissolved in PBS at 10 pg/ml and stored at -80 °C).
Roche Products Ltd, (Welwyn Garden City, Herts, UK); Ro-31-8220 (dissolved
in DMSO at 30 mM and stored at 4 °C).
Schering Health Care, (West Sussex, UK); ZK 118.182 (dissolved in DMSO at 10
mM and stored at -20 °C).
Sigma Chemical Company, (Poole, Dorset, UK); Dulbecco's phosphate buffered
saline (PBS) sterile, endotoxin-free, pH 7.4, PBS with 1.2 mM Ca2+ and 0.8 mM
Mg2+, trypan blue, propidium iodide, cycloheximide (dissolved in DMSO at 10 mM
and stored at 4 °C), dextran-500 (dissolved in sterile 0.9% saline (6% w/v) and stored
at 4 °C), dimethyl sulphoxide (DMSO), N6, 2'-0-dibutyrladensine 3L5"-cyclic
monophosphate (dibutyryl-cAMP) (dissolved in Iscove's DMEM at 20 mM and
stored at -20 °C), lipopolysaccharide (LPS; E Coli 0127:B8) (dissolved in PBS at 1
mg/ml, sonicated (ultrawave sonic bath, Belmont Instruments, Glasgow, UK) and
stored at -20 °C), thapsigargin (dissolved in DMSO at 10 mM and stored at - 20 °C),
gelatin, paraformaldehyde, guanidine hydrochloride, N-lauroyl sarcosine,
chloroform, TRIZMA base, boric acid, ethylenediaminetetraacetic acid (EDTA),
RNase A, ethidium bromide, dithiothreitol (dissolved in H2O at 50 mM and stored at
4 °C), aprotinin (dissolved in H2O at 100 pg/ml and stored at -20 °C), leupeptin
pepstatin A (dissolved in methanol at 100 pg/ml and stored at -20 °C), 4-(2-
amonoethyl)-benzenesufonyl fluoride (dissolved in H2O at 50 mM and stored at -20
°C), sodium orthovanadate (dissolved in H2O at 100 mM and stored at -20 °C),
benzamidine (dissolved in H2O at 50 mM and stored at -20 °C), levamisole
(dissolved in H2O at 200 mM and stored at - 20 °C), bromophenol blue,
prostaglandin E2 (dissolved in ethanol at 3 mM and stored at - 20 °C), prostaglandin
A2 (dissolved in ethanol at 2.99 mM and stored at - 20 °C), prostaglandin J2
(dissolved in ethanol at 2.99 mM and stored at -20 °C), gliotoxin (dissolved in
DMSO at 2 mg/ml), methylthiogliotoxin (dissolved in DMSO at 2 mg/ml),
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pyrrolidine dithiocarbamate (PDCT) (dissolved in PBS at 300 mM and stored at - 20
°C), and Tosyl-Phe-chloromethylketone (TPCK) (dissolved in ethanol at 50 mM and
stored at - 20°C).
The hybridoma clone 3G8 (CD16) was a generous gift from Dr. J. Unkeless, Mount
Sinai Medical School, NY.; 5-oxo-ETE was synthesised from arachidonate by Dr. J.
O'Flaherty and Dr. A. G. Rossi as previously described (O'Flaherty & Rossi, 1993,
O'Flaherty et al., 1993).
All other chemicals were of molecular, reagent or cell culture grade and were
obtained from BDH, (Leicestershire, UK).
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CHAPTER 3
THE MODULATION OF GRANULOCYTE APOPTOSIS BY
INFLAMMATORY MEDIATORS
3.1 Introduction
Apoptosis is thought to play a major role in the processes of inflammatory resolution
by allowing the removal of effete cells without the release of intracellular contents,
which, by itself constitutes an inflammatory stimulus (Section 1.4, 1.5 and 1.6).
However, the physiological mediators that drive this process in granulocytes remain
ill defined. Most inflammatory mediators investigated increase the longevity of
inflammatory cells (Lee et ah, 1993). Cytokines released by inflammatory cells and
likely to be present at an inflammatory site, such as TNF-a, GM-CSF and IL-5, are
known to prolong granulocyte life span (Colotta, et ah, 1992, Alam et al, 1994a,
Murray et ah, 1997) but others are likely to be important. Few studies have
considered the role of other factors, such as eicosanoids and chemokines in
controlling the longevity of neutrophils and eosinophils. We therefore examined the
effects of other inflammatory mediators on the rate of constitutive apoptosis of these
cells in vitro.
The inhibition of apoptosis by cytokines and other mediators may be due to the
synthesis of survival proteins. Cycloheximide, an inhibitor of protein synthesis, can
either block the induction of apoptosis, promote it, or have no effect, depending on
the cell type studied (Cohen et al., 1992). For example, in thymocytes treated with
glucocorticoids or irradiation, cell death is delayed by protein synthesis inhibitors,
suggesting that the cell-death pathway is protein synthesis dependent (Cohen &
Duke, 1984, Wyllie et al., 1984, Kizaki et al., 1989). In granulocytes, protein
synthesis inhibitors induce apoptosis, and therefore cell death may be held in check
by survival proteins (Whyte et al., 1997).
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Glucocorticoids are the most potent and effective agents for controlling chronic
inflammatory diseases (Goulding & Guyre, 1993); little is known of the mechanisms
involved, although they are known to modulate gene transcription (Beato, 1989).
Dexamethasone, a synthetic glucocorticoid, inhibits apoptosis in neutrophils, while
inducing cell death in eosinophils (Cox, 1995, Meagher et ah, 1996, Cox & Austin,
1997). While this would explain the therapeutic efficiency of steroids in eosinophilic
inflammation, it does not account for their efficacy in other inflammatory diseases.
Other inflammatory mediators such as lipopolysaccharide (LPS) inhibit apoptosis in
both neutrophils and eosinophils (Colotta et ah, 1992, Takanaski et ah, 1994).
Neutrophil responses to LPS include actin assembly, chemotaxis, adherence and the
ability to prime for enhanced secretory responses to other stimuli such as platelet
activating factor (PAF) (Kitchen et ah, 1996, Nick et ah, 1996).
During extravasion from the peripheral blood to the tissues, granulocytes will come
into contact with other factors that may activate, or affect the lifespan of these cells.
RANTES and eotaxin are chemokines that act as direct eosinophil chemoattractants
(Kameyoshi et ah, 1992, Rot et ah, 1992, Meurer et ah, 1993, Ebisawa et ah, 1994,
Jose et ah, 1994a, b, Schroder et ah, 1994, Garcia-Zepeda et ah, 1996). RANTES
induces mild activation of eosinophils in vitro-, it increases cationic protein release,
O2" production, and induction of a hypodense phenotype (Rot et ah, 1992, Alam et
ah, 1993, Schweizer et ah, 1994); it is also synthesised and released by human
eosinophils (Lim et ah, 1995).
Eotaxin was first isolated as an eosinophil chemoattractant in a guinea pig model of
asthma and cloned in 1996 (Griffiths-Johnson et ah, 1993, Jose et ah, 1994a, b,
Rothenberg et ah, 1994, Ponath et ah, 1996). It is constitutively expressed at high
levels in normal human small bowel and colon while detectable levels are also found
in the lungs; however it is upregulated in certain human inflammatory diseases
(Garcia-Zepeda et ah, 1996).
Eotaxin and human RANTES elevate [Ca2+]j in human eosinophils. Both chemokines
bind to the CCR3 chemokine receptor and therefore may have similar effects on
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human eosinophils in vitro (Jose et ah, 1994a, Rothenberg et ah, 1995, Ponath et ah,
1996, Premack & Schall, 1996).
Granulocytes themselves synthesise and release chemotactic inflammatory
mediators, many of which are metabolites of arachidonic acid (AA). There are
various pathways by which AA can be metabolised to products with biological
activity. For example, leukotriene B4 (LTB4), a product of the 5-lipoxygenase
pathway, is among the most potent neutrophil chemotactic factors and is produced by
neutrophils, eosinophils, macrophages, mast cells, and endothelial and other cell
types (Chatila et al., 1989, Borgeat & Naccache, 1990, Nolan et al., 1990). LTB4
rapidly activates neutrophils and is a potent stimulus for chemotaxis, homotypic and
heterotypic adhesion, diapedesis, O2" generation, and degranulation (Ford-Hutchison
et al., 1980, Samuelsson et al., 1987, Rossi et al., 1988, Tonnesen et al., 1989, Lewis
et al., 1990, O'Flaherty et al., 1991, Henderson, 1994). A rapid, transient rise in
[Ca2+]j is seen after activation with LTB4 (Naccache et al., 1985, Rossi et al., 1988,
O'Flaherty et al., 1991). LTB4 primes neutrophils and like other priming agents has
been found to inhibit neutrophil apoptosis (Gay et al., 1984, Stewart et al., 1991,
Hebert et al., 1996). High affinity binding sites for LTB4 have been identified in
human neutrophils (Kriesle & Parker, 1983, Goldman & Goetzl, 1984, O'Flaherty
al., 1994). While LTB4 has potent activity on human neutrophils, it is only weakly
active on human eosinophils (Morita et al., 1989, Richards et al., 1991, Powell et al.,
1995). In these cells, LTB4 stimulates chemotaxis and the oxidative burst, but not
degranulation (Palmblad et al., 1984).
Another product of the 5-lipoxygenase pathway, 5-oxo-6, 8,11,14-eicosatetraenoic
2_|_ ... . . .acid (5-oxo-ETE), stimulates [Ca ]i mobilisation, chemotaxis and aggregation in
neutrophils and has similar effects on eosinophils (O'Flaherty et al., 1993, 1994,
1996, O'Flaherty & Rossi, 1993, Powell et al., 1993, 1995, Schwenk & Schroder,
1995). It is synthesised by both granulocytes (Powell et al., 1992, 1995). 5-oxo-ETE
stimulates the expression of adhesion molecules on neutrophils and may therefore
influence the infdtration of neutrophils into inflammatory sites (Powell et al., 1997).
5-oxo-ETE does not cause neutrophils to produce O2", but it primes PAF-induced 0{
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release and GM-CSF or TNF-a degranulation responses (O'Flaherty & Rossi, 1993,
O'Flaherty et al., 1994). Little is known about the specificity of the cellular
recognition mechanism for 5-oxo-ETE and its precursor 5 (S)-HETE. Although they
are less active than LTB4 on neutrophils, studies using cross-desensitisation and an
LTB4 antagonist showed that 5 (S)-HETE and 5-oxo-ETE do not act through the
LTB4 receptor (O'Flaherty & Rossi, 1993, Powell et al., 1993, O'Flaherty et al.,
1994).
The synthesis of other metabolites such as prostaglandins is detailed in Figure 1.1.
There are five primary active PG metabolites, prostaglandin E2 (PGE2),
prostaglandin F2« (PGF201), prostaglandin I2 (PGI2), prostaglandin D2 (PGD2) and
thromboxane A2 (TXA2) (Pierce et al., 1995a). Both neutrophils and eosinophils
synthesise, to varying degrees, some of these prostaglandins (Hubscher, 1975,
Goldstein et al., 1977).
PGEs inhibit the production of O2", chemotaxis, aggregation, and lysosomal enzyme
release in neutrophils (Zurier et al., 1974, Marone et al., 1980, Babior et al., 1981,
Fantone & Kinnes, 1983, Ham et al., 1983, Sedgwick et al., 1985, Ney & Schror,
1991,). PGE2 inhibits both opsonised zymosan-induced LTB4 release and FMLP-
induced O2 release in neutrophils and degranulation responses to LTB4 and PAF
(Rossi & O'Flaherty, 1989, Wheeldon & Vardey, 1993). In eosinophils, PGE2
weakly inhibits FMLP-induced eosinophil cationic protein (ECP) release and also
stimulates migration, but it does not raise [Ca2+]i (Butchers & Vardey, 1990, Raible
et al., 1992).
PGE2 is thought to suppress neutrophil function and inhibit neutrophil apoptosis
through elevation of cAMP levels (Ottonello et al., 1995, Rossi et al., 1995, Walker
et al., 1997). It also delays apoptosis of U937 cells by the same mechanism, but it
induces programmed cell death in thymocytes (McConkey et al., 1990, Heidenreich
et al., 1996).
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PGE2 can be further metabolised to prostaglandin A2 (PGA2) which is produced by
the enzymatic dehydration of PGE2, or from non-enzymatic dehydration in aqueous
solutions (Ohno et ah, 1986, Fukushima, 1990, 1992, Noyori & Suzuki, 1993).
Cyclopentenone prostaglandins such as PGA2 have antiproliferative effects on
various cultured tumour cells (Narumiya & Toda, 1985, Ohno et ah, 1986). Although
PGE2 increased cAMP during studies of its effects on growth inhibition, PGA2 did
not, suggesting that cAMP was not involved in PGA2 activity (Willey et ah, 1983,
Narumiya & Toda, 1985, Ohno et ah, 1986). PGA2 is actively transported into cells
by a specific carrier and accumulates in the nucleus by a temperature-sensitive
process (Narumiya et ah, 1986, 1987, Narumiya & Fukushima, 1986). The uptake
and accumulation correlates closely with growth inhibition. Therefore, these effects
may be due to influences on gene activation or transcription via nuclear receptors.
PGA2 has been demonstrated to cause apoptosis in murine leukaemia L1210 cells,
but there are no reports on its effects on granulocyte lifespan (Kim et ah, 1993).
PGD2 is formed in virtually all mammalian tissues and has diverse biological effects
(Ito et ah, 1989). It is the major product of arachidonic acid metabolism in human
mast cells in which it is selectively produced and released after immunological
challenge (Lewis et ah, 1982, Hardy et ah, 1984, Peters et ah, 1984). Both
neutrophils and eosinophils produce PGD2 (McGuire & Sun, 1980, Kroegel &
Matthys, 1993). This PG is considered to be an important mediator in allergic
disorders such as allergic rhinitis and is found in the airways of patients with allergic
asthma after antigen challenge (Murray et ah, 1986, Johnson et ah, 1993). However,
the biological effects elicited by PGD2 show considerable species variability (Giles
& Leff, 1988).
PGD2 inhibits 02" release in neutrophils stimulated by FMLP, but has no stimulatory
effect on its own (Johnson et ah, 1985, Simpkins et ah, 1990). PGD2 has no effect on
9+
the initial increase in [Ca ]j in FMLP-stimulated neutrophils, but causes a more
rapid decrease in elevated [Ca2+]j. However, dbcAMP, a non-hydrolysable, cell-
permeable cAMP analogue, produced similar results to PGD2 leading to the
suggestion that PGD2 increases cAMP levels in neutrophils (Simpkins et ah, 1990).
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PGD2 inhibits opsonised zymosan-induced LTB4 release, FMLP-induced O2" release,
lysosomal enzyme release, and LTB4 and PAF-induced degranulation in neutrophils
(Zurier et al., 1974, Ham et al., 1983, Rossi & O'Flaherty, 1989, Ney & Schror,
1991, Wheeldon & Vardey, 1993). This prostanoid also has biological activity on
9+
eosinophils, in which it stimulates Ca mobilisation, and primes eosinophils for
enhanced release of LTC4 in response to the calcium ionophore A23187 (Raible et
al., 1992). In addition, it reduces the number of circulating blood eosinophils and is
chemotactic for eosinophils in a dog trachea animal model (Marsden et al., 1984,
Emery et al., 1989).
The metabolic fate of PGD2 has been extensively investigated in vivo in primates
including humans (Ellis et al., 1979, Liston & Roberts, 1985a, b, Roberts &
Sweetman, 1985). Products of PGD2 metabolism include other cytopentenone PGs
with biological activity such as 9-deoxy-A9-PGD2 (PGJ2), A12-PGJ2 and 15-deoxy-
AI2,AI4TGJ2 (15dPGJ2) (Fitzpatrick & Wynalda, 1983, Kikawa et al., 1984, Ito et al.,
1988). Early work suggested that PGD2 could inhibit the growth of rodent and
human tumour cells (Fitzpatrick & Stringfellow, 1979, Fukushima et al., 1982a, b,
Simmet & Jaffe, 1983, Sakai et al., 1984). However, further studies demonstrated
that PGD2 per se was inactive in these studies, and that the cyclopentenone
metabolites of PGD2 were the active forms (Fukushima et al., 1982a, Narumiya &
Fukushima 1985).
A large problem in defining the effects of PGD2 is the biological activity of some of
these possible metabolites. A metabolically stable prostaglandin D2 mimetic,
(5Z, 13E)-(9R, 11R, 15S)-9-chloro-15-hydroxy-16,17,18,19,20-pentano-3-oxa-5,13-
prostadienoic acid, (ZK 118.182) has been synthesised (Schulz et al., 1990). This
compound caused a concentration-dependent activation of adenylate cyclase,
comparable to PGD2, and it also concentration-dependently reduced FMLP- or PAF-
induced O2" release and degranulation responses in human neutrophils (Darius et al.,
1994). ZK118.182 might therefore help to distinguish between cellular responses to
PGD2 and its metabolites.
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PGJ2 is one such PGD2 metabolite formed by albumin transformation of PGD2. It
has known biological activity and has been demonstrated to inhibit platelet
aggregation and produce vasodilation (Coleman et al., 1990). PGJ2 has anti-tumour
effects in vivo, and stimulates TNF-a release from LPS-activated monocytes (Vedin
et al., 1996).
Another metabolite, A12-PGJ2, has been reported to have potent growth inhibitory
activities in some tumour cells, but unlike PGD2, it does not elicit an increase in
cAMP levels when used in growth inhibition studies (Mahmud et al., 1984,
Narumiya & Fukushima, 1985, Ohno et al., 1986). A12-PGJ2 is also actively
transported into cells by a specific carrier and accumulates in the nucleus (Narumiya
& Fukushima, 1986, Narumiya et al., 1986). Binding of this molecule to nuclear
proteins appears to regulate the expression of specific genes that are responsible for
growth inhibition since, as is the case for PGA2, nuclear accumulation correlates with
growth inhibition (Narumiya et al, 1987). A12-PGJ2 induces apoptosis in human
hepatocarcinoma SK-F1EP-1 cells and in murine leukaemia L1210 cells (Kim et al.,
1993, Lee et al., 1995a). The molecular mechanisms by which A12-PGJ2 causes cell
death have not been determined.
15-dPGJ2, another PGD2 metabolite, like PGJ2, stimulates TNF-a release from LPS-
activated monocytes (Vedin et al., 1996). This metabolite is formed via prostaglandin
D2 synthase, which is highly expressed in macrophages and specialised antigen-
presenting cells (Urade et al., 1989). 15-dPGJ2 also binds to a nuclear receptor and
appears to stimulate or repress transcription of target genes especially, those involved
in lipid metabolism (Forman et al., 1995, Kliewer et al., 1995, 1997, Krey et al.,
1997).
PGF2a is identical to PGD2 except that PGF2a has a hydroxyl group instead of a
carbonyl group at the CI 1 position (Simpkins et al., 1990). PGF2a is reported to have
inhibitory effects on neutrophils. It impedes 02" production, opsonised zymosan-
induced LTB4 release and FMLP-induced 02" release (Gryglewski et al., 1987,
9+ •
Wheeldon & Vardey, 1993). PGF2a reportedly elevates [Ca ]j levels in neutrophils
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and is known to stimulate eosinophil migration, but there are no reports of its effects
on granulocyte survival (Ito et ah, 1990).
Almost all the inflammatory mediators discussed above have been demonstrated to
94-
affect either intracellular cAMP or [Ca ]j levels. Cyclic AMP can regulate certain
eosinophil functions, such as inhibition of degranulation, thromboxane and LTC4
generation, O2" production and apoptosis (Dent et al., 1991, Kita et al., 1991, Munoz
et al., 1994, Souness et al., 1994, Hallsworth et al., 1996, Cousin et al., 1997). It
inhibits apoptosis in cultured rat sympathetic neurones (Edwards et al., 1991, Nobes
& Tolkovsky, 1995) and rat phaetochromocytoma PC 12 cells (Michel et al., 1995),
and human neutrophils (Rossi et al., 1995), but induces apoptosis in rat primary
granulosa cells (Keren-Tal et al., 1995) and in resting human B lymphocytes (Lomo
et al., 1995).
Studies using lymphoid cells implicate increases in [Ca2+]i in the triggering of
2+ . 9_|_
apoptosis. For example, elevation of [Ca ], using Ca ionophores induces apoptosis
in thymocytes (Cohen & Duke, 1984, Durant et al., 1980, McConkey et al., 1989,
Wyllie et al., 1984). However, neutrophil apoptosis is delayed by inflammatory
mediators associated with [Ca2+]j mobilisation (Lew et al., 1987, Smith et al., 1987,
Korchak et al., 1988). The Ca2+ ionophore A23187 inhibits neutrophil apoptosis
while chelation of [Ca2+]j promotes it (Whyte et al., 1993b). For eosinophils, the
converse is true; agents that elevate [Ca2+]j promote eosinophil apoptosis (Cousin et
al., 1997).
Although many researchers have investigated the role of pro-inflammatory cytokines
in granulocyte survival, few have considered the effects of chemokines and AA
metabolites on the fate of these cells. Many chemotaxins act to down-regulate
granulocyte function when present in high concentrations; prostaglandins and other
eicosanoids have various effects as detailed above. This study therefore investigated
the role of these mediators on neutrophil and eosinophil apoptosis with the specific
aim of dissecting possible underlying regulatory mechanisms involved in the
apoptotic programme of these closely related granulocytes.
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3.2 Results
3.2.1 The Effect of Cycloheximide, Dexamethasone and LPS on Granulocyte
Apoptosis
The onset of apoptosis in granulocytes can be recognised by morphological changes
such as chromatin condensation and cytoplasmic shrinkage, using oil immersion
microscopy. Examples of apoptotic and normal morphology of neutrophils and
eosinophils are shown in Figures 5.4 and 5.5 (See Chapter 5). Time courses for
constitutive apoptosis in both cell types are shown in Figure 3.1. Eosinophils are
known to survive for longer periods than neutrophils in the tissues; Figure 3.1
illustrates that this is also true of cultured cells. For example neutrophils cultured
for 20 h exhibit 69.7 ± 6.8 % apoptosis whereas eosinophils exhibited only 13.4 ±
1.8 % at the same time point.
Cycloheximide accelerates the apoptotic process in neutrophils (Figure 3.2 A), where
apoptosis was increased from 63.6 ± 7.5 % to 80.8 ± 5.3 % in cycloheximide-treated
cells at 20 h. Eosinophils were also susceptible to the effects of protein synthesis
inhibition with apoptosis increased from 11.8 ± 3.0 % to 88.5 ± 7.7 % at 20 h (Figure
3.2 B). These data suggest that the survival of granulocytes may depend on synthesis
of one or more proteins that suppress the process of programmed cell death, in
striking contrast to the case in T cells, where protein synthesis inhibitors protect
against apoptotic stimuli.
As shown in Figure 3.3 A and B, dexamethasone, a synthetic glucocorticoid,
significantly inhibits neutrophil apoptosis at 20 h, (65.4 ± 3.0 % control; 42.5 ±3.3
% with dexamethasone treatment) while significantly increasing programmed cell
death in eosinophils at both 20 and 40 h. For example, in eosinophils, control
apoptosis at 40 h was 28.2 ± 6.9 % compared with 63.7 ±11.8 % in dexamethasone
treated cells. These data suggest that apoptosis in neutrophils and eosinophils is
differentially regulated, notwithstanding their ontogenic and functional similarities
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and that inflammatory mediators may have dissimilar effects on the rate of apoptosis
in specific inflammatory cells.
LPS dramatically inhibits neutrophil apoptosis by 20 h with constitutive apoptosis
reduced from 53.6 ± 5.5 % to 20.6 ± 1.9 % with LPS treatment, an inhibition of
greater than 50% (Figure 3.4 A). In eosinophils (Figure 3.4 B) there was no
significant inhibition at the early 20 h timepoint, but by 40 h a significant decrease in
programmed cell death had occurred indicating that LPS, a potent stimulus for
initiating the innate inflammatory response, is a survival factor in both types of
granulocytes.
3.2.2 The Effect of the Chemokines RANTES and Eotaxin on Granulocyte
Apoptosis
Figures 3.5 and 3.6 illustrate the effects of RANTES and eotaxin respectively on
granulocyte apoptosis. Because both of these chemokines are considered to be
chemotactic for eosinophils but not for neutrophils, it was expected that only
eosinophils would show responses to these factors. However, as indicated in Figures
3.5 B and 3.6 B neither RANTES nor eotaxin significantly affected the constitutive
rate of eosinophil apoptosis. However, while the constitutive rate of neutrophil
apoptosis was unaltered by eotaxin (Figure 3.6 A), the higher concentrations of
RANTES (10 and 100 nM), (Figure 3.5 A) showed a small but significant inhibition






Figure 3.1 Constitutive Apoptosis in Granulocytes
Neutrophils (5 x 106/ml) and eosinophils (2 x 106/ml) were incubated in Iscove's
DMEM supplemented with 10% autologous serum and harvested at various
timepoints as shown above. Apoptosis was assessed morphologically. Data




Figure 3.2 The Effect of Cycloheximide on Constitutive Granulocyte
Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or in the presence of
cycloheximide (50 pM) and harvested at 20 h. Apoptosis was assessed
morphologically. Data represent the mean ± SEM of 7 separate experiments for
neutrophils, and 4 separate experiments for eosinophils. All experiments were
performed in triplicate (* p < 0.05 compared with control values).
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Time (h)
Figure 3.3 The Effect of Dexamethasone on Constitutive Granulocyte
Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with dexamethasone (1
pM) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 7 separate experiments for neutrophils, and 4 separate experiments
for eosinophils. All experiments were performed in triplicate (* p < 0.05 compared
with control values).
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Figure 3.4 The Effect of Lipopolysaccharide on Constitutive Granulocyte
Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with LPS (1 pg/ml) and
harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars represent
treated cells. Apoptosis was assessed morphologically. Data represent the mean ±
SEM of 4 separate experiments for neutrophils, and 4 separate experiments for

















































Figure 3.5 The Effect of RANTES on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with RANTES (1-100
nM) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Open bars
indicate 20 h timepoint, filled bars are results for 40 h. Apoptosis was assessed
morphologically. Data represent the mean ± SEM of 3 separate experiments for
neutrophils, and 4 separate experiments for eosinophils. All experiments were
performed in triplicate (* p < 0.05 compared with control values).
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Figure 3.6 The Effect of Eotaxin on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with eotaxin (100
ng/ml) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils, and 5 separate experiments
for eosinophils. All experiments were performed in triplicate.
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3.2.3 The Effect of the 5-Iipoxygenase products, LTB4 and 5-oxo-ETE on
Granulocyte Apoptosis
As shown in Figure 3.7 A, LTB4 significantly decreased the rate of neutrophil
apoptosis from 61.2 ± 6.3 % (control) to 43.1 ± 4.4 %. However this mediator had
no significant effect on eosinophil apoptosis at either the 20 or 40 h timepoints
(Figure 3.7 B). Similarly, 5-oxo-ETE produced a small but significant reduction in
neutrophil apoptosis at 20 h (Figure 3.8 A) but had no effect on eosinophil apoptosis
at either 20 or 40 h (Figure 3.8 B).
3.2.4 The Effect of PGE2, PGA2 and the EP2 agonist 11-deoxy PGEi on
Granulocyte Apoptosis
The prostaglandin PGE2 displayed similar effects to the 5-lipoxygenase products. As
illustrated in Figure 3.9 A and B, PGE2 inhibited neutrophil apoptosis at 20 h with a
reduction from a control value of 65.9 ± 6.6 % to 45.8 ± 6.8 % in PGE2 treated cells,
but had no effect on eosinophil survival. The enhanced survival of neutrophils was
mediated by PGE2 and not by its metabolite PGA2; Figure 3.10 A and B demonstrate
that PGA2 had no significant effect on apoptosis in either neutrophils or eosinophils.
PGE2 can bind to several subtypes of the EP receptor (discussed in Section 1.9.3)
which have been linked to different intracellular signalling pathways. We therefore
used 11-deoxy PGEi, which is an EP2 receptor agonist. This agonist produced
similar results to PGE2, inhibiting neutrophil apoptosis from 65.3 ± 6.9 % in control
cells to 50.3 ± 7.0 % in treated cells, but having no significant effect on eosinophil




Figure 3.7 The Effect of LTB4 on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with LTB4 (300 nM)
and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils, and 3 separate experiments
for eosinophils. All experiments were performed in triplicate (* p < 0.05 compared
with control values).
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Figure 3.8 The Effect of 5-oxo-ETE on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with 5-oxo-ETE (300
nM) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils, and 5 separate experiments
for eosinophils. All experiments were performed in triplicate (* p < 0.05 compared
with control values).
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Figure 3.9 The Effect of PGE2 on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with PGE2 (10 pM)
and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 4 separate experiments for neutrophils, and 3 separate experiments











































Figure 3.10 The Effect of PGA2 on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with PGA2 (10 pM)
and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils, and 3 separate experiments
for eosinophils. All experiments were performed in triplicate.
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Figure 3.11 The Effect of 11-deoxy PGEi on Constitutive Granulocyte
Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with 11 deoxy-PGEi
(10 pM) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled
bars represent treated cells. Apoptosis was assessed morphologically. Data represent
the mean ± SEM of 4 separate experiments for neutrophils, and 3 separate
experiments for eosinophils. All experiments were performed in triplicate (* p < 0.05
compared with control values).
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3.2.5 The Effect of PGD2, the PGD2 Mimetic ZK118.182, PGF2ct and PGJ2 on
Granulocyte Apoptosis
As shown in Figure 3.12 A, PGD2 had no effect on neutrophil apoptosis, though it
significantly and dramatically increased the rate of eosinophil programmed cell death
at 20 and 40 h. For example, at 40 h PGD2 increased control apoptosis from 19.9 ±
5.0 % to 83.7 ± 5.5 % in eosinophils. To directly demonstrate the efficacy of the
PGD2 effect, experiments were performed with PGD2 and dexamethasone on the
same day with the same donors. Figure 3.13 compares eosinophil apoptosis driven
by dexamethasone, an inhibitor of eosinophil survival (See Figure 3.3 B), with
PGD2. At 20 h, control apoptosis was 13.7 ± 5.6 %, apoptosis induced by
dexamethasone 21.7 ± 8.8 %, and PGD2 induced a rate of apoptosis of 49.3 ±8.1 %.
This result shows for the first time that PGD2 is a powerful inducer of programmed
cell death in eosinophils.
However, as already discussed, PGD2, like PGE2, can be metabolised to various
biologically active breakdown products. Therefore to further characterise this result,
the effect on granuloctye apoptosis of ZK118.182, a stable PGD2 mimetic, was
examined. This compound would allow investigation of the effects of activating the
DP receptor without the production of active PGD2 metabolites. Figure 3.14 A and B
show that ZK118.182 produced increased eosinophil apoptosis (40 h control, 14.9 ±
4.5 %; ZK118.182, 23.8 ±6.1 %) but in contrast to PGD2, it significantly inhibited
apoptosis in neutrophils from 50.0 ±6.1 % to 19.1 ±3.3 % in treated cells. This
suggests that activation of the DP receptor by PGD2 should cause elevated levels of
apoptosis in eosinophils, but decrease neutrophil programmed cell death.
PGD2 has been shown to bind to other prostanoid receptors such as the FP receptor,
which also binds PGF2a. PGF2a inhibits several functional activities in human
neutrophils but little is known of its effects on eosinophils. As shown in Fig 3.15 A
and B, there was a small, but significant increase in neutrophil survival, while at 40
h, eosinophil apoptosis was almost 50% of control values with a decrease from 12.8
± 1.0 % to 6.9 ± 0.7 % in treated cells.
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PGJ2 is an active PGD2 metabolite that is a potent and highly selective DP agonist
(Bundy et al., 1983). As demonstrated in Fig 3.16 A, PGJ2 produced similar results
to PGD2 in neutrophils, causing no significant change in the constitutive rate of
apoptosis at 20 h. Like PGD2, it significantly increased eosinophil apoptosis at both
20 h (7.7 ± 1.4 % control, to 15.7 ± 1.7 % with PGJ2 treatment) and 40 h (12.8 ± 1.0
% control, to 29.8 ± 4.2 % with PGJ2 treatment) (Fig 3.16 B). This increase is less
than that induced by the parent compound, PGD2. As shown in Figure 3.17, after 40
h of culture apoptosis in control eosinophils was 12.8 ± 1.0 %, PGJ2 produced a rate
of apoptosis of 29.8 ± 4.2 %, while PGD2 increased apoptosis to 87.9 + 3.8 %.
These results suggest that activation of the DP receptor causes elevated levels of
apoptosis in eosinophils. However, although the stable mimetic ZK118.182
increased eosinophil apoptosis, it decreased neutrophil programmed cell death. The
DP agonists PGD2 and PGJ2 did not increase neutrophil survival. Neither
ZK118.182 nor PGJ2 achieved the levels of apoptosis in eosinophils caused by
PGD2. It is therefore possible that PGD2 is metabolised by both eosinophils and
neutrophils. In the case of neutrophils, the metabolite may be inactive with regard to
apoptosis, while in eosinophils, a metabolite with more powerful pro-apoptotic
effects may be produced. Such metabolites may bind to receptors other than the DP
receptor.
3.2.6 The Effect of the PGD2 Metabolites A12PGJ2 and 15-deoxy PGJ2 on
Granulocyte Apoptosis
12
It has been previously demonstrated that A PGJ2 can induce apoptosis in other cell
types, however, there have been no prior reports of 15d-PGJ2 being associated with
programmed cell death. Neutrophils and eosinophils were therefore cultured with
1 9
these metabolites. The results for A PGJ2 and 15d-PGJ2 are shown in Figure 3.18 A
and B and Figure 19 A and B respectively. These graphs demonstrate that both
metabolites are potent inducers of programmed cell death in both granulocytes and at
i *y
all timepoints shown. A PGJ2 induced neutrophil apoptosis from 66.0 ± 6.7 % to
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91.1 ± 3.4 %, while 15d-PGJ2 increased the control rate to 89.5 ± 4.1 %. In
eosinophils at 40 h of culture, control apoptosis (32.0 ± 10.5 %) was increased
dramatically to 97.4 ± 2.3 % by AI2PGJ2 and to 99.0 ± 0.6 % by 15d-PGJ2. Therefore
17 • • • •
both A PGJ2 and 15d-PGJ2 caused increases in eosinophil apoptosis which were
similar to those achieved by PGD2, however they also had a potent stimulatory effect








Figure 3.12 The Effect of PGD2 on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with PGD2 (10 pM)
and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils, and 7 separate experiments
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Figure 3.13 A Comparison of the Effects of PGD2 and Dexamethasone on
Constitutive Eosinophil Apoptosis
Eosinophils (2 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control) (open bars), dexamethasone (1 pM) (solid bars), or with PGD2
(10 pM) (hatched grey bars) and harvested at 20 and 40 h. Apoptosis was assessed
morphologically. Data represent the mean ± SEM of 3 separate experiments. All
experiments were performed in triplicate (* p < 0.05 compared with control values).
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Figure 3.14 The Effect of the PGD2 Mimetic ZK 118.182 on Constitutive
Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with ZK 118.182 (30
pM) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
indicate treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils, and 3 separate experiments
for eosinophils. All experiments were performed in triplicate (* p< 0.05 compared
with control values).
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Figure 3.15 The Effect of PGF2a on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with PGF2a (10 pM)
and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 4 separate experiments for neutrophils, and 3 separate experiments





Figure 3.16 The Effects of PGJ2 on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with PGJ2 (10 pM) and
harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars indicate
treated cells. Apoptosis was assessed morphologically. Data represent the mean ±
SEM of 3 separate experiments for neutrophils, and 3 separate experiments for
eosinophils. All experiments were performed in triplicate (* p < 0.5 compared with
control values).
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Figure 3.17 A Comparison of the Effects of PGJ2 and PGD2 on Constitutive
Eosinophil Apoptosis
Eosinophils (2 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), or with PGJ2 (10 pM) or PGD2 (10 pM) and harvested at and
20 and 40 h. Open bars indicate 20 h timepoint, filled bars are results for 40 h.
Apoptosis was assessed morphologically. Data represent the mean ± SEM of 3
separate experiments All experiments were performed in triplicate (* p < 0.05
compared with control values).
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Figure 3.18 The Effect of A12-PGJ2 on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
• 12Iscove's DMEM supplemented with serum alone (control) or with A -PGJ2 (10 pM)
and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 4 separate experiments for neutrophils, and 4 separate experiments




Figure 3.19 The Effect of 15 deoxy-PGJi on Constitutive Granulocyte
Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with 15 deoxy-PGJ2
(10 pM) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled
bars represent treated cells. Apoptosis was assessed morphologically. Data represent
the mean ± SEM of 4 separate experiments for neutrophils, and 4 separate
experiments for eosinophils. All experiments were performed in triplicate (* p < 0.05
compared with control values).
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3.2.7 The Effect of Increased Levels of Intracellular cAMP and on
Granulocyte Apoptosis
DP receptors have been reported to activate adenylate cyclase activity causing
increases in intracellular levels of cAMP (Chapter 1, Table 1.1). In this work, the
stable, cell-permeable analogue of cAMP, dbcAMP, was used to mimic elevation of
the second messenger cAMP in both eosinophils and neutrophils. As shown in Fig
20 A and B, both granulocytes show inhibition of programmed cell death in response
to increased intracellular cAMP levels. For example, in these experiments,
neutrophil apoptosis was reduced from a control value of 58.5 ± 3.7 % to 27.4 ± 6.9
% in treated cells at 20 h, while eosinophil apoptosis was decreased from 21.8 ± 3.6
% to 4.5 ± 1.1 % at 40 h with dbcAMP treatment. This indicates that PGD2 and the


























Figure 3.20 The Effect of Increased Intracellular cAMP on Constitutive
Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with dbcAMP (0.2
mM) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils, and 3 separate experiments




The results show that both neutrophils and eosinophils undergo constitutive
apoptosis in vitro, and that this process can be modulated by a variety of agents.
Granulocyte survival appears to be dependent on de novo protein synthesis since
both cells types show enhanced rates of apoptosis when cultured with cycloheximide,
a protein synthesis inhibitor. However, this could be an indirect effect on cell
processes not directly involved in the cell death pathway.
Interestingly, the synthetic glucocorticoid, dexamethasone has differential effects on
granulocyte apoptosis. Dexamethasone inhibits neutrophil apoptosis while driving
programmed cell death in eosinophils; these results are in accordance with Meagher
et al., (1996) and others. Dexamethasone does not prime or activate neutrophils, but
still increases the survival of these cells (Cox, 1995). This enhanced survival is
prevented by co-treatment with protein synthesis inhibitors suggesting that
dexamethasone enhances neutrophil survival by the induction of a protein or proteins
(Cox & Austin, 1997).
Why glucocorticoids should have differential effects on the survival of these cells is
currently unknown. Glucocorticoid receptors are expressed in almost every type of
cell although the density of glucocorticoid receptors may differ from cell to cell,
giving different responses (Burnstein & Cidlowski, 1992). However, binding
characteristics have been shown to be similar in both neutrophils and eosinophils
(Peterson et al., 1981). The pro- and anti-apoptotic effect of dexamethasone has
been demonstrated to occur via GR receptors as the effect is not mimicked by
mineralocorticoids or steroid sex hormones and is blocked by the glucocorticoid
receptor antagonist RU486 (Meagher et al., 1996)
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Transcriptional repression of AP-1 response elements involving the physical
interaction of the GR and the transcription factor AP-1 has been described (Diamond
et al., 1990, Jonat et al., 1990, Schiile et al., 1990, Yang et al., 1990, Heck et al.,
1994). AP-1 is formed from dimers of the Jun and Fos family, usually c-Jun and c-
Fos; but other family members of AP-1 interact differently with the GR, being
positively regulated (Miner & Yamamoto, 1991, Teurich & Angel, 1995). Since
different cell types contain one or more of these AP-1-related proteins (Jun B, Jun D,
Fos B, Fra-1 and Fra-2), the AP-l/GR interaction can cause positive or negative
regulation of genes in a specific cell (Teurich & Angel, 1995). The role of AP-1 in
the control of apoptosis is controversial, but it is possible that neutrophils and
eosinophils have different profiles of AP-1 family proteins and that this could
account for differences in their responses to glucocorticoids.
Dexamethasone can enhance the expression of IkBoc, the inhibitory subunit of NF-
kB (Auphan et al., 1995, Scheinman et al., 1995a, b). However, the role ofNF-kB in
cell survival is unclear since activation ofNF-kB correlates with apoptosis in some
systems and enhanced survival in others (Grimm et al., 1996, Wu et al., 1996).
However, in granulocytes, many pro-inflammatory stimuli cause NF-kB activation.
This transcription factor regulates genes for cytokines that are associated with
enhanced survival in granulocytes such as GM-CSF (Stein et al., 1993a, b), and it is
therefore unlikely that this would lead to differential effects on granulocyte
apoptosis. However, in T cells, which also undergo apoptosis in response to
treatment with glucocorticoids, activation of the GR causes the abrupt
downregulation of c-myc RNA, and this gene is under the influence ofNF-kB (Yuh
& Thompson, 1989).
NF-kB is also known to interact with AP-1 (Stein et al., 1993a, b), causing
synergistic activation of both kB and AP-1 response elements. However, while both
AP-1 and NF-kB can be inhibited by activated GR, synergistic NF-kB/AP-1 activity
is largely unaffected (Scheinman et al., 1995b).
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Therefore the end result of GR activation by glucocorticoids may be dependent on
the spectrum of AP-1 family proteins in a specific cell, and the interactions of these
isoforms with NF-kB. If these differ between neutrophils and eosinophils, this may
account for the dissimilar effects of dexamethasone on apoptosis in these cells.
However, in dexamethasone-induced apoptosis of rat thymocytes, both AP-1 and
NF-kB were shown to be activated rather than inhibited at early timepoints, but
whether this activation was synergistic or not is unknown (Sikora et al., 1993).
LPS primes and activates both neutrophils and eosinophils, and like most priming
agents, it enhances the longevity of both cell types (Lee et al., 1993, Nick et al.,
1996). LPS, a powerful survival factor for these cells, is known to strongly activate
NF-kB in granulocytes (See Chapter 5, Figure 5.14) (McDonald et al., 1997a) which
again suggests that the dexamethasone-mediated survival of neutrophils is unlikely to
be due to NF-kB suppression.
RANTES and eotaxin are both eosinophil chemoattractants (Griffiths-Johnson et al.,
1993, Rot et al., 1992), but had no effect on the rate of eosinophil apoptosis.
Although, it was expected that neutrophils would not respond to these chemokines,
RANTES at higher concentrations did inhibit programmed cell death in these cells.
Chemokines have been traditionally divided into two main groups, C-C and C-X-C.
Generally, neutrophils are affected by C-X-C chemokines, and eosinophils primarily
by C-C chemokines (Premack & Schall, 1996). However, this division is not
complete; IL-8, a neutrophilic C-X-C chemotaxin, has been shown to be a potent
chemoattractant for activated or primed eosinophils (Sehmi et al., 1993, Villar et al.,
1993). Therefore it is possible that RANTES may bind to chemokine receptors on
neutrophils, causing a small but significant decrease in apoptosis. Another
explanation is that RANTES may cause contaminating eosinophils to release a
neutrophil survival factor, while eotaxin may not or may cause the generation of
different mediators.
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LTB4 activates neutrophils and eosinophils by binding to a cell-surface receptor
(Bomalaski & Mong, 1987, Goetzel et al., 1995, Ng et ah, 1991, O'Flaherty et ah,
1991, Alexander & Peters 1997). However, while it significantly enhanced the
survival of neutrophils, it had no effect on eosinophil apoptosis. This result for
neutrophils is in agreement with Hebert et ah, (1996). Since LTB4 is weakly active
on human eosinophils (Powell et ah, 1995), the differential apoptotic response in
granulocytes to LTB4 may reflect this.
LTB4-binding is associated with increased [Ca2+]; in neutrophils, eosinophils and
other cells, as well as an inhibition of adenylate cyclase activity (Raible et ah, 1992,
Powell et ah, 1996, Yokomizo et ah, 1997). However, it has recently been shown that
LTB4 can react with both cell-surface and nuclear receptors (Fiore et ah, 1992,
Devchand, 1996, Yokomizo et ah, 1997). Whether each type of receptor is
differentially expressed in specific cells is unknown.
5-oxo-ETE is synthesised by both eosinophils and neutrophils (Powell et ah, 1992,
1995). Although it does not act through the LTB4 receptor (Powell et ah, 1993,
O'Flaherty et ah, 1994), it produced similar results to LTB4 in these studies,
inhibiting neutrophil apoptosis but having no effect on eosinophil programmed cell
death. 5-oxo-ETE is known to increase [Ca2"]; in both types of granulocytes (Powell
et ah, 1995, 1996), but there are no reports of its effects on adenylate cyclase activity
in these cells.
The prostaglandins used in these studies produced diverse results. PGE2 is a
prostanoid with suppressive effects on neutrophil function (Rivkin et ah, 1975,
Ottonello et ah, 1995, Rossi et ah, 1995). However, this mediator significantly
enhanced neutrophil survival, but had no effect on eosinophil apoptosis. Rossi et ah,
(1995) and Walker et ah, (1997), reported that this PGE2-induced enhancement of
survival was mediated by elevation of intracellular cAMP concentration.
Eosinophils showed no significant change in rates of apoptosis in response to this
prostanoid.
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PGE2 can bind to several different EP receptor subtypes that utilise different
intracellular signalling pathways (Table 1.1). It is possible that there are differences
in types of EP receptor on neutrophils and eosinophils and that this would account
for the contrasting responses observed. However, since PGE2 may be metabolised in
culture, the results could be due to breakdown products rather than the actions of
PGE2 per se. However, the metabolite PGA2 had no effect on programmed cell
death in either cell type. The EP2 receptor agonist, 11-deoxy PGEi, produced similar
results to PGE2, indicating that EP2 is the probable receptor involved in inhibition of
neutrophil apoptosis. This receptor is known to be present on human neutrophils
(Wheeldon & Vardey, 1993), and its activation has been demonstrated to cause
increases in intracellular cAMP (Jumblatt & Peterson, 1991).
PGD2 is thought to bind to a specific DP receptor that is found on neutrophils and
eosinophils (Rossi & O'Flaherty, 1989, Butchers & Vardey, 1990, Ney & Schror,
1991, Wheeldon & Varday, 1993, Darius et al., 1994). In COS-M6 and HEK 293
cells transfected with the cloned human DP receptor, ligand-binding caused
increased cAMP production, and increased [Ca2r]; in a concentration-dependent
manner (Boie et al., 1995). However [Ca2+], rises were not observed in neutrophils
treated with PGD2 (Raible et al., 1992). Unlike other stimuli which increase [Ca2+]j
in human eosinophils, such as PAF and LTB4, PGD2 induced another secondary rise
in [Ca2^];, seen after the initial increase (Raible et al., 1992).
PGD2 is known to bind to different prostaglandin receptors; for example it has been
demonstrated to bind to the PGF2a and/or thromboxane A2 receptors (Narumiya &
Toda, 1985, Balapure et al., 1989, Hamid-Bloomfield et al., 1990). Therefore it is
possible that receptors other than DP are involved in cellular responses to PGD2.
The results shown in Figure 3.15 suggest that if it is binding to the PGF2a receptor,
an inhibition of apoptosis should have been noted in both eosinophils and
neutrophils.
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Although PGF2a, at high concentrations, has been shown to inhibit certain neutrophil
functions, and is chemotactic for eosinophils (Gryglewski et al., 1987, Wheeldon &
Vardey, 1993), this prostaglandin significantly inhibited both neutrophil and
eosinophil apoptosis and may therefore have pro-inflammatory properties. Its
structure is similar to PGD2, but PGD2 proved to be a powerful inducer of eosinophil
apoptosis, though it had no effect on neutrophil apoptosis.
The effect of thromboxane A2 on apoptosis in both cell types should be examined to
investigate whether the pro-apoptotic effects of PGD2 are mediated via the
thromboxane receptor, although there is no direct evidence for the presence of IP, FP
or TP receptors on granulocytes (Giembycz et al., 1990).
PGD2 can be rapidly metabolised, and in many studies there is confusion over
whether the results are due to this prostanoid or to its breakdown products. Such
metabolites could be inactivation products since in a number of instances they are
less active than the parent compound. In the specific case of PGD2, however, some
metabolites have been shown to be more potent with regard to several activities. It is
possible that this mediator is broken down into different products by neutrophils and
eosinophils, hence its differential effects on these cells.
PGJ2 is a PGD2 metabolite that is a potent, selective agonist on the DP receptor
(Bundy et al., 1983). This prostanoid gave similar results to PGD2, but the
enhancement of eosinophil apoptosis was significantly less than PGD2. This indicates
that activation of the DP receptor does induce eosinophil apoptosis, but does not rule
out the possibility that PGD2 may be metabolised by either cell type; and in the
eosinophil, the breakdown product is a more powerful inducer of apoptosis than the
parent compound. To address this possibility, the stable PGD2 mimetic ZK118.182
was used. This produced similar results to PGJ2 in the eosinophil, but significantly
inhibited neutrophil apoptosis, suggesting that PGD2 can be rapidly metabolised in
the neutrophil to a breakdown product with no effect on apoptosis or one which may
counteract any PGD2 mediated inhibition.
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While the results in the eosinophil are not conclusive, they are suggestive of a
metabolite with more powerful effects on apoptosis than PGJ2. The results obtained
12with A -PGJ2 and 15dPGJ2 would support this hypothesis. Both these metabolites
significantly and efficiently induced apoptosis in neutrophils and eosinophils.
Therefore, eosinophils possibly metabolise PGD2 to breakdown products with pro-
apoptotic activity, while neutrophils may not.
How A,2-PGJ2 and 15dPGJ2 induce apoptosis is unknown, but cell surface receptors
12
are not necessarily involved. Accumulating evidence indicates A -PGJ2 and PGA2
have their primary targets in the nucleus, where they regulate the expression of
specific genes. However, A12-PGJ2 dramatically induced apoptosis while PGA2 did
not, which suggests that either they have different receptors or that there are no
nuclear receptors for PGA2 in these granulocytes. Alternatively, receptor affinity
differences could be involved. Studies have shown that PGA2 nuclear binding is
reversible whereas A12-PGJ2 causes an irreversible effect via nuclear protein binding
(Narumiya et al., 1987, Ohno et al., 1988).
Possible candidates for these intracellular receptors are peroxisome proliferator-
activated receptors (PPARs). PPARs are transducer proteins belonging to the
steroid/thyroid/retinoid receptor superfamily which regulate the expression of target
genes by binding to DNA sequence elements termed PPAR response elements
(Lemberger et al., 1996). Members of one family of these receptors have all been
identified in humans; PPAR-y, PPAR-5, PPAR-a (Schmidt et al., 1992, Sher et al.,
1993, Greene et al., 1995). PPAR-a is primarily expressed in tissues that have high
fatty acid catabolism, including the liver and the immune system, while PPAR-y is
expressed in adipose tissue, adrenal gland, spleen and several myeloid cell lines
(Kliewer et al., 1994, Tontonoz et al., 1994, Greene et al., 1995, Braissant et al.,
1996, Lemberger et al., 1996).
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Prostanoids with the most potent anti-tumour and growth inhibitory effects on human
cancer cells, are the same subset which have subsequently been shown to bind to
PPARs (Bregman et al., 1986, Choi et al., 1992, Fukushima et al., 1992, Holbrook et
al., 1992, Kim et al., 1993, Yu et al., 1995). Studies from several investigators have
suggested that PPAR subtypes are differentially activated by various agents (Dreyer
et al., 1992, Schmidt et al., 1992, Zhu et al., 1993, Kliewer et al., 1994, Yu et al.,
1995). Many PPAR activators exert their effects indirectly by either being
metabolised in the cell to an active form or by inducing the release or synthesis of
endogenous PPAR ligands (Issemann & Green, 1990, Gottlicher et al., 1992).
Prostaglandins from the A, D, and J series have been shown to activate all three
PPAR subtypes when applied at concentrations of 10 pM, as used in the experiments
described in Section 3.2 (Yu et al, 1995). PPAR-y was the most responsive subtype
with A12-PGJ2 and 15dPGJ2 its most powerful activators (Forman et al, 1995,
Kliewer et al., 1995). No binding of PGD2 was detected in these studies, suggesting
that PGD2 activates PPAR-y through one or more of its metabolites.
PPAR-y inhibits gene expression by antagonising the transcription factors AP-1,
STAT and NF-kB. Therefore activation of PPAR-y results in inhibition of at least
three different classes of transcription factors involved in regulating inflammatory
responses in granulocytes and other cell types. This suggests that PPAR-y and its
ligands 15dPGJ2 or A12-PGJ2 could be involved in the regulation of inflammatory
responses (Ricote et al., 1998). Prostaglandin D2 synthase, which is required for
15dPGJ2 synthesis, is expressed in macrophages and specialised antigen-presenting
cells (Urade et al., 1989). Whether this enzyme is also expressed in eosinophils but
not in neutrophils is currently unknown.
PPAR-y is markedly upregulated in activated macrophages and inhibits the
expression of inducible nitric oxide synthase in response to 15d-PGJ2 (Ricote et al.,
1998).
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In RAW 264.7 cells, which contain little PPAR-y, PGD2 only affected these
responses in the presence of co-transfected PPAR-y (Ricote et al., 1998). Since
PGD2 does not bind to PPAR-y (Forman et al., 1995, Kliewer et al., 1995), this
indicates metabolic conversion of PGD2 to an activating ligand by this macrophage
cell line. A similar mechanism may be involved in the pro-apoptotic responses of
eosinophils to PGD2, which raises the exciting possibility that PPAR-y may regulate
inflammatory responses as a result of local production of 15dPGJ2 from eosinophils
and macrophages.
The antidiabetic group of thiazolidinedoine compounds are known ligands of PPARy
(Lehmann et al., 1995). These drugs could therefore be used to try to mimic the
effects of PPAR-y activation in granulocytes; results would indicate whether this is
12
the mechanism involved in inducing apoptosis in granulocytes via 15dPGJ2 or A -
pgj2.
Another hypothesis which should be considered is that these PGD2 metabolites may
mediate apoptosis by inducing synthesis of proteins which actively drive
programmed cell death in granulocytes. If this type of mechanism is involved, a
protein synthesis inhibitor such as cycloheximide should block the induction of
apoptosis, therefore this hypothesis could be readily investigated.
LTB4 has also been demonstrated to bind and activate the intranuclear transcription
factor PPARa, resulting in the activation of genes that terminate inflammatory
processes in macrophages (Devchand et al., 1996). Also of interest is the finding that
DHEA-S, an endogenous steroid, mediates gene induction through PPAR-y (Peters et
al, 1996). This allows the possibility that steroids may also utilise these receptors to
influence gene transcription.
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Many of the inflammatory mediators examined in this work are known to affect
9+
intracellular concentrations of Ca or cAMP or both. As shown in Figure 3.20,
increases in intracellular levels of cAMP inhibited apoptosis in both neutrophils and
eosinophils. DbcAMP is a nonhydrolyzable, cell-permeable cAMP analogue
(Cronstein et al., 1988) that has been shown to inhibit neutrophil apoptosis (Rossi et
al., 1995, Yasui et al., 1997). This suggests that in granulocytes, PGD2 and its
metabolites do not induce apoptosis through increasing intracellular cAMP or
adenylate cyclase activity.
2+
However, increases in [Ca ]j cause inhibition of neutrophil apoptosis but
dramatically increase eosinophil apoptosis (Cousin et al., 1997, Whyte et al., 1993b).
This could be due to differential effects on eicosanoid synthesis. After stimulation
with A23187, a Ca2+ ionophore, the major AA metabolites formed in eosinophils are
thromboxane B2 and LTC4 with LTB4 and 5-HETE, the precursor to 5-oxo-ETE,
formed in neutrophils (O'Flaherty & Rossi, 1993, Parsons & Roberts, 1988, Sehmi et
al., 1992). As already discussed, PGD2 can bind to the thromboxane receptor and
this should be examined as a possible mechanism inducing apoptosis in the
9+
eosinophil. Also of note is the fact that increases in [Ca ]i cause degranulation in
both cell types (O'Flaherty et al., 1991, O'Flaherty & Rossi, 1993, and personal
observation). Therefore the differences in responses observed in these cells may be
due to the effects of the granule contents of each particular cell type. This possibility
also merits investigation.
In signalling responses, intracellular Ca2+ and cAMP levels will normally fluctuate
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transiently, but the use of Ca ionophores and stable cAMP analogues may cause
larger, more persistent increases, that do not allow natural homeostatic responses to
occur, and therefore do not reflect physiological processes. Changing concentrations
2_|_of [Ca ]j, have been shown to cause differential effects in specific cells. For
9 1
example, in B lymphocytes, amplitude and duration of Ca signals controls
differential activation of the transcription factors NF-kB, JNK and NFAT. NF-kB
and JNK are selectively activated by a large transient [Ca2+]i rise, whereas NFAT is
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activated by a low, sustained [Ca2+]i plateau (Dolmetsch et al., 1997). Therefore, the
^ i
cellular responses to increased [Ca ]i may be more complicated than many results
suggest. [Ca2+]i measurements should be made in eosinophils treated with PGD2 and
• • 2+ •
its metabolites. However, because increased [Ca ]j, inhibits neutrophil apoptosis, it
19




THE EFFECT OF PRO- AND ANTI-INFLAMMATORY CYTOKINES ON
GRANULOCYTE APOPTOSIS
4.1 Introduction
The initation, amplification and resolution of an immune response are regulated in
part through the release of cytokines. This chapter investigates the effects of pro¬
inflammatory (GM-CSF and TNF-a) and anti-inflammatory cytokines (IL-10 and
TGF-p) (as defined in Chapter 1, Sections 1.10.1 and 1.10.4 respectively),
granulocyte apoptosis in vitro.
GM-CSF interacts with a specific receptor that is present on both neutrophils and
eosinophils (Park et al., 1986, Dipersio et al., 1988). In neutrophils, GM-CSF causes
the release of AA from membrane phospholipids (Sullivan et al., 1987), and
increases fMLP receptor expression (Weisbart et al., 1986, Atkinson et al., 1988).
GM-CSF can prime neutrophils, causing the cell to become hyperresponsive to a
second stimulus such as fMLP or LTB4 that induces the oxidative burst (Wiesbart et
al., 1985, 1987), membrane depolarisation (Fletcher & Gasson, 1988) and
phagocytosis (Fleischmann et al., 1988). It also increases tyrosine phosphorylation,
activates the Na+/H+ antiporter, increases adhesion and guanylate cyclase activity,
and reduces adenylate cyclase activity (Begley et al., 1986, Lopez et al., 1986,
Weisbart et al., 1986, Coffey et al., 1988, Gomez-Cambronero et al., 1989, Monroy
et al, 1990). GM-CSF also activates and primes eosinophils (Monroy et al., 1990).
GM-CSF is released by both neutrophils and eosinophils and inhibits constitutive
apoptosis of both cell types (Begley et al., 1986, Vancheri et al., 1989, Kita et al.,
1991, Moqbel et al., 1991, Colotta et al., 1992, Lee et al., 1993, Hallsworth et al.,
1996).
TNF-a exerts multiple effects on different cell types at inflamed tissue sites
(Dinarello, 1992). For example, it acts on stromal cells, including fibroblasts and
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endothelial cells, causing the release of a secondary wave of cytokines such as IL-8,
a neutrophil chemoattractant (Matsushima & Oppenheim, 1989). TNF-a also
produces extravascular accumulation of granulocytes through its action on vascular
endothelium (Gamble et ah, 1985, Cavender et ah, 1987, Sayers et ah, 1988, Furie &
McHugh, 1989, Godding et ah, 1995). TNF-a produced by macrophages (Warren et
ah, 1989) upregulates vascular adhesion molecules, including ICAM-1 and E-
selectin (Tosi et ah, 1992, Bevilacqa, 1993). This leads to adhesion and neutrophil
interaction with endothelial E-selectin and ICAM-1 (Mulligan et ah, 1991, 1995),
allowing neutrophil extravasion. Eosinophils adhere to vascular endothelium
through interactions between CDlla/CD18 and ICAM-1 and between VLA-4 and
VCAM-1 (Bochner et ah, 1991, Weller et ah, 1991). TNF-a increases the adhesion
of activated eosinophils to respiratory epithelial cell cultures in vitro (Godding et ah,
1995) and induces eosinophil accumulation in a rat skin model; this effect is
inhibited by a soluble TNFR1 IgG fusion protein that affects a4 integrin/VCAM-1
adhesion pathways (Hartnell et ah, 1997). TNF-a also enhances the cytotoxic
capability of eosinophils, which may damage the endothelium (Slungaard et ah,
1990), and increase airway hyperreponsiveness in man (Kips et ah, 1992).
After entering the tissue, granulocytes themselves become important sources of
chemotactic factors (Xing et ah, 1993, 1994). For example, activated neutrophils
synthesise and secrete IL-8 (Bazzoni et ah, 1991a), TNF-a (Bazzoni et ah, 1991b,
Costa et ah, 1993), IL-ip (Cassatella et ah, 1993) and MlP-la (Kasama et ah, 1993).
Such factors act not only as chemotaxins but as activating stimuli for PMN, T cells,
basophils, eosinophils and monocytes (Baggiolini et ah, 1989, Larsen et ah, 1989,
Alam et ah, 1992, Rot et ah, 1992). The release of these chemokines may be
responsible for the influx of other inflammatory cells into the area. Blocking TNF-a
activity in vivo using a TNF receptor fusion protein inhibits the influx of
granulocytes into BAL fluid and skin sites in animal models of lung and dermal
inflammation respectively (Gater et ah, 1996, Norman et ah, 1996, Renzetti et ah,
1996); TNF-a expression also correlates closely with mononuclear cell infiltration in
such models (Williams et ah, 1997).
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TNF-a primes for neutrophil phagocytosis (Shalaby et ah, 1985, Klebanoff et ah,
1986, Seow et ah, 1987), antibody-dependent cellular cytotoxicity (Shalaby et ah,
1985, Klebanoff et ah, 1986, Perussia et ah, 1987), intracellular microbicidal activity
(Ferrante, 1989), release of oxidants (Berkow et ah, 1987), degranulation (Atkinson
et ah, 1988, Renesto & Chignard, 1991), and responses to secondary stimuli such as
fMLP (Berkow et ah, 1987). TNF-a also primes and activates eosinophils
(Silberstein & David, 1987). Although TNF-a is a powerful priming agonist, it has
been shown to induce apoptosis in cells such as T lymphocytes (Zheng et ah, 1995),
HL-60 cells (Obeid et ah, 1993) and neutrophils (Murray et ah, 1997). However,
some data indicate that TNF-a may also delay apoptosis, for example, in human
monocytes, neutrophils, and B104 lymphoma cells (Mangan et ah, 1991, Colotta et
ah, 1992, Genestier et ah, 1995, Murray et ah, 1997).
IL-10 is synthesised by T cells, monocytes, macrophages, bronchial epithelial cells
and activated B cells and is considered anti-inflammatory because it inhibits
synthesis of proinflammatory cytokines (de Waal Malefyt et ah, 1991, Vieira et ah,
1991, Moore et ah, 1993, Mosmann, 1994, Bonfield et ah, 1995). For example, in
monocytes stimulated with LPS, or LPS plus INF-y, IL-10 reduces synthesis of IL-
la, IL-ip, IL-6, IL-8, TNF-a, and GM-CSF (de Waal Malefyt et ah, 1991, Oswald
et al, 1992). At the same time, IL-10 enhances production of the IL-1 receptor
antagonist (IL-lra) that has anti-inflammatory properties (Hammum et ah, 1990).
IL-10 also has suppressive effects on T cell proliferation, macrophage microbicidal
activity (nitric oxide-dependent), and production of prostaglandins by macrophages
(Bogdan et ah, 1991, Ding & Shevack, 1992, Oswald et ah, 1992, Taga et ah, 1992,
Gazzinelli et al, 1992, Mertz et ah, 1994, Niiro et ah, 1994). IL-10 does not suppress
all cytokine release, since it has no effect on the constitutive expression of TGF-P (de
Waal Malefyt et ah, 1991); therefore its effects are selective.
IL-10 inhibits the expression of cytokines and chemokines from LPS-stimulated
neutrophils by shortening the half-live of mRNA for these factors; but it has no
influence on O2" production in response to fMLP or TNF-a (Cassatella et ah, 1994,
1994, Kasama et ah, 1994). However, it inhibits the oxidative burst induced by INF-
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y, opsonised zymosan and phorbol esters (Chaves et al., 1996, Capsoni et al., 1997).
Eosinophils contribute to the inflammatory process by the release of lipid mediators
such as LTB4, PAF and prostaglandins, and cytokines such as TNF-a, MlP-la, IL-1,
IL-5, IL-8 and GM-CSF (Broide et al., 1992, Braun et al., 1993, Costa et al., 1993).
IF-10 inhibits the synthesis of these factors and inhibits FPS-induced eosinophil
survival (Takanaski et al., 1994). Human eosinophils express CD40, a member of
the TNF receptor superfamily, ligation of which enhances their survival via the
autocrine release of GM-CSF. IF-10 decreases CD40 mRNA and suppresses the
production of GM-CSF, and might therefore inhibit this enhanced survival
(Ohkawara et al., 1996). Cycloheximide abrogates the inhibitory effects of IF-10,
suggesting that these effects are mediated through a synthesised repressor protein
(Kasama et al., 1994).
An anti-inflammatory role for IF-10 is supported by data from IF-10 gene knockout
mice. These mice die prematurely, and suffer from chronic enterocolitis thought to
be caused by uncontrolled immune responses to enteric antigens, with chronically
activated macrophages causing amplification of the inflammatory process (Khun et
al., 1993). Mucosal lesions in the intestines contain abundant inflammatory cells
including neutrophils and eosinophils, with high levels of pro-inflammatory
cytokines such as TNF-a. TNF neutralising antibodies do not improve the condition,
which is however reversed by IF-10 administration. These mice have prolonged
immune reactions in the tissues when stimulated with antigen, resulting in excessive
inflammation and tissue damage (Rennick et al., 1995). Neutralising anti-TNF-a
antibodies prevent this tissue damage, suggesting that one function of IL-10 is to
control the local production of pro-inflammatory cytokines such as TNF-a.
Other in vivo studies using rodent models support the idea of IF-10 as an anti¬
inflammatory cytokine. Systemic administration of IF-10 suppresses delayed-type
hypersensitivity reactions and T-cell-mediated inflammatory bowel disease (Powrie
et al., 1993, Fi et al., 1994). In a model of endotoxin shock, neutralisation of IF-10
enhances TNF synthesis and lethality and IgG immune-complex-induced lung injury
(Gerard et al., 1993, Howard et al., 1993, Mulligan et al., 1993, Marchant et al.,
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1994a, Kasama et al., 1995, Shanley et al., 1995). In this model there was increased
lung permeability, increased numbers of neutrophils and higher myeloperoxidase
levels in bronchoalveolar lavage. The effects of IL-10 neutralisation were attributed
to increased TNF-a levels, resulting in enhanced expression of adhesion molecules
promoting neutrophil recruitment and activation (Shanley et al., 1995). IL-10
administration was also of benefit in a collagen-induced model of polyarthritis
(Joosten et al, 1997), chronic granulomatous inflammation (Herfarth et al., 1996),
and acute pancreatitis (Rongione et al., 1997), and had a protective effect against
lung reperfusion injury (Eppinger, 1996).
Animal models demonstrate a protective role for IL-10 in allergic inflammation. IL-
10 is a natural suppressor of cytokine production and inflammation in a murine
model of allergic bronchopulmonary aspergillosis (Grtinig et al, 1997). Endogenous
IL-10 is thought to act via several mechanisms to limit this response (Zuany-Amorim
et al., 1995). These include inhibition of TNF-a production which promotes
neutrophil and eosinophil accumulation in bronchoalveolar fluid; inhibition of IL-5
production (Schandene et al., 1994), which is a major mediator of eosinophil
differentiation, activation and survival; and by direct inhibition of eosinophil effector
functions (Takanaski et al., 1994). Although IL-10 production is upregulated by
TNF-a, several anti-inflammatory drugs that inhibit TNF-a release increase IL-10
synthesis. For example, PGE2 and other agents elevating intracellular cAMP
suppress TNF-a production and upregulate IL-10 production in
monocytes/macrophages (Strassmann et al., 1994, Platzer et al., 1995). Neutrophils
constitutively produce small amounts of PGE2 in culture supernatants, but this is not
affected by IL-10 (Niiro et al., 1997). LPS stimulation causes a large increase in
PGE2 levels through COX-2, which IL-10 does inhibit in a concentration-dependent
fashion (Niiro et al., 1997).
An anti-inflammatory role for IL-10 is also supported by human studies. In patients
with rheumatoid arthritis, neutralisation of IL-10 upregulates TNF-a, while TNF-a
increases the production of IL-10 in vitro in human monocytes (Wanidworanun &
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Strober, 1993, Platzer et al., 1995). These data suggest a negative feedback
inhibition of TNF-a production by IL-10 (Katiskis et al., 1994).
TGF-P is a pleiotropic cytokine produced by platelets and inflammatory cells such as
macrophages, T cells, eosinophils and neutrophils (Roberts et al., 1985, Grotendorst
et al., 1989, Ohno et al., 1992). It acts to limit the growth and activity of
inflammatory cells (Wahl, et al., 1994). TGF-p has inhibitory activities on T cells
and monocytes and, like IL-10, TGF-P deactivates macrophages, inhibiting
production of reactive oxygen species, and cytokines such as TNF-a, (Espevik et al,
1987, Tsunawaki et al., 1988, Massague, 1990, Nelson et al., 1991, Sporn & Roberts,
1992, Vodovotz et al., 1993); but it enhances IL-10 production in these cells (Maeda
et al., 1995).
Both the initiation and resolution of general inflammatory responses seem to involve
TGF-P 1. TGF-P stimulates leukocyte migration (Wahl, 1992), but it has potent anti¬
inflammatory effects including inhibition of neutrophil and T-lymphocyte adhesion
to endothelium (Gamble & Vadas, 1988, Gamble et al., 1993, Wahl et al., 1993),
antagonism of TNF-a function (Espevik et al., 1987, Ranges et al., 1987), inhibition
of proliferation of all T-cells subsets, inhibitory effects on proliferation and function
of B lymphocytes, down-regulation of natural killer cell activity, and regulation of
cytokine production by immune cells (Goey et al., 1989, Gresham et al., 1991, Keller
et al., 1991, Palladino et al., 1991, Wahl, 1992). It also affects neutrophil migration
by inhibiting the production of IL-8 (Smith et al., 1996). TGF-P does not cause
exocytosis, (V production or priming of neutrophils (Brandes et al., 1991, Reibman
et al., 1991), but it activates neutrophils adherent to fibrinogen to release H2O2 and
lactoferrin (Balazovich et al., 1996). TGF-P inhibits activation and survival of
eosinophils induced by IL-3, IL-5 and GM-CSF (Alam et al., 1994a).
TGF-P is important for wound healing (Sporn et al., 1983, Roberts et al., 1986). This
process, which involves both fibrogenisis and angiogenesis is characterised by an
ordered progression of inflammatory cells, beginning with platelets, followed by
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neutrophils, macrophages, and then lymphocytes (Wahl, 1987). At femtomolar
concentrations, TGF-P is a potent chemoattractant for human blood monocytes and
neutrophils in vivo and in vitro (Mustoe et ah, 1987, Wahl et ah, 1987, Wiseman et
al., 1988, Allen et al., 1990, Reibman et ah, 1991). TGF-P bypasses classic
signalling mechanisms for chemotaxis (GTPase activity, calcium, and actin
polymerisation) and triggers protein synthesis (Reibman et ah, 1991). It increases
collagen formation and angiogenesis (Roberts et ah, 1986, Postlethwaite et ah, 1987,
Sprugel et ah, 1987). In wound healing models, TGF-p increases wound strength
(Mustoe et ah, 1987) and accelerates wound healing (Mustoe et ah, 1990). Oestrogen
accelerates cutaneous wound healing by increasing TGF-P 1 levels (Ashcroft et ah,
1997).
In vivo, TGF-P applied or released locally promotes leukocyte adhesion, infiltration
and activation by regulating the synthesis and expression of receptors for integrins
such as fibronectin and laminin (Wahl et ah, 1993). However, TGF-P administered
systemically has the opposite effect, inhibiting the expression of endothelial cell
adhesion proteins and decreasing leukocyte recruitment to sites of inflammation
(Gamble et ah, 1993). In vitro, TGF-P promotes neutrophil chemotaxis but blocks
neutrophil adhesion to fibrinogen in response to phorbol ester (Gresham et ah, 1994).
Thus, TGF-P may selectively promote or inhibit PMN functional responses,
depending upon specific environmental conditions.
TGF-p enhances macrophage phagocytosis of apoptotic neutrophils (Ren & Savill,
1995). Phosphatidylserine (PS) recognition by macrophages is involved in the
removal of apoptotic cells that express PS on their cell membranes. TGF-P is
involved in P-glucan induction of PS recognition by macrophages (Rose et ah, 1995).
Phagocytosis of apoptotic neutrophils inhibits the production of IL-ip, IL-8, IL-10,
GM-CSF, TNF-a, LTC4 and TXB2 by human monocytic-derived macrophages,
while TGF-P 1, PGE2 and PAF are increased (Fadok et ah, 1998). Culturing with
TGF-p 1, PGE2 or PAF in this system inhibits LPS-stimulated cytokine production
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(Fadok et al., 1998). This again suggests a potential role for TGF-P in inflammatory
resolution.
Bacterial infection, or direct administration of LPS or TNF-a, can induce isoforms of
nitric oxide synthase (iNOS, NOS2), which produce large amounts of NO over a
period of hours in animal models (Pittet et al., 1995). This mimics the situation in
patients with sepsis (Rixen et al., 1997). TGF-P suppresses expression of NOS2 by
regulating the rate of gene transcription, mRNA stability, translation and protein
stability (Vodovotz et al., 1993, Perella et al., 1994, Finder et al., 1995). Lack of
TGF-pl in TGF-P null mice is associated with aberrant expression of NOS2
(Vodovotz et al., 1996).
TGF-pi knock out mice suffer from excessive, multifocal inflammatory responses,
with massive infiltration of leukocytes to different organs, beginning during the first
week of life and causing severe wasting and death by week four (Schull et al., 1992,
Kulkarni et al., 1993). These animals exhibit inflammatory cell infiltration and tissue
necrosis in organs such as liver, heart and stomach (Schull et al., 1992). The
stomach infiltration consists mainly of neutrophils and some eosinophils, while in
liver, granulocytes and lymphocytes are involved (Schull et al., 1992). Elevation of
blood neutrophil and monocyte counts are observed (Schull et al., 1992). Thus, TGF-
pi deficiency results in severe pathology and death associated with dysfunction of
the immune and inflammatory systems (Schull, et al., 1992).
The phenotype of this mouse suggests that inflammation can be initiated without
TGF-P, but the ability to control and promote the resolution of inflammation is lost.
This might be the most critical function of this cytokine (Letterio & Roberts, 1996).
Chronic systemic exposure to inflammatory cytokines including INF-y, IL-1, and
TNF-a can lead to a progressive wasting syndrome and associated tissue
inflammation similar to the phenotype of the TGF-pi knock-out mouse (Tracey et
al., 1988). However, the profound dysregulation of immune cells present in TGF-P 1
null mice is not reversed by systemically injected TGF-pi, suggesting that these cells
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rely solely on autocrine or possibly even intracrine TGF-pl (Letterio & Roberts,
1996). This is supported by bone marrow transplantation studies which show the
same pathology as the TGF-pl knock-out mouse, even in the presence of
endogenous TGF-pi produced by other cells in the recipient (Yaswen et al., 1996).
In some epithelial and hematopoietic cells, TGF-pi has been reported to induce
programmed cell death (Rotello et al., 1991, Lotem & Sachs, 1992, Oberhammer et
9+
al., 1992, Lomo et al., 1995). It acts synergistically with Ca to trigger T and B
lymphocyte apoptosis (Andjelic et al., 1997), and has been shown to mediate
osteoclast apoptosis induced by oestrogen (Hughes et al., 1996). However, TGF-P
has also been shown to inhibit apoptosis in normal human keratinocytes grown in
suspension (Sachsenmeier et al., 1996).
The aim of the work presented in this chapter was to examine the capacities of the
anti-inflammatory cytokines IL-10 and TGF-P to upregulate granulocyte apoptosis.
Both IL-10 and TGF-P 1 null mice can mount inflammatory responses, but appear to
be unable to resolve the process. Therefore, if these cytokines potentiate granulocyte
apoptosis, then given that ingestion of apoptotic cells will cause the release of
mediators that downregulate pro-inflammatory cytokines (Fadok et al., 1998), this
could be relevant to the mechanism of inflammatory resolution.
128
4.1 Results
4.2.1 The Effects ofGM-CSF and TNF-a on Granulocyte Apoptosis
Figure 4.1 A and B demonstrates that GM-CSF significantly decreased apoptosis in
both neutrophils and eosinophils at all timepoints examined. In neutrophils,
apoptosis fell from 73.8 ± 2.2 % to 40.9 ±3.5 % with GM-CSF treatment at 20 h,
while control apoptosis in eosinophils fell from 32.0 ± 8.4 % to 21.3 ± 4.6 % at 40h.
As shown in Figure 4.2 B, TNF-a had no significant effect on eosinophil apoptosis at
either 20 or 40 h. However, this cytokine significantly increased apoptosis in
neutrophils at 6 h (control 3.4 ± 1.3 %, TNF-a, 12.0 ± 2.5 %), but it significantly
inhibited apoptosis at 20 h (control 56.1 ± 3.7 %, TNF-a, 47.4 ± 3.3 %) (Figure 4.2
A).
4.2.2 The Effect of IL-10 on Granulocyte Apoptosis
IL-10 had no significant effect on the constitutive rate of neutrophil or eosinophil
apoptosis over the range of timepoints shown in Figure 4.3 A and B. To ensure that
the IL-10 used in the foregoing and following studies was biologically active,
monocytes and monocyte-derived macrophages were incubated with IL-10 after LPS
stimulation. Macrophages and monocytes activated by LPS are potent producers of
TNF-a (Mannel, et ah, 1980, Matthews, 1981, Mosmann, 1994). IL-10 has been
shown to attenuate such production (Bogdan et al., 1991). As illustrated in Figure
4.4 A and B, the IL-10 used in these experiments significantly inhibited the release
of TNF-a from both monocytes and monocyte-derived macrophages. In monocytes
treated with LPS, TNF-a production was decreased from 555.1 ± 27.1 pg/ml to
127.3 ± 5.9 pg/ml in cells treated with 100 ng/ml IL-10, while in activated
macrophages, it fell from 210.2 ± 4.8 pg/ml to 31.0 ± 2.1 pg/ml. This demonstrates
that although IL-10 had no effect on granulocyte apoptosis, this was not due to loss
of biological activity.
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Figure 4.1 The Effect ofGM-CSF on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with GM-CSF (50
U/ml) and harvested at 20 h (neutrophils) and 20 and 40 h (eosinophils). Filled bars
represent treated cells. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments for neutrophils and 5 separate experiments














Figure 4.2 The Effect of TNF-a on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with TNF-a (12.5
ng/ml) and harvested at 6 and 20 h (neutrophils) and 20 and 40 h (eosinophils).
Filled bars represent treated cells. Apoptosis was assessed morphologically. Data
represent the mean ± SEM of 7 separate experiments for neutrophils and 8 separate
experiments for eosinophils. All experiments were performed in triplicate (* p <
0.05 compared with control values).
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Control 1 ng/ml 5 ng/ml 10/ng/ml
IL-10
Control 1 ng/ml 5 ng/ml 10 ng/ml
IL-10
Figure 4.3 The Effect of IL-10 on Constitutive Granulocyte Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control) or with IL-10 (10, 5 or 1
ng/ml) and harvested at 6 and 20 h (neutrophils) and 20 and 40 h (eosinophils). In A,
filled bars represent 20 h, in B filled bars represent 40 h. Apoptosis was assessed
morphologically. Data represent the mean ± SEM of 3 separate experiments for










Figure 4.4 The Effect of IL-10 on TNF-a Production by Monocytes and
Macrophages
A) Monocytes and B) macrophages (1 x 106/ml) were incubated in Iscove's DMEM
supplemented with serum alone (control) or LPS (lpg/ml) ± IL-10 (100, 10 or 1
ng/ml) for 4 h and supernatants were collected for ELISA determination of TNF-a
production (pg/ml). Sensitivity limit was 5pg/ml TNF-a. Data represent the mean ±
SEM of 3 separate experiments, performed in duplicate (* p < 0.05 in comparison
with LPS-stimulated TNF-a production). (Corroborative data provided by L. Bruce,
University ofEdinburgh).
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4.2.3 The Effect of IL-10 on the Inhibition of Granulocyte Apoptosis Mediated
by LPS, Dexamethasone, GM-CSF, TNF-a, dbcAMP, 5-oxo-ETE and
ZK118.182
Because in an in vivo situation, cytokines and inflammatory factors have been shown
to work in concert, we examined the effects of IL-10 on other mediators that affect
the constitutive rate of apoptosis in neutrophils and/or eosinophils. As shown in
Figure 4.5 A, IL-10 (10 ng/ml) significantly inhibited LPS-induced (1 pg/ml)
neutrophil survival at 20 h (Control 58.5 ± 3.7 %, LPS 19.8 ± 2.5 %, LPS + IL-10
35.9 ± 4.2 %). This inhibition was however partial rather than total. In eosinophils,
IL-10 had no significant effect on apoptosis, and as shown in Figure 3.4 B, LPS
enhanced survival at the 40 h timepoint only.
Because IL-10 can inhibit LPS-induced neutrophil survival, we examined whether it
had effects on other inhibitors of apoptosis. Dexamethasone inhibits apoptosis in
neutrophils but increases eosinophil programmed cell death, as shown in Figure 3.3
A and B (Chapter 3). However, Figure 4.6 demonstrates that IL-10 had no effect on
glucocorticoid-mediated granulocyte survival or apoptosis.
Similarly, as illustrated in Figure 4.7 A and B, IL-10 had no significant effect on
either neutrophil (at 20 h, control, 58.5 ± 3.7 %, GM-CSF 34.17 ± 6.4 %, GM-CSF +
IL-10 33.8 ± 2.8 %) or eosinophil survival induced by GM-CSF (at 40 h, control
18.87 ± 3.8 %, GM-CSF 11.9 ± 1.2 %, GM-CSF + IL-10 12.7 ± 1.2 %.
Figure 4.8 A demonstrates the effect of IL-10 on neutrophils cultured with TNF-a.
Because TNF-a has differential effects on neutrophil apoptosis at early and late
timepoints (Figure 4.2 A), the effect was examined at 6 and 20 h. As shown in
Figure 4.8 A, IL-10 did not affect the pro-apoptotic response (6 h) or the inhibitory
response (20 h) induced by TNF-a. In eosinophils (Figure 4.8 B) neither TNF-a nor
IL-10 affected the constitutive rate of apoptosis, nor did co-culture with both
cytokines.
134
The effect of IL-10 on dbcAMP-induced granulocyte survival is illustrated in Figure
4.9. IL-10 did not reverse dbcAMP inhibition of neutrophil apoptosis at the timepoint
examined, (Figure 4.9 A), nor did it significantly inhibit dbcAMP-induced survival
in eosinophils (Figure 4.9 B). Figures 4. 10 and 4.11 demonstrate the co-culture of
neutrophils with IL-10 and 5-oxo-ETE and with IL-10 and ZK118.182 respectively.
As shown in these figures, culture with 5-oxo-ETE alone or with both 5-oxo-ETE
and IL-10 had no effect on the constitutive rate of neutrophil apoptosis; IL-10 also
did not significantly alter the inhibition of neutrophil apoptosis induced by
ZK118.182 alone.
IL-10 had no effect on constitutive granulocyte apoptosis. Although it partially
reversed LPS-mediated neutrophil survival, it did not significantly effect the rates of
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Figure 4.5 The Effect of IL-10 on LPS-induced Granulocyte Survival
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control), IL-10 (10 ng/ml), LPS (1
pg/ml) or IL-10 + LPS, and harvested at 20 h (neutrophils) and 20 and 40 h
(eosinophils). Filled bars represent 40 h timepoint for eosinophils. Apoptosis was
assessed morphologically. Data represent the mean ± SEM of 3 separate
experiments for neutrophils and 4 separate experiments for eosinophils. All
experiments were performed in triplicate (* p < 0.05 compared with control values; #








































Control IL-10 DEX DEX/IL-10
Treatment
Figure 4.6 The Effect of IL-10 on Dexamethasone-induced Neutrophil
Survival and Eosinophil Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control), IL-10 (10 ng/ml),
dexamethasone (1 pM) or IL-10 + dexamethasone, and harvested at 20 h
(neutrophils) and 20 and 40 h (eosinophils). Filled bars represent 40 h timepoint in
eosinophils. Apoptosis was assessed morphologically. Data represent the mean ±
SEM of 3 separate experiments for neutrophils and 3 separate experiments for







































Control IL-10 GM-CSF GM-CSF/IL10
Treatment
Figure 4.7 The Effect of IL-10 on GM-CSF-induced Granulocyte Survival
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control), IL-10 (10 ng/ml), GM-
CSF (50 U/ml) or IL-10 plus GM-CSF and harvested at 20 h (neutrophils) and 20
and 40 h (eosinophils). Filled bars represent 40 h of treatment in eosinophils.
Apoptosis was assessed morphologically. Data represent the mean ± SEM of 3
separate experiments for neutrophils and 3 separate experiments for eosinophils. All













































Figure 4.8 The Effect of IL-10 and TNF-a on Granulocyte Survival
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control), IL-10 (10 ng/ml), TNF-a
(12.5 ng/ml) or IL-10 + TNF-a, and harvested at 6 and 20 h (neutrophils) or 20 and
40 h (eosinophils). Filled bars represent 20 h timepoint (neutrophils) and 40 h
(eosinophils). Apoptosis was assessed morphologically. Data represent the mean ±
SEM of 7 separate experiments for neutrophils and 3 separate experiments for

























Figure 4.9 The Effect of IL-10 on dbcAMP-induced Granulocyte Survival
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control), IL-10 (10 ng/ml),
dbcAMP (0.2 mM) or IL-10 + dbcAMP at the same concentrations, and harvested at
20 h (neutrophils) or 20 and 40 h (eosinophils). Filled bars represent 40 h timepoint
in eosinophils. Apoptosis was assessed morphologically. Data represent the mean ±
SEM of 3 separate experiments for neutrophils and 3 separate experiments for























Control IL-10 5-oxo-ETE 5-oxo-ETE/IL-10
Treatment
Figure 4.10 The Effect of IL-10 on 5-oxo-ETE-induced Neutrophil Survival
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), IL-10 (10 ng/ml), 5-oxo-ETE (300 nM) or IL-10 + 5-oxo-ETE
at the same concentrations above and harvested 20 h. Apoptosis was assessed
morphologically. Data represent the mean ± SEM of 3 separate experiments. All























Figure 4.11 The Effect of IL-10 on ZK118.182-induced Neutrophil Survival
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), IL-10 (10 ng/ml), ZK118.182 (30 pM) or IL-10 plus
ZK118.182 at the same concentrations, and harvested at 20 h. Apoptosis was
assessed morphologically. Data represent the mean ± SEM of 3 separate
experiments for neutrophils and 3 separate experiments for eosinophils. All
experiments were performed in triplicate (* p < 0.05 compared with control values).
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4.2.4 The Effect of TGF-P on Granulocyte Apoptosis
TGF-P induces apoptosis in some immune cells (Lomo et al., 1995), but as shown in
Figure 4.12, it significantly inhibited neutrophil apoptosis at 20 h using
concentrations above 300 pM (e. g. Control 61.5 % ± 5.0, TGF-P 300 pM 46.4 ± 3.4
%). A concentration of 400 pM was used in the following neutrophil experiments.
Figure 14.3 A demonstrates the significant inhibition of constitutive neutrophil
apoptosis using this concentration (control 70.7 ± 2.3 %, TGF-P 400 pM 44.4 ± 4.7
%). Figure 4.13 B illustrates the effect of TGF-P on eosinophil programmed cell
death using 1000 pM and 50 pM TGF-p. There was no significant difference at
either concentration at 40 h, but at 20 h, 1000 pM TGF-P significantly inhibited
apoptosis in these cells (control 23.2 ± 2.0 %, TGF-P 1000 pM 12.2 ± 0.1 %).
4.2.5 The Effect of TGF-P on Dexamethasone and GM-CSF Inhibition of
Neutrophil Apoptosis
Figure 4.14 illustrates the effect of TGF-p on dexamethasone-induced neutrophil
survival. As shown, both TGF-P and dexamethasone significantly inhibited
neutrophil apoptosis. Flowever, the co-culture of neutrophils with TGF-P and
dexamethasone potentiated the inhibition induced by both factors alone.
Interestingly, the level of inhibition significantly increased in comparison with that
mediated by dexamethasone treatment alone (control 69.4 ±2.1 %, dexamethasone
49.9 ± 0.4 %, TGF-P plus dexamethasone 34.1 ± 3.9 %). Similar results were
obtained using GM-CSF and TGF-p (Figure 4.15). Again, TGF-p and GM-CSF both
significantly reduced neutrophil apoptosis at 20 h, but co-culture of neutrophils with
both cytokines together caused a further significant decrease (TGF-P 46.0 ±6.1 %,
GM-CSF 40.9 ± 3.7 %, TGF-P plus GM-CSF (27.7 ± 1.8 %). These results (Figures
4.14 and 4.15) indicate that TGF-P, rather than inducing neutrophil apoptosis, can




Figure 4.12 The Effect of TGF-P on Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), or with TGF-P at the concentrations shown and harvested at
20 h. Apoptosis was assessed morphologically. Data represent the mean ± SEM of 4
separate experiments. All experiments were performed in triplicate (* p < 0.05
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Figure 4.13 The Effect of TGF-P on Neutrophil and Eosinophil Apoptosis
A) Neutrophils (5 x 106/ml) and B) eosinophils (2 x 106/ml) were incubated in
Iscove's DMEM supplemented with serum alone (control), or with TGF-P (400 pM
for neutrophils and 50 or 1000 pM for eosinophils) and harvested at 20 h
(neutrophils) or 20 (open bars) and 40 h (filled bars) (eosinophils). Apoptosis was
assessed morphologically. Data represent the mean ± SEM of 8 separate
experiments for neutrophils and 3 separate experiments for eosinophils. All


























Figure 4.14 The Effect of TGF-P on Dexamethasone Inhibition of Neutrophil
Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), or with TGF-P (400 pM), dexamethasone (1 pM) or both
TGF-P and dexamethasone at the same concentrations, and harvested at 20 h.
Apoptosis was assessed morphologically. Data represent the mean ± SEM of 3
separate experiments. All experiments were performed in triplicate (* p < 0.05






















Control TGF-P GM-CSF TGF-P/GM-CSF
Treatment
Figure 4.15 The Effect of TGF-P on GM-CSF Inhibition of Neutrophil
Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), or with TGF-p (400 pM), GM-CSF (50 U/ml) or both TGF-p
and GM-CSF at the same concentrations, and harvested at 20 h. Apoptosis was
assessed morphologically. Data represent the mean ± SEM of 3 separate
experiments. All experiments were performed in triplicate (* p < 0.05 compared
with control values; # p < 0.05 compared with TGF-P or GM-CSF alone).
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4.2.6 The Effect of TGF-P on TNF-a Mediated Apoptosis and Survival of
Neutrophils
Neutrophils were cultured for 4 h to examine whether TGF-P could potentiate or
inhibit the pro-apoptotic response to TNF-a, and for 20 h to investigate its effect on
TNF-a-mediated survival. At 4 h, TGF-P significantly enhanced the pro-apoptotic
effect of TNF-a (TNF-a 17.9 ± 2.1 %, TGF-P plus TNF-a 29.9 ± 0.7 %), but TGF-P
alone did not inhibit constitutive apoptosis at this timepoint. At 20 h, both TGF-P
and TNF-a inhibited neutrophil apoptosis, but co-culture with both cytokines was
not significantly different from results with each cytokine alone (Figure 4.16).
To further examine the potentiation of the pro-apoptotic actions of TNF-a,
neutrophils were cultured with both cytokines for 2, 4, 6 and 8 h (Figure 4.17). This
illustrates significant enhancement of TNF-a-induced apoptosis by TGF-P at early
timepoints (2 and 4 h). Although TGF-P produced a slight increase in TNF-a-
mediated neutrophil apoptosis in all experiments at 6 and 8 h, the differences at these
timepoints between TNF-a and TNF-a plus TGF-P treated cells were not significant.
4.2.7 The Effect of Dexamethasone and GM-CSF on TNF-a-induced
Neutrophil Apoptosis
To determine the specificity of the upregulation of the TNF-a effect by TGF-P,
neutrophils were incubated with TNF-a plus dexamethasone or TNF-a plus GM-
CSF. Both factors enhance neutrophil survival; GM-CSF activates and primes
neutrophils but dexamethasone does not (Cox, 1995). As illustrated in Figure 4.18,
TGF-P, dexamethasone and GM-CSF significantly decreased neutrophil apoptosis at
6 h. Dexamethasone and GM-CSF also significantly reduced TNF-a induced
apoptosis at this timepoint (TNF-a 30.3 ± 2.7 %, dexamethasone plus TNF-a 22.6 ±





Control TGF-P TNF-a TGF-P/TNF-a
Treatment
Figure 4.16 The Effect of TGF-P on TNF-a Induction and Inhibition of
Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), or with TGF-P (400 pM), TNF-a (12.5 ng/ml) or both TGF-P
and TNF-a at the same concentrations, and harvested at 4 h (open bars) or 20 h
(filled bars). Apoptosis was assessed morphologically. Data represent the mean ±
SEM of 3 separate experiments. All experiments were performed in triplicate (* p <




Figure 4.17 The Effect of TGF-P on TNF-a Induced Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), or with TGF-P (400 pM), TNF-a (12.5 ng/ml) or both TGF-P
and TNF-a at the same concentrations, and harvested at 2, 4, 6 and 8 h. Apoptosis
was assessed morphologically. Data represent the mean ± SEM of 6 separate
experiments. All experiments were performed in triplicate (* p < 0.05 compared


















Control TGF-P TNF-ct DEX GM-CSF TGF-P DEX GM-CSF
/TNF-a /TNF-a /TNF-a
Treatment
Figure 4.18 The Effect of Dexamethasone, GM-CSF and TGF-p on TNF-a
Induced Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), or with TGF-P (400 pM), TNF-a (12.5 ng/ml),
dexamethasone (1 pM), GM-CSF (50 U/ml) or both TGF-p and TNF-
a, dexamethasone and TNF-a, or GM-CSF and TNF-a at the same concentrations,
and harvested at 6 h. Apoptosis was assessed morphologically. Data represent the
mean ± SEM of 3 separate experiments. All experiments were performed in




The pro-inflammatory cytokines and granulocyte priming agents, GM-CSF and
TNF-a, enhanced neutrophil survival, but only GM-CSF inhibited eosinophil
apoptosis. The results for GM-CSF are in agreement with Wallen et al., (1991), Lee
et al., (1993), Kroegel et al., (1994), and Takanaski et al., (1994). TNF-a had no
effect on eosinophil programmed cell death, although nerve growth factor, a member
of the TNF family, has been shown to enhance the survival of human eosinophils
(Flamada et al., 1996). Of great interest is the observation that TNF-a has pro-
apoptotic effects at early timepoints in human neutrophils. These results are in
agreement with Murray et al., (1997), who demonstrated that the time in culture is
crucial for examining the pro-apoptotic effects of this cytokine. In neutrophils,
incubation of cells for less than 8 h induces apoptosis, and greater than 12 h causes a
decrease in neutrophil apoptosis. Few physiological mediators have been
demonstrated to induce programmed cell death in neutrophils; other priming agonists
do not have this effect. The early proapoptotic effects of TNF-a appear to be
dependent on both TNF receptor subtypes whereas priming, and the later inhibitory
effect on neutrophil apoptosis, are mediated via TNFRII (Murray et al., 1997).
Culture of neutrophils and eosinophils with IL-10 produced no differences in rates of
apoptosis in comparison with control cells [in agreement with Cox, (1996), and Keel
et al., (1997) who found no effect of IL-10 on constitutive neutrophil apoptosis, and
Takanaski et al., (1994), who found parallel results in IL-10 treated eosinophils],
although IL-10 effectively reduced TNF-a production by LPS-stimulated monocytes
and monocyte-derived macrophages.
IL-10 partially reversed LPS-inhibition of apoptosis but did not significantly reduce
this inhibition in eosinophils. These results for eosinophils contradict those obtained
by Takanaski et al., (1994). However, this group divided eosinophil donors into
responders and non-responders to LPS and their published data included only
responders. In contrast, all donors in the experiments described in this chapter
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showed inhibition of eosinophil apoptosis by LPS. However, of the donors used,
results from 2 showed that IL-10 inhibited LPS-induced eosinophil survival, while
the other 2 showed no significant difference. It is possible that as a result of
selecting donors whose eosinophils show a good response to LPS, the results from
Takanaski are skewed, showing a more marked inhibition of LPS-induced survival
by IL-10 than those obtained by selecting donors at random as presented here.
Alternatively, there may be some donors whose eosinophils do not respond to IL-10
when activated by LPS. All eosinophil donors used in these studies were either non-
or mildly atopic and were on no medication at the time of sampling. The atopic
eosinophil donors were prone to allergic reactions such as rhinitis or eczema, and
therefore it is possible that some were undergoing mild allergic reactions while this
study was undertaken. If some of the cells obtained were slightly activated before
the experiments began, this might account for differences between donors with
regard to the effects of IL-10 on LPS-induced eosinophil survival. The number of
donors in this experiment (n = 4) are too small to draw firm conclusions with regard
to non-responders to IL-10. It would be interesting to extend the study to include
subjects with moderate or severe allergies to examine if there are differences in the
response to IL-10 with regard to LPS-activation, and to other functional responses as
well as apoptosis. It is unlikely that differences between these results and those
obtained by Takanaski et al., (1994) are due to differences in IL-10 concentration,
since their experiments were conducted using 5 ng/ml IL-10 and those presented in
this chapter used 10 ng/ml. LPS concentrations were also similar.
IL-10 had no effect on the inhibition or stimulation of apoptosis mediated by
dexamethasone, GM-CSF, TNF-a, dbcAMP, 5-oxo-ETE or ZK118.182. Takanaski
et al., (1994) also found that IL-10 did not inhibit GM-CSF-induced eosinophil
survival. However, Keel et al., (1997), found that IL-10 inhibited neutrophil survival
induced by LPS, TNF-a and GM-CSF. However, many of these experiments were
performed using cells from patients with severe sepsis. This means that the cells
they examined could have been exposed to LPS in vivo, which would explain the
inhibition by IL-10. Such cells might also have been activated by a plethora of pro¬
inflammatory cytokines in the peripheral blood; for example, as shown by many
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studies, TNF-a is markedly upregulated in sepsis (Gerard et al., 1993, Marchant et
al., 1994b).
The mechanism of IL-10 inhibition of LPS-induced neutrophil survival is not known.
This cytokine may act as a "deactivating factor", as has been demonstrated in
macrophages, but inhibition might only occur in activated cells. GM-CSF and TNF-
a also prime and activate granulocytes and IL-10 did not affect inhibition of
apoptosis induced by these factors. Nevertheless, IL-10 might inhibit other
functional activities mediated by TNF-a or GM-CSF in these cells. IL-10 is known
to inhibit the synthesis of pro-inflammatory cytokines from both neutrophils and
eosinophils (Casatella et al., 1993, Takanaski et al., 1994). GM-CSF neutralising
antibodies partially reversed LPS-induced survival of eosinophils (Takanaski et al.,
1994), but had no effect on LPS-induced neutrophil survival (Cox, 1996). Therefore
there may be differences in the mechanism of IL-10 inhibition between these two cell
types.
The production of pro-inflammatory cytokines such as GM-CSF, TNF-a and IL-8,
which is inhibited by IL-10, is controlled at least partially by the transcription factor
NF-kB, which LPS is known to activate (Wang et al., 1995). IL-10 has been shown
to suppress NF-kB activity. For example, in monocytes stimulated with LPS, IL-10
inhibits nuclear localisation of NF-kB in a concentration-dependent manner (Wang
et al., 1995), with inhibition detectable at 10 ng/ml IL-10. In a rat model of lung
injury, IL-10 was shown to inhibit NF-kB activation, reducing levels of TNF-a
(Lentsch et al., 1997). This appeared to be due to upregulation of iKBa, which may
have been caused by induction of IxBa gene expression by IL-10 or by the inhibition
of IxBa proteolysis (Lentsch et al., 1997). These examples might suggest that
inhibition of apoptosis by the cytokines and other factors used in these studies is not
mediated solely by NF-kB; alternatively, such factors may activate NF-kB in a more
rapid manner. For example, TNF-a can activate NF-kB within two to four minutes
after binding to the cell, even when only 20 - 25 % of the receptors are occupied
(Hohmann et al., 1990). This possibility could be examined by pre-incubating cells
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with IL-10 before the addition of cytokines and other mediators. In the results shown
in Figure 4.4, IL-10 inhibited the production of TNF-a from LPS-stimulated
monocytes and macrophages, but even at concentrations 10 times greater than those
used in the other IL-10 experiments presented in this chapter, the inhibition was
partial rather than total. In LPS-treated granulocytes, there was again only a partial
reversal of LPS-inhibition. This may indicate that NF-kB is an important mediator of
enhanced survival, but that granulocytes may need only a partial activation of this
transcription factor to prevent apoptosis from occurring.
Another possible explanation is that GM-CSF, TNF-a and other mediators used in
these studies inhibit granulocyte apoptosis using other signalling pathways that
cannot be inhibited by IL-10 either instead of or in concert with NF-kB. For
example, other transcription factors such as AP-1, GR, CREB, Oct-1 and Sp-1 are
not affected by IL-10 (Wang et al., 1995).
LPS upregulates tyrosine phosphorylation (Geng et ah, 1994) which is also
implicated in the regulation of apoptosis (Yousefi et ah, 1994, 1996). IL-10 strongly
inhibits tyrosine kinase activity (Geng et ah, 1994). The signal transduction pathways
triggered by IL-10 remain to be specified (Goldman et al, 1996). IL-10 has been
shown to activate Statl, Stat3 and in certain cells, Stat5 leading to the formation of
three or in some cells four distinct DNA binding complexes (Weber-Nordt et ah,
1996), but little is known of how this affects gene transcription.
However, because IL-10 blocks LPS enhancement of neutrophil survival, it may play
a physiologically relevant role in resolution of bacterial infection and inflammation.
In an in vivo model of mild acute lung injury using LPS-induced inflammation, IL-10
shortens the period of pulmonary neutrophilia (Cox, 1996). The levels of recruited
cells are unchanged, suggesting that clearance of these cells is enhanced by IL-10
(Cox, 1996).
TGF-P enhanced survival of both neutrophils and eosinophils (but only at 20 h in
eosinophils). There were no effects on constitutive apoptosis in either cell type at a
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concentration of 50 pM, which gives maximal autoinduction of TGF-(3 (Van
Obberghen-Schilling et al., 1988). Rather than inhibiting GM-CSF or dexamethasone
induced survival in neutrophils, TGF-|3 increased this effect to levels that were
significantly enhanced compared to those achieved by dexamethasone or GM-CSF
alone.
TGF-P did however enhance the pro-apoptotic potential of TNF-a at early
timepoints (2 and 4 h), whereas dexamethasone and GM-CSF both significantly
inhibited TNF-a-mediated apoptosis at 6 h. The mechanism by which TGF-P
upregulates TNF-a-induced apoptosis is unknown, but synergistic and additive
effects of TNF-a and TGF-P with co-culture of immune cells have been noted
(Kamijo et al., 1990, Hori et al., 1994).
In neutrophils, both TNFRs are required for apoptosis and TNF stimulation results in
rapid downregulation of both receptors (Porteu & Hiebolt, 1994, Murray et al.,
1997). The number of binding sites and the affinity of TNF-a for its receptors were
found to be unchanged by TGF-p, in various cells which respond to co-culture with
both cytokines with synergistic effects (Kamijo et al., 1990). This should however,
be verified in neutrophils.
TNF cytotoxicity does not require new protein synthesis (Ruff & Gifford, 1981),
therefore it is unlikely that TGF-p potentiates the pro-apoptotic effect of TNF-a
through this mechanism. TGF-P could upregulate the TNF effect by either inhibiting
a survival pathway or by upregulating an apoptotic pathway. Because the induction
of apoptosis by TNF-a requires both receptors, TGF-P could interact with signals
from either receptor. The signalling pathways known to be activated by TNF-a are
illustrated in Figure 1.2.
As shown in Figure 1.2, the transcription factors responsible for many of the TNF-
a-mediated effects are NF-kB and AP-1 (Brenner et al., 1989, Israel et al., 1989,
Angel & Karin, 1991, Baldwin, 1996). AP-1 is activated through the JNK and p38
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kinase (Karin, 1995, Karin et al., 1997). TNF-a induces the simultaneous activation
ofNF-kB, JNK and p38 kinase.
TRAF2 is part of the signal cascade involved in the activation of both NF-kB and
JNKs. However, inhibition of TRAF2 activity prevents the activation of JNK, but
not NF-kB, suggesting that TRAF2 has a specific role in the regulation of the JNK
pathway. TRAF2 activates anti-apoptotic signals independently of NF-kB genes
during TNF-a-mediated apoptosis (Lee et al., 1997b). Examination of TRAF2
deficient cells revealed a severe reduction in TNF-a-mediated JNK/SAPK activation
but only a mild effect on NF-kB activation, while thymocytes and other
haematopoetic progenitors were found to be highly sensitive to TNF-induced cell
death (Yeh et al., 1997). These results suggest that JNK activation mediates a
survival effect.
TGF-P also activates AP-1 (Kim et al., 1989, Pertovaara et al., 1989). TGF-P can
signal via TAK1 binding protein (TAB1) (Shibuya et al., 1996), which activates a
MAPKKK, TGF-P activated kinase (TAK-1), which can activate MEKK1 (Shibuya
et al., 1996). This would lead to activation of JNK and p38. From the studies
detailed above (Lee et al., 1997, Yeh et al., 1997), this is unlikely to be responsible
for the potentiation of the pro-apoptotic effect of TNF-a. It might however, explain
the inhibitory effect of TGF-P on granulocyte apoptosis.
TNF-a is known to mediate apoptosis via the caspase cascade pathway that is also
utilised by Fas (Figure 1.2). It is not known whether TGF-P can enhance the activity
of this pathway, but it would be interesting to examine whether this cytokine can also
potentiate the effects of Fas receptor ligation on neutrophil apoptosis.
Other studies in which TNF-a causes apoptosis or growth inhibition correlate this
response with a reduction in levels of c-myc expression. For example, in HL-60
cells, TNF-a treatment causes growth inhibition and apoptosis with a 50% reduction
in c-myc mRNA in less than an hour (Kronke et al., 1987, Tobler et al., 1987). c-
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Myc protein was rapidly down-regulated in apoptotic HL-60 cells and apoptosis
could be induced by c-myc antisense oligonucleotides (Kumakura et al., 1996).
These results suggest that the down-regulation of c-myc may be closely associated
with apoptosis in HL-60 cells treated with TNF-a (Kumakura et al., 1996).
In U937 cells, both TNF-a and TGF-P could marginally inhibit cell proliferation, but
together they acted synergistically (Hori et al., 1994). TNF-a concentration-
dependently reduced c-myc expression in these cells, and again TGF-P behaved
synergistically, only marginally reducing c-myc mRNA alone. Changes in the half-
life of c-Myc were not involved: the effect was mediated via a reduction in
transcriptional activity of the gene (Hori et al., 1994). In B cell lymphoma cells,
WEH1 231 and CH31 cells, TGF-P mediated apoptosis was preceded by a decline in
c-Myc expression (Warner et al., 1992, Fischer et al., 1994, Arsura et al. 1996).
The c-myc gene has been strongly implicated in the regulation of cellular death.
Overexpression or inappropriate expression of the c-myc gene promotes apoptosis in
myeloid and fibroblast cells upon removal of growth factors (Askew et al., 1991,
Evan et al., 1992). In contrast, in immature B cell models of tolerance, such as
WEH1 231 and CH31 and CH33 cells (Kim et al., 1979, Ralph, 1979, Boyd &
Schrader, 1981, Monroe & Seyfert, 1988), a drop in c-Myc expression is correlated
with induction of apoptosis. An early transient increase, followed by a dramatic
decline in levels of c-myc RNA and protein, precedes anti-Ig receptor-mediated
induction of apoptosis in WEH1 231 and CH 31 B cells (McCormack et al., 1984,
Levine et al., 1986, Ales-Martinez et al., 1988; Benhamou et al., 1990, Hasbold &
Klaus, 1990, Maheswaran et al., 1991). When these cells are stably transfected to
express IgD, anti IgM and anti IgD treatments cause transient increases of c-Myc
expression. However, only IgM caused a decline in c-myc RNA levels below
baseline, followed by apoptosis. Anti-IgD treatment maintained c-myc expression at
or above control levels and no induction of apoptosis was noted (Ales-Martinez et
al., 1988, Tisch et al., 1988). Similarly, mutants of WEH1 231 that failed to induce
apoptosis in response to anti-immunoglobulin displayed sustained c-Myc expression
(Hibner et al., 1993).
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c-myc gene expression is controlled, in part by NF-kB binding (Lee et al., 1995b).
Treatment ofWEH 231 cells with TGF-(31 decreased NF-kB binding in the nucleus
(Arsura et ah, 1996), correlating with increased expression of the IkBo. gene (Arsura
et ah, 1996). In turn, the reduction in NF-kB binding correlated with a drop in c-Myc
levels (Arsura et al., 1996). It therefore seems likely that inhibition of NF-kB
downmodulates c-Myc expression inducing death of these cells (Arsura et al., 1996).
TGF-P treatment rapidly downregulates c-myc mRNA and protein levels in TGF-P
sensitive cells (Pientenpol et al., 1990, Munger et al., 1992, Malliri et al., 1996).
Neutrophils and eosinophils are both sensitive to the effects of TGF-p (Figure 4.4),
Therefore the effects on c-Myc levels of TNF-a and TGF-p both alone and in co-
culture in neutrophils should be examined. This could be achieved using in situ
hybridisation, northern and western blots.
Enhanced sensitivity to TNF-a in NF-kB deficient cells has been demonstrated (Beg
& Baltimore, 1996, Van Antwerp et al., 1996, Wang et al., 1996). Therefore the
most likely explanation for the enhancement of the pro-apoptotic effect of TNF-a by
TGF-P is that this cytokine upregulates expression of iKBa leading to suppression of
NF-kB. This would not cause a permanent suppression but would ensure a faster
cycling of the transcription factor from the nucleus back to the cytoplasm. This in
turn would cause a fall in levels of c-Myc, a protein with a half-life of only 15-30
min (Blackwood & Eisenman, 1991).
Why IL-10, which also inhibits NF-kB, does not potentiate the pro-apoptotic effects
of TNF-a is not known. However, Thompson et al., (1995) showed that while some
inducers of NF-kB rapidly and transiently activate this transcription factor through
IKBa (TNF-a), others such as LPS cause a more persistent activation by affecting
IKBa and IkBP. One possibility is that IL-10 inhibits this more persistent induction
through interference with IkBP activation rather through IKBa. This would explain
why IL-10 does not inhibit the effects of TNF-a on neutrophil apoptosis and why
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only a partial reversal of LPS-induced activation is achieved. It would therefore be
of interest to co-culture neutrophils with TNF-a, TGF-p and IL-10 to examine
whether this could further potentiate the pro-apoptotic effect of TNF-a.
In view of the findings discussed here, we concluded that NF-kB might play an
important role in granulocyte survival and apoptosis. Therefore we decided to
examine the role of this transcription factor in these processes (Chapter 5).
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CHAPTER 5
THE ROLE OF THE TRANSCRIPTION FACTOR NF-kB IN
GRANULOCYTE APOPTOSIS
5.1 Introduction
The results depicted in Chapter 4, showing an upregulation of TNF-a-induced
neutrophil apoptosis by TGF-P, which has been demonstrated to inhibit NF-kB
activity by the production of IkB-cc (Arsura et al., 1996), prompted an in depth study
of the effect of this transcription factor on granulocyte apoptosis. The signalling
pathways and activation ofNF-kB are discussed in Section 1.14.3.
The role of NF-kB in apoptosis is controversial. Because NF-kB is activated by
some apoptotic stimuli, it may be involved in some aspects of programmed cell death
(Siebenlist et al., 1994, Verma et al., 1995, Baldwin, 1996). TNF-a, which induces
apoptosis in some cells, while also activating NF-kB, is an example of this (Figure
1.2). NF-kB activation in HL60 cells and thymocytes is associated with apoptosis
(Marinovich et al., 1996). Pyrrolidine dithiocarbamate (PDTC), a potent non¬
specific inhibitor of NF-kB activation prevents apoptosis in HL-60 cells and in
glucocorticoid-treated thymocytes (Bessho et al., 1994). Several groups have
therefore suggested that NF-kB may function pro-apoptotically under some
conditions and in certain cell lines (Jung et al., 1995, Lin et al., 1995a, Grimm et al.,
1996).
However, since the onset ofmy PhD studies, inhibition ofNF-kB has been shown to
induce apoptosis in other cell types, for example, murine B cells (Wu et al., 1996),
PC 12 cells (Taglialatela et al., 1997), and HT 1080 fibrosarcoma cells (Wang et al.,
1996). In HeLa and MCF7 cells, TNF-a-induced NF-kB activation prevents cell
death (Lui et al., 1996). The active form ofNF-kB is most frequently composed of
p50/RelA heterodimers (Blank et al., 1992, Nolan & Baltimore, 1992); mice lacking
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the p65/RelA gene die from extensive apoptosis within the liver, suggesting an anti-
apoptotic function for NF-kB (Beg et ah, 1995). Many cells that respond to TNF-a
with strong activation ofNF-kB are resistant to programmed cell death (Holtmann et
ah, 1991). More pertinently to this thesis, disruption of IkB-oc in mice results in
prolonged activation of NF-kB in response to inflammatory stimuli, with animals
dying of widespread inflammation (Klement et ah, 1996). Rel B or p50 null mice
have defects in both immune and inflammatory responses (Sha et ah, 1995, Weih et
ah, 1995). Several groups have also reported that inactivation of NF-kB increases
the cytotoxic effects of TNF-a (Beg & Baltimore, 1996, Van Antwerp et ah, 1996,
Wang et ah, 1996,).
Such studies emphasise the importance ofNF-kB in inflammatory responses and cell
survival and suggest that NF-kB inhibition might be necessary for resolution to
occur, but the role of NF-kB in granuloctye apoptosis is currently unknown. It has
recently been reported that LPS, TNF-a and fMLP activate NF-kB in neutrophils
(McDonald et ah, 1997), but Browning et ah, (1997) found no activation in these
cells despite obvious NF-kB activation in peripheral blood mononuclear cells.
Because granulocytes are short-lived, terminally differentiated cells, NF-kB
inhibition by genetic manipulation is not feasible; therefore the studies discussed in
this chapter were performed using other methods of inhibition. Most studies use
antioxidants or protease inhibitors to block activation ofNF-kB.
Antioxidants with this ability include N-acetyl-L-cysteine, 2-mercaptoethanol,
dithiocarbamates, a-lipoic acid, vitamin E, and iron and copper chelators (Schreck et
ah, 1991, 1992a, b, Meyer et ah, 1993). These findings suggest that NF-kB
activation depends on the cell's redox status which is determined by the
concentrations of ROS that occur as intermediates in the reduction of O2 to H2O
during cellular respiration (Halliwell & Gutteridge, 1989). Important ROS are O2 ",
H2O2, hydroxyl radicals, and singlet oxygen ('02). GSH (glutathione), a major
intracellular reducing agent (Hedley & Chow, 1991), reduces and might therefore
block NF-kB activation in vivo. Well-established roles of GSH are to reduce the
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intracellular H2O2 load, reduce intracellular free radicals and to maintain protein thiol
groups in the reduced state (Ratan et ah, 1994). Interestingly, GSH levels fall in
neutrophils as the cells undergo ageing (Narayanan et ah, 1997).
H2O2 activates NF-kB in Jurkat T cells and HeLa cells and this is inhibitable by
antioxidants (Schreck et ah, 1991). It is notable that in many cell lines, O2 '(^ and
nitric oxide do not cause rapid activation ofNF-kB, suggesting that NF-kB might be
specifically influenced by H2O2 and other peroxides rather than other ROS (Schreck
et ah, 1992a, Meyer et ah, 1993). However, since in some cell types H2O2 does not
induce transcription from kB-reporter constructs in unless PMA or TNF-a are added
(Israel et ah, 1992, Ziegler-Heitbrook et ah, 1993), H2O2 might act not directly but
by establishing a redox state that facilitates activation ofNF-kB by other stimuli. In
intact cells oxidant treatment induces rather than inhibits NF-kB activity (Schreck et
ah, 1991). Nevertheless antioxidants, for example reduced thiols such as
dithiothreitol, cysteine, dihydrolipoate, and reduced thioredoxin, can enhance the
DNA binding of activated NF-kB (Matthews et ah, 1992, Okamoto et ah, 1992,
Hayashi et ah, 1993, Gaiter et ah, 1994, Suzuki et ah, 1995a, b). Overall, these
results suggest the possibility of redox facilitation of both NF-kB activation and
DNA binding of the transcription factor.
Redox regulation of DNA binding has also been proposed for AP-1 (Abate et ah,
1990), the role of which in cell survival is also controversial. AP-1-related effects
might therefore complicate studies of NF-kB inhibition by antioxidants. TNF-a-
induced ROS production stimulates AP-1 expression (Lo & Cruz, 1995), and
mitogen-induced AP-1 activity is inhibited by antioxidants, suggesting that it is ROS
mediated (Goldstone et ah, 1995). N-acetyl-choline, (NAC) inhibits AP-1 activation
and prevents the induction of c-fos and c-jun mRNAs (Datta et ah, 1992, Collart et
ah, 1995, Janssen et ah, 1995). However, contradictory data have been obtained
concerning the mode of AP-1 regulation by reduced thiols; for instance, NAC
enhanced DNA binding activity and transactivation (Meyer et ah, 1993, Schenk et
ah, 1994). Treatment with antioxidants alone also strongly activated DNA binding
and transactivation of AP-1, suggesting that AP-1 behaves as an antioxidant-
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responsive transcription factor (Choi & Moore, 1993, Meyer et al., 1993).
Thioredoxin, a powerful thiol reducer and major protein oxidoreductase inside the
cell (Holmgren 1985), increased PMA-induced AP-1 transcriptional activity in a
concentration-dependent manner in HeLa and L929 cells. This effect was shown to
be specific to the antioxidant property of thioredoxin (Meyer et al., 1993, Schenk et
ah, 1994). These studies also demonstrated that other thiol reducing agents (PDTC,
2-mercaptoenthanol, butylated hydroxyanisole and NAC) enhance DNA binding
activity and transactivation of AP-1 (Schenk et ah, 1994). Conversely, elevation of
intracellular levels of GSSG before stimulation increased AP-1 transactivation
(Gaiter et ah, 1994).
PDCT has been shown to inhibit NF-kB in many studies (Beg et ah, 1993, Henkel et
ah, 1993, Sun et ah, 1993), but again no simple generalisations can be made. PDTC
(3 - 30 pM) increased GSSG levels in Molt-4 (lymphocyte cell line) cells and
inhibited NF-kB activity, but a higher concentration (300 pM) reconstituted the NF-
kB activity (Gaiter et ah, 1994). Protein tyrosine phosphatase (PTP) inhibitors
strongly activate NF-kB, but PDCT did not prevent this activation in lymphocytes,
and conversely pre-treatment of these cells with PDCT enhanced rather than
inhibited NF-kB activity (Krejsa et ah, 1997). Therefore PTP inhibitors can activate
NF-kB by a mechanism that is independent of intracellular redox status (Krejsa et ah,
1997).
Currently, the interaction between NF-kB activation through IkB phosphorylation
and degradation, oxidative stress, and ceramide is not well understood (Akira &
Kishimoto, 1997). Therefore, using antioxidants to inhibit NF-kB in this work might
be complicated by any effects on the activity of AP-1, since the role of this
transcription factor on cell survival is also controversial.
Serine protease inhibitors are powerful inhibitors of NF-kB activation in intact cells,
but they are not specific (Henkel et ah, 1993). For example, TPCK (Tosyl-Phe-
chloromethylketone) inhibited AP-1 binding in TNF-a treated HeLa cells (Finco et
ah, 1994). Also, TPCK did not strongly interfere with NF-kB activity when added
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after stimulation with PMA, IL-1 or LPS (Henkel et al., 1993). Other NF-kB
inhibitors with more specific effects are now available. Gliotoxin, a member of the
epipolythiodioxoperazine family (Braithwaite et al., 1987), synthesised as a
secondary metabolite by Aspergillus fumigatus and other pathogenic fungi (Cole &
Cox, 1981, Jordan & Cordiner, 1987, Shah & Larsen, 1991), is reported to be a
specific inhibitor of the RelA/p50 NF-kB isoform (Pahl et al., 1996). Gliotoxin
exhibits immunosuppressive activity both in vivo and in vitro. For example, it
inhibits mitogen-induced proliferation of both T and B cells, induces macrophage
and osteoclast apoptosis in vitro (Waring et al., 1988, 1990, Ozaki et al., 1997), and
causes thymocyte and spleen cell apoptosis in vivo (Sutton et al. 1994). The known
biological properties of gliotoxin include the ability to undergo redox cycling and
generate oxygen free radicals that cause oxidative damage to isolated DNA in vitro
(Eichner et al., 1988).
The pleiotropic effects of gliotoxin described in various studies may be attributed to
the use of different concentrations of the compound. As an
epipolythiodioxopiperazine derivative, gliotoxin has the potential to react covalently
at high concentrations with sulphydryl residues in polypeptides. However, at
relatively low concentrations, gliotoxin was found to selectively inhibit the activation
of NF-kB in a number of cell lines, with no detectable effect on the DNA-binding
activity of CREB, Oct-1, NFAT, or Statl, or any inhibition of the tyrosine kinase
activities of Lck and Fyn in intact cells (Pahl et al., 1996). Gliotoxin did not directly
modify and inactivate NF-kB in intact cells; this only occurred at high concentration
(millimolar) in vitro, suggesting that the redox-sensitive cysteine residues in the
DNA-binding domains of NF-kB proteins remained intact under cell culture
conditions, and ipso facto that the fungal immunosuppressant very selectively
interfered with NF-kB activation (Pahl et al., 1996).
As IkBoc and (3 subunits are degraded, the NLS of NF-kB is exposed and allows
nuclear translocation (Cordle et al., 1993, Donald et al., 1995). Synthetic peptides
containing a cell-permeable motif and the nuclear localisation sequence (NLS) of
p50 have been developed. These peptides inhibit movement of NF-kB complexes
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from the cytoplasm to the nucleus by blocking the intracellular recognition
mechanism for the NLS present on p50 heterodimers (Lin et ah, 1995b). Therefore
they should also block translocation of p50/RelA heterodimers.
Several physiological mediators such as protein kinase C (PKC) and nitric oxide
(NO) may also be involved in the regulation of NF-kB activity. PKC isoforms are
categorised in three groups: conventional PKCs (cPKCs a, pi, P2 and y), new PKCs
(nPKCs 5, s, and p.) and atypical PKCs (aPKCs and X) (Nishizuka, 1992). PKC C,
activation via ceramide may link the TNF-a receptor to NF-kB since TNF-a or
ceramide increase phosphorylation of this isoform (Lozano et ah, 1994, Muller et ah,
1995, Spiegel et ah, 1996). PKC C,, has been suggested to phosphorylate IkB-oc and
has been demonstrated to cause dissociation of the NF-kB-IkB-cc complex in vitro
(Shirikawa & Mizel, 1989) and is necessary for NF-kB activation in Xenopus
oocytes and mammalian cells (Diaz-Meco et ah, 1994); it might act by
phosphorylating IkB-cl In apoptotic U937 cells, the expression of PKC C, is reduced
while that of PKC pi is increased (Pongracz et ah, 1995). If PKC C, is linked to the
induction of active NF-kB and NF-kB is a survival factor, this would suggest a role
in programmed cell death for both these PKC isoforms. A dominant negative PKC £
protein inhibits NF-kB activation by TNF-a, while constitutively active PKC C,
activates NF-kB in NIH3T3 cells (Diaz-Meco et ah, 1993); though it has been
reported that some inhibitors of PKC, which block PMA-induced activation of NF-
kB, fail to block TNF-a-induced activation (Meichle et ah, 1990). Other studies
support a role for PKC in NF-kB activation. Full activation in T cells requires the
2+combined action of a Ca -mobilizing and a protein kinase C-activating signal
(Emmel et ah, 1989, Tong-Starksen et ah, 1989). NF-kB is activated in many cell
types by PMA, which is a direct stimulator of PKC, and this activation can be
efficiently blocked by antioxidants which are known inhibitors ofNF-kB (Schreck et
ah, 1992a, Meyer et ah, 1993). H8, a membrane-permeable inhibitor of cyclic
nucleotide-dependent protein kinases and PKC, inhibits NF-kB activation by IL-1
and LPS (Shirikawa & Mizel, 1989). A range of antineoplastic agents which activate
both PKC and NF-kB in A549 cells were blocked by the PKC inhibitors calphostin C
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and GF109203X again suggesting a role for PKC in activation (Das & White, 1997).
Pharmacological data argue against a direct phosphorylation of IkB by PKC in intact
cells, but PKC may be indirectly involved, for example in a kinase cascade which
leads to ultimate phosphorylation and activation of the actual kinase responsible.
Nitric oxide (NO) plays an important role in a number of physiological and
pathological processes, displaying pro-inflammatory or anti-inflammatory effects
depending on its effective concentration at the inflammatory site (Barnes & Belvisi,
1993, Brady & Poole-Wilson, 1993, Kubes, 1995, Moilanen & Vapaatalo, 1995,
Barnes, 1996). It can modulate certain neutrophil responses (Kaplan et al., 1989,
Kubes, 1991, Clancey et al., 1992, Moilanen et al., 1993) and induce apoptosis in
several other cell types (Albina et al., 1993, Blanco et al., 1995, Kuo et al., 1996).
Treatment of cells with nitric oxide (NO)-generating compounds such as sodium
nitroprusside (SNP), S-nitroso-N-acetylpenicillamine and S-nitrosoglutathione
(GSNO) influences activation of NF-kB (Siebenlist et al., 1994, Matthews & Hay,
1995); in human vascular endothelial cells, activation of NF-kB was inhibited by
treatment with SNP and GSNO by a mechanism thought to involve both stabilization
of IkBgc and increased transcription of the IkBcc gene (Peng et al., 1995a, b).
However, NO has also been found to inhibit p50 and p65 DNA binding activity
(Matthews et al., 1996). NO modulates the biological activity of proteins by direct
interactions with their iron centres or by S-nitrosylation of cysteines to form S-
nitrosothiols, and this could affect the activity of NF-kB (Matthews et al., 1996).
Inhibition of NF-kB by physiological mediators such as NO may represent an
important mechanism for resolution of inflammation especially since this
transcription factor is linked to the survival of inflammatory cells. The controversies
surrounding the role of NF-kB in apoptosis and cell survival may be due to
characteristic cell differences in responses to inhibitors and activators, or to other
non-specific effects of the inhibitors used in blocking studies. Therefore the work
presented in this chapter examines the role ofNF-kB, using a broad range of reported
NF-kB inhibitors on granulocyte survival and on the pro-apoptotic effects of TNF-




5.2.1 The Effect of Gliotoxin on Constitutive and TNF-a Mediated
Granulocyte Apoptosis
Figure 5.1 A illustrates the rapid induction of neutrophil apoptosis in vitro by
gliotoxin. This induction was both concentration (e.g. at 6 h EC50 = 76.1 ± 22.1
ng/ml) and time-dependent. Using a concentration of 1 pg/ml, apoptosis was readily
apparent within 2 h and reached 100 % by 6 h. At 20 h, when the rate of constitutive
neutrophil apoptosis was 58.7 ± 2.9 %, gliotoxin increased this to 100% at all
concentrations greater than 0.1 pg/ml. The inactive analogue of gliotoxin,
methylthiogliotoxin (30 pg/ml), did not affect the constitutive rate of neutrophil
apoptosis at any of the time-points studied (2, 6 and 20 h) (Figure 5.1 B). Neither
gliotoxin nor methylthiogliotoxin caused cell necrosis since less than 1% of the
treated cells were permeable to the vital dye trypan blue.
Figure 5.2 A illustrates the effect of gliotoxin on TNF-a-induced neutrophil
apoptosis. These experiments were performed at 2 h when the independent pro-
apoptotic effects ofTNF-a (12.5 ng/ml) and gliotoxin (0.1 pg/ml) (Figure 5.1 A) are
only just apparent. As shown in Figure 5.2 A, gliotoxin synergistically increased
TNF-a-mediated neutrophil apoptosis even at gliotoxin concentrations as low as 3
ng/ml. A concentration of gliotoxin of 0.1 pg/ml in combination with TNF-a (12.5
ng/ml) caused almost 100 % apoptosis at 2 h. With gliotoxin alone, only 6.2 ± 2.2 %
apoptosis was noted at 2 h with 65.9 ± 9.6 % at 6 h (Figure 5.1 A). Interestingly, the
synergy between the two agents decreased as the concentration of gliotoxin was
increased above 0.1 pg/ml. Again, methylthiogliotoxin (30 pg/ml) had no effect on
constitutive or TNF-a-induced apoptosis at 2 h (Figure 5.2 B) and despite the rapid
induction of apoptosis, the levels of necrosis were less than 1 % as assessed by
trypan blue exclusion.
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Figure 5.1 The Effect of Gliotoxin on Constitutive Neutrophil Apoptosis
A) Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control) or with gliotoxin (0.001 - 30 pg/ml) and harvested at 2, 6 or 20
h. B) Neutrophils were incubated as above with gliotoxin (30 pg/ml) or
methylthiogliotoxin (30 pg/ml) and harvested at 2, 6 or 20 h. Apoptosis was
assessed morphologically. Data represent the mean ± SEM of 3 separate
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Figure 5.2 The Effect of Gliotoxin on Constitutive Neutrophil Apoptosis
A) Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control) or with gliotoxin (0.001 — 30 pg/ml) ± TNF-a (12.5 ng/ml)
and harvested at 2 h. Filled bars indicate gliotoxin alone; open bars indicate TNF-a
+ gliotoxin. B) Neutrophils were incubated as above with gliotoxin (30 pg/ml) or
methylthiogliotoxin (30 pg/ml) ± TNF-a and harvested at 2 h. Apoptosis was
assessed morphologically. Data represent the mean ± SEM of 3 separate
experiments. All experiments were performed in triplicate (* p < 0.05 compared
with control values; # p < 0.05 compared with control or TNF-a alone).
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5.2.2 The Effect of Gliotoxin on Constitutive Eosinophil Apoptosis and Co-
culture with TNF-a
Eosinophils do not undergo apoptosis in response to TNF-a (Figure 4.8 B). Since
NF-kB inhibition has been shown to increases the susceptibility of cells to the
cytotoxic effects of TNF-a (Beg & Baltimore, 1996, Van Antwerp et ah, 1996,
Wang et ah, 1996), we investigated the effect of gliotoxin on eosinophil apoptosis at
4 h in the presence and absence of this cytokine. The results shown in Figure 5.3 A
demonstrated that gliotoxin induced apoptosis in eosinophils (EC50 = 0.37 ± 0.22
pg/ml) as it does in neutrophils, and caused a synergistic increase in the rate of
apoptosis when the cells were co-cultured with TNF-a. Almost 100% apoptosis was
observed using a gliotoxin concentration of 0.1 pg/ml plus TNF-a at a time-point of
4 h. In comparison, eosinophils cultured in the absence of gliotoxin would normally
show only 40% apoptosis at a 40 h time-point (Figure 3.1) (Stern et ah, 1992, Ward
et ah, 1997). Again the synergistic action of TNF-a plus gliotoxin was greatest
using a concentration of gliotoxin of 0.1 pg/ml. Necrosis in these cells was less than
2% and the inactive analogue of gliotoxin had no effect on either the constitutive rate
of apoptosis alone or in conjunction with TNF-a (Figure 5.3 B).
5.2.3 The Mode of Cell Death Induced by Gliotoxin and TNF-a is Apoptotic
Not Necrotic
Figures 5.4 and 5.5 demonstrate the classic apoptotic morphology of neutrophils and
eosinophils when treated TNF-a (12.5 ng/ml) and gliotoxin (0.1 pg/ml). The
changes from normal cell morphology to apoptotic morphology are clearly seen in
Figure 5.4 A, where non-apoptotic neutrophils contain a multi-lobed nucleus, and
Figure 5.4 D, where the apoptotic cells have a shrunken appearance with pyknotic
nuclei. Figure 5.5 A and D demonstrate a similar effect in eosinophils.
To ensure that this rapid induction of cell death was genuine apoptosis, the effect of
gliotoxin and its synergy with TNF-a were also assessed by annexin V binding and
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DNA fragmentation. In Figure 5.6 the annexin V 'low peak' represents non-apoptotic
cells and the 'high-peak' represents apoptotic cells. Although control cells at 2 h
exhibit low rates of apoptosis, the small increase in annexin V positive cells observed
with TNF-ct and gliotoxin alone is dramatically augmented when the cells are
cultured in the presence of both reagents together. These results are consistent with
Figure 5.2. Analysis by DNA fragmentation (Figure 5.7) demonstrates that cells
cultured alone or in combination with the above reagents exhibit the classical
"ladder" ofDNA fragmentation associated with apoptosis.
Initial studies used trypan blue as a marker of plasma membrane integrity. However,
given the rapid rate of apoptosis mediated by co-culture of granulocytes with TNF-a
and gliotoxin, it was important to validate this by assessing necrosis in an
independent manner. Figure 5.8 shows the profile of neutrophils at 4 h (2 h later than
the experiments shown in Figure 5.2 A) after treatment with gliotoxin (0.1 pg/ml)
and TNF-a (12.5 ng/ml). Despite apoptotic rates of 100% at 2 h, almost all cells,
showed low fluorescence using propidium iodide staining detected by flow
cytometry, indicating that the cell membrane had remained intact. As a positive
control, cells cultured initially with TNF-a and gliotoxin were heat-treated (60 °C for
5 min) to ensure 100% necrosis. This resulted in a uniform and major increase in
propidium iodide staining (Fig 5.8). These data coincide completely with the results
obtained with trypan blue staining and confirm that the cells had undergone apoptotic
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Figure 5.3 The Effect of Gliotoxin on Constitutive Eosinophil Apoptosis
A) Eosinophils (2.0 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control) or with gliotoxin (0.001 - 30 pg/ml) ± and harvested at 4 h. B)
Eosinophils were incubated as above with gliotoxin (0.01 - 30 pg/ml) ± TNF-a and
harvested at 4 h. (Filled bars, gliotoxin alone, open bars, gliotoxin + TNF-a).
Apoptosis was assessed morphologically. Data represent the mean ± SEM of 3
separate experiments. All experiments were performed in triplicate (* p < 0.05
compared with control values; # p < 0.05 compared with control or TNF-a alone).
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figure 5.4 Morphology ofNeutrophils Treated with Gliotoxin and TNF-a
'hotomicrographs (x 1250 magnification) of cytocentrifuge preparations.
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
erum alone A) (control), B) with gliotoxin (0.01 pg/ml), C) with TNF-a (12.5
.g/ml) or D) with both gliotoxin and TNF-a. Cells were harvested at 2 h.
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Figure 5.5 Morphology ofEosinophils Treated with Gliotoxin and TNF-a
Photomicrographs (xl250) of cytocentrifuge preparations of cultured eosinophils.
Eosinophils (2 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone A) (control), B) with gliotoxin (0.01 pg/ml), C) with TNF-a (12.5












Figure 5.6 Flow Cytometry Profiles of Neutrophils Stained with Annexin V
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone A) (control), B) with gliotoxin (0.01 pg/ml), C) with TNF-a (12.5
ng/ml) or D) with both gliotoxin and TNF-a. Cells were harvested at 2 h and
samples from each condition incubated with Annexin 'V'. Data shown are from 1
representative experiment.
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Figure 5.7 DNA Fragmentation
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum. Lane 1) freshly isolated neutrophils, lane 2) control, lane 3) cells cultured
with gliotoxin (0.1 pg/ml), lane 4) cells cultured with TNF-a (12.5 ng/ml), lane 5)
gliotoxin (0.1 pg/ml), and TNF-a (12.5 ng/ml). Cells were harvested at 2 h and
DNA extracted and electrophoresed.
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Figure 5.8 Flow Cytometry Profiles of Necrotic and Apoptotic Neutrophils
Stained with Propidium Iodide
A) Neutrophils (5 x 106/ml) were incubated for 4 h with gliotoxin (0.1 pg/ml) and
TNF-a (12.5 ng/ml). B) Cells were treated as above but heated-treated to ensure
necrosis. Samples were stained with propidium iodide and analysed by flow
cytometry. Data shown are from 1 representative experiment.
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5.2.4 The Effect of Gliotoxin on NF-kB Activation
Gliotoxin has been reported to act as a specific inhibitor ofNF-kB (Pahl et al., 1996).
Experiments were aimed to identify and characterise the expression of NF-kB in
human neutrophils and to determine whether gliotoxin could inhibit such activity.
Because apoptosis results in the fragmentation of DNA (Figure 5.7), inhibition of
NF-kB activity could be due to the loss of binding sites in apoptotic cells. Therefore
a preliminary time-course was performed (Figure 5.9 A and B). At 1 h, no
synergistic interactions were noted between TNF-a and gliotoxin. Ninety minutes
was established as the optimal time to examine basal gliotoxin and TNF-a regulated
NF-kB activity in neutrophils, and coincided with the onset of the biologically
observable effect of gliotoxin (Figure 5.9 B).
As shown in Figure 5.10, NF-kB EMSAs performed on neutrophil nuclear extracts
indicated the presence of 3 discrete bands. To ascertain which of these bands were
specifically NF-kB, an excess of unlabelled probe was included in the labelling
reaction to displace specific binding; as shown in Figure 5.11, two NF-kB bands
were identified and designated A and B. No change in the intensity of band B was
observed with any of the treatments undertaken (Fig 5.10). This, together with its
strong expression in freshly prepared untreated neutrophils, suggests that this band
may represent a form of constitutively active NF-kB. However, band A was
markedly upregulated by TNF-a (Fig 5.10), and as shown in Figure 5.10, gliotoxin
caused a concentration-dependent inhibition of this NF-kB activity and abolished the
TNF-a-stimulated increase in this band. As shown in Figure 5.12, densitometric
analysis of these data confirmed that co-treatment of neutrophils with TNF-a and
gliotoxin at a lower concentration (0.1 pg/ml) inhibited this band more than
treatment with gliotoxin alone. Treating neutrophils with LPS (100 ng/ml for 20 min)
was found to cause the appearance of this inducible isoform ofNF-kB (Figure 5.13)
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Figure 5.9 The Effect of Gliotoxin on Constitutive Neutrophil Apoptosis
A) Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control) or with gliotoxin (0.1 pg/ml) ± TNF-a (12.5 ng/ml) and
harvested at 1 h. Data represent the mean ± SEM of 3 separate experiments
performed in triplicate, (* p < 0.05 compared with control values). B) Neutrophils
were incubated as above with gliotoxin (0.1 pg/ml) or TNF-a (12.5 ng/ml) and
harvested at the timepoints shown. Data shown are from a representative
experiment. Apoptosis was assessed morphologically.
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Figure 5.10 EMSA ofNK-kB in Neutrophil Nuclear Extracts
Neutrophils (5 x 106/ml) were incubated for 90 min. Lane 1) control, lane 2) TNF-a
(12.5 ng/ml), lane 3) gliotoxin (1 pg/ml), lane 4) gliotoxin (0.1 pg/ml) and lane 5)
gliotoxin (0.1 ug/ml) with TNF-a. Nuclear extracts were prepared as detailed in
Section 2.1.11 and samples electrophoresed.
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Figure 5.11 Displacement ofNK-kB Binding by Cold Probe
Neutrophils (5 x 106/ml) were incubated for 90 min with serum alone (control) or
TNF-a (12.5 ng/ml) for 90 min. Nuclear extracts were prepared as detailed in
Section 2.2.10 Samples were incubated with labelled probe. Lane 1 Control, Lane 2
TNF-a, Lane 3 TNF-a with the addition of 50 x excess cold probe, Lane 4 TNF-a
with the addition of 100 x excess cold probe. Excess cold AP-1 (negative control) did
not displace binding (M. Lawson - personal communication).
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Figure 5.12 Densitometry Scanning of Gel Shown in Figure 5.11




Figure 5.13 EMSA ofGliotoxin and LPS-treated Neutrophils
Neutrophils (5 x 106) were incubated in Iscove's DMEM. Lane 1) control, lane 2)
LPS (100 ng/ml), and lane 3) LPS plus gliotoxin (0.1 p.g/ml). Cells were harvested
at 20 min and nuclear extracts prepared as detailed in Section 2.1.11.
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5.2.5 The Role of Caspases in TNF-a- and Gliotoxin-Induced Apoptosis
To determine whether the pro-apoptotic effects of gliotoxin and the marked
synergism displayed by TNF-a and gliotoxin were mediated via activation of the
caspase pathway, neutrophils were co-incubated with TNF-a, gliotoxin
and benzyloxycarbonyl-valinyl-alaninyl-aspartyl (O-methyl)-flouromethylketone
(zVAD-fmk) (Figure 5.14). At 2 h, zVAD-fmk completely inhibited the increase in
apoptosis induced by gliotoxin, TNF-a and by both factors together [TNF-a (12.5
ng/ml) 9.9 ± 3.1 %, TNF-a plus gliotoxin (0.1 pg/ml) 91.7 ± 4.0 %, gliotoxin in the
presence of TNF-a plus ZVAD-fmk (10 pM) 2.9 ± 1.0 %]. This demonstrates that
apoptosis induced by both factors, alone or together, is dependent on caspase
activation.
The results shown in Figure 5.14 suggest that activation of the inducible form ofNF-
kB may inhibit the pro-apoptotic effects of TNF-a which are mediated by activation
of the caspase pathway, possibly by the production of a protective protein or
protein(s). As shown in Figure 5.15, the protein synthesis inhibitor CHX used
specifically at a concentration (5 pM) that alone had almost no effect on neutrophil
apoptosis at 2 h but caused a synergistic increase in the level of apoptosis when cells
were co-cultured with TNF-a. [Control 0.5 ± 0.2 %, TNF-a (12.5 ng/ml) 5.9 ± 1.5
%, CHX (5 pM), 1.0 ± 0.2 %, CHX plus TNF-a 75.5 ± 4.9 %, CHX plus TNF-a and
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Figure 5.14 The Effect of zVAD-fmk on Gliotoxin and TNF-a-mediated
Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), zVAD-fmk (10 mM), TNF-a (12.5 ng/ml) or gliotoxin (0.1
mg/ml), or in combination as shown. Cells were harvested at 2 h. Apoptosis was
assessed morphologically. Data represent the mean ± SEM of three separate












































Figure 5.15 The Effect of Cycloheximide on TNF-a-induced Neutrophil
Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control). TNF-a (12.5 ng/ml), CHX (5 pM) or zVAD-fmk (10 pM), or
in combination as shown. Cells were harvested at 2 h. Apoptosis was assessed
morphologically. Data represent the mean ± SEM of 3 separate experiments. All
experiments were performed in triplicate (*p < 0.05 compared with control values).
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5.2.6 Other NF-kB Inhibitors
Cell permeable NF-kB inhibitory peptides (Lin et al., 1995b) also increased the rate
of constitutive neutrophil apoptosis (Figure 5.16) despite the fact that less than 5 %
of the peptide reportedly enters the cell (Lin et al., 1995b). At 6 h, the SN50 peptide
increased neutrophil apoptosis from 4.7 ± 1.2 % to 15.0 ± 3.2 %, whereas the less
active peptide SN50M only increased apoptosis from 4.7 ± 1.2 to 5.6 ± 0.8 %.
Similar effects on neutrophil apoptosis were seen at 20 h.
Figure 5.17 illustrates the effect of the PKC inhibitor Ro 31,8220 on neutrophil
apoptosis at 2h. At this timepoint, concentrations of Ro 31,8220 (0.01 - 10 pM) had
no affect on constitutive neutrophil apoptosis alone, but a concentration of 10 pM
with TNF-a caused a synergistic increase from 8.0 ± 4.6 % (TNF-a) to 67.0 ± 7.0 %.
NO has also been reported to inhibit NF-kB activity (Matthews et al., 1996). As
demonstrated in Figure 5.18, the NO donor GEA 3162 also induced neutrophil
apoptosis at 4 h [control 1.4 ± 0.4 %; GEA 3162 (30 pM) 14.8 ± 4.6 %], and more
than doubled the TNF-a effect from 11.3 ± 1.9 to 26.3 ± 1.5 % at this timepoint.
The antioxidant PDCT (Figure 5.19) significantly increased neutrophil apoptosis at
20 h [control 59.2 ± 8.0 %; PDCT (300 pM) 85.4 ± 3.3 %]. However there was no
significant difference in rates of apoptosis between TPCK (20 pM) treated





Figure 5.16 The Effect of the NF-kB Inhibitory Peptide SN50 on Neutrophil
Apoptosis
Neutrophils (5 x 106/ml) were pre-incubated for 15 min with SN50 or SN50 M (100
pg/ml) in Iscove's DMEM before the addition of 10% autologous serum to all
treatments. Cells were harvested at 6 and 20 h. Apoptosis was assessed
morphologically. Data represent the mean ± SEM of 3 separate experiments. All






















Figure 5.17 The Effect of the PKC inhibitor Ro 31,8220 on Constitutive and
TNF-a-induced Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control) or Ro 31,8220 (0.01 - 10 pM) or TNF-a (12.5 ng/ml) as
shown. Cells were harvested at 2 h. Apoptosis was assessed morphologically. Data
represent the mean ± SEM of 3 separate experiments. All experiments were



























Figure 5. 18 The Effect of the NO Donor GEA 3162 on Constitutive and TNF-
a-Induced Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control), TNF-a (12.5 ng/ml) or GEA 3162 (30 pM) as shown. Cells
were harvested at 2 and 4 h. Apoptosis was assessed morphologically. Data
represent the mean ± SEM of 3 separate experiments. All experiments were
preformed in triplicate (*p < 0.05 compared with control values, # p < 0.05
compared with TNF-a alone).
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Figure 5.19 The Effect of the Antioxidant PDCT on Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum (control) or PDTC (300 pM). Cells were harvested at 20 h. Apoptosis was
assessed morphologically. Data represent the mean ± SEM of 3 separate
experiments. All experiments were performed in triplicate (*p <0.05 compared with
control values).
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Figure 5.20 The Effect of TPCK on Neutrophil Apoptosis
Neutrophils (5 x 106/ml) were incubated in Iscove's DMEM supplemented with
serum alone (control) or TPCK (20 pM). Cells were harvested at 20 h. Apoptosis
was assessed morphologically. Data represent the mean ± SEM of 3 separate
experiments. All experiments were performed in triplicate.
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5. 3 Discussion
Collectively, the results described in this chapter suggest that the transcription factor
NF-kB has a central role in the survival of neutrophils and eosinophils.
Gliotoxin, a reportedly specific inhibitor of the RelA/p50 isoform of NF-kB at the
concentrations used in these experiments (Pahl et ah, 1996), induced a rapid, time-
and concentration-dependent increase in apoptosis in both neutrophils and
eosinophils (Figure 5. 1 A and 5.3 A), which was not mimicked by
methylthiogliotoxin, an inactive analogue (Pahl et al., 1996). Gliotoxin produced a
synergistic increase in TNF-a-mediated apoptosis in neutrophils (Figure 5.2 A), and
rendered eosinophils responsive to the pro-apoptotic effects of this cytokine (Figure
5.3). Co-culture of both granulocyte types with gliotoxin and TNF-a produced
maximal effects at the same concentration of gliotoxin (0.1 pg/ml), suggesting a
common mechanism for the induction of apoptosis in these cells. Although rates of
apoptosis fell as the concentration of gliotoxin increased in co-culture experiments,
the higher concentrations might have produced non-specific effects, perhaps
activating survival pathways. Pahl et al. (1996) found that concentrations of
gliotoxin higher than 1.0 pg/ml had inhibitory and stimulatory effects on the
activities of several unrelated gene promoters and enhancers. The concentrations
that give specific effects may also vary with cell type, therefore the effects of
gliotoxin in granulocytes should be examined further by investigating its effects on
transcription factors other than NF-kB. However, data (Figures 5.10 - 5.13) clearly
show that low concentrations of gliotoxin inhibit NF-kB in neutrophils (Figure 5.10 -
5.13).
EMSAs showed 2 specific bands in neutrophil nuclear extracts. Band B appeared to
be constitutively active while Band A showed inducible activity being upregulated
by TNF-a and LPS (Figure 5.10 and 5. 14). These results are in accordance with
McDonald et al. (1997), who also found constitutive activity in these cells. Band A
was markedly diminished by gliotoxin at 1.0 and 0.1 pg/ml. However, the greatest
inhibition of this band was induced by gliotoxin at 0.1 pg/ml plus TNF-a. These
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concentrations corresponded with those giving the greatest increase in apoptosis in
both neutrophils and eosinophils (Figure 5.2 A and 5.3 B). EMSAs distinctly show
inhibition of the inducible isoform of this transcription factor (Figure 5.10 to 5.13)
before the onset of apoptosis at 90 min (Figure 5.9). Data presented in Figures 5.4 -
5.8 confirm that cell death was apoptotic, and not necrotic, and demonstrate that
despite the rapid induction of apoptosis in granulocytes by co-culture with these two
agents, no cytotoxic effects were produced. These results suggest a strong
correlation between inhibition of this inducible isoform of NF-kB and the onset of
apoptosis. This observation is further strengthened by the induction of this band by
treatment with LPS (Figure 5. 13), a known inhibitor of granulocyte apoptosis (Lee
et al., 1993) and confirmed in Figure 3.4. In control neutrophils incubated for 20 h,
where the constitutive rate of apoptosis is approximately 70% (Figure 2.1), the
density of the constitutive NF-kB band was unaffected (data not shown), implying
that survival effects are mediated totally by the inducible band.
Embryonic fibroblasts from RelA-deficient mice are defective in the TNF-a-
mediated induction ofmRNA for MBa and GM-CSF, although basal levels of these
transcripts are unaltered. This indicates that RelA controls inducible, but not basal
transcription in NF-kB regulated pathways and that Rel A is a key regulator of genes
inducible by TNF-a (Beg et al., 1995). These differences in the inducible and
constitutive forms of NF-kB are most likely due to differential regulation of
activation, for example, by the involvement of different isoforms of the inhibitory
IkB subunit, or perhaps to the formation of the constitutively active NF-kB from a
different set of dimers from the classical RelA/p50 heterodimer. It has recently been
demonstrated that neutrophils contain c-Rel, p50, and pi05 (the p50 precursor
protein) as well as RelA (Druker et al., 1994, McDonald et al., 1997). The inducible
band observed has also been reported to be upregulated by phagocytosis of IgG
opsonised yeast particles (McDonald & Cassatella, 1997), and has been shown to
consist mainly of RelA/p50 heterodimers and possibly a small amount of c-Rel. In
that study, particle phagocytosis did not affect the activity of the constitutive
complex.
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Several mechanisms, aside from NF-kB inhibition, have been proposed for the pro-
apoptotic actions of gliotoxin in other cells. Sutton et al. (1995), have shown that
2~b
although this fungal metabolite did not affect intracellular Ca levels, there was a
correlation between increases in cAMP levels and apoptosis in gliotoxin-treated
splenocytes. However, agents that elevate intracellular cAMP inhibit apoptosis in
both neutrophils and eosinophils (Rossi et al., 1995, Hallsworth et al., 1996 and
Figure 3.20). It has also been suggested that PKA-dependent phosphorylation of
histone H3 correlates with gliotoxin-induced apoptosis in thymocytes (Waring et al.,
1997), but again in neutrophils, activation of PKA inhibits apoptosis (Rossi et al.,
1995). Although gliotoxin has been reported to inhibit protein synthesis (Waring,
1990) it is highly unlikely that this mechanism is directly responsible for its pro-
apoptotic effects. Firstly, gliotoxin induces apoptosis in thymocytes whereas
cycloheximide inhibits it. Secondly, NF-kB activation is involved in the control of
multiple genes, many of which encode inflammatory mediators so inactivation of
NF-kB would be expected to inhibit protein synthesis in granulocytes. Thirdly,
while protein synthesis inhibitors do upregulate the rate of constitutive cell death in
granulocytes, the kinetics of this response are very different from those observed
with gliotoxin. For example, Whyte et al. (1997), have reported that cycloheximide
(50 pg/ml) and actinomycin D (1 pM) induce apoptosis in approximately 30% of
neutrophils by 6 h. In the present study, gliotoxin (0.1 pg/ml) induced a rate of
almost twice this, whereas 1.0 pg/ml gliotoxin induced 100 % neutrophil apoptosis
by 6 h (Figure 5.1 A). Likewise the results with cycloheximide (Figure 5.15)
indicate that protein synthesis inhibition alone does not affect the rate of neutrophil
apoptosis at 2 h, whereas gliotoxin alone produced almost 15% apoptosis over this
period (Figure 5.1 A). This suggests that other mechanisms, such as inhibition of
NF-kB, may be involved.
This is supported by our data from other NF-kB inhibitors in neutrophils. The cell-
permeable NF-kB inhibitor peptide SN50 (Lin et al., 1995b) significantly increased
neutrophil apoptosis at the timepoints examined, although this increase was not as
marked as that produced by gliotoxin. However, since less than 5 % of this peptide
enters the cell within 30 min (Lin et al., 1995b) the actual intracellular concentration
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of this inhibitor in the cell is unknown, but it is likely to be low. The peptide
competes with activated NF-kB complexes for translocation to the nucleus,
presumably by binding to a receptor/transportation protein, but it is not known
whether binding is reversible. Therefore, inhibition could be transient, allowing
some activation of NF-kB to occur. It is also possible that other transcription
factors/nuclear proteins share the same NLS sequence, so while the peptide inhibits
nuclear NF-kB import, the effect may not be specific.
Inhibition of PKC by Ro 31,8220 did not affect constitutive apoptosis in neutrophils
after 2 h, but it did synergistically increase the pro-apoptotic effect of TNF-a when
used at 10 pM, suggesting that PKC might be involved in NF-kB activation. Ro
31,8220 is a broad spectrum PKC inhibitor, but unfortunately there is no readily
available specific PCK t, inhibitor that would allow investigation of the effect of this
isoform, which has been linked to NF-kB activation. These data in Figure 5.17, do
suggest a role for PKC in protecting cells against the cytotoxic effects of TNF-a, but
further work on activation/inhibition of NF-kB when PKC is manipulated would
have to be undertaken before supporting evidence could be obtained.
The NO donor GEA 3162 also induced apoptosis in neutrophils. These results are in
agreement with data produced in our laboratory [Wong et al., (1997)]. NO has also
been reported to inhibit NF-kB activity (Matthews et al., 1996) and interestingly, it
also increased the pro-apoptotic effect of TNF-a. Again, EMSAs should be
performed to check the effect of GEA 3162 and other NO donors on NF-kB activity
in granulocytes, both alone and in concert with TNF-a.
The antioxidant PDCT and the serine protease inhibitor TPCK are used widely in
NF-kB inhibition studies. Interestingly, PDCT significantly induced neutrophil
apoptosis, while TPCK had no effect. The results for PDCT are in concert with those
obtained by other putative NF-kB inhibitors in these studies, but the negative result
for TPCK might be attributed to by non-specific effects of this inhibitor. Increases in
ROS have been linked to possible mechanisms for inducing apoptosis, particularly
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via TNF-a. However, the results for PDCT treatment (Figure 5.19) would suggest
that this is not the mechanism involved in neutrophils, since antioxidants would
decrease ROS and therefore should inhibit apoptosis as does hypoxia in these cells
(Hannah et ah, 1995). However, it is questionable whether reactive oxygen species
are widely used by cells to commit suicide. Apoptosis has been observed in the
absence of mitochondrial respiration and in cells grown essentially without oxygen,
conditions that should greatly reduce the amount of free radicals (Jacobson et ah,
1993).
One group has claimed that antioxidants can inhibit spontaneous neutrophil apoptosis
(Oishi & Machida, 1997). In this thesis, no neutrophil data are presented on cells
incubated for more than 20 h in culture because control cells exhibit rising levels of
necrosis after this timepoint. Since Oishi & Machida, (1997) used neutrophils in
culture for 60 h, the neutrophils would have been mainly necrotic, and not apoptotic.
Other studies, in contrast, have shown that resting neutrophils respond to Fas
engagement with accelerated rates of apoptosis, but activated neutrophils, with
increased ROI production, are refractory to signals delivered through Fas (Watson et
ah, 1997). Fas engagement did not alter levels of intracellular ROIs or thiols
(Watson et ah, 1997), but depletion of endogenous antioxidant thiols induced
apoptosis of resting neutrophils (Watson et ah, 1997). Pretreatment of neutrophils
with butionine sulfoximine (BSO), a specific inhibitor of GSH biosynthesis, did not
prevent an LPS-induced reduction in apoptosis (Watson et ah, 1997). These studies
suggest that ROS production should inhibit neutrophil apoptosis. However,
granulocytes use ROS as a major defence against microorganisms and therefore they
might have protective mechanisms to prevent self-damage from ROS release.
Therefore, granulocytes might respond differently from other cell types to ROS.
Cytotoxic effects of TNF-a have recently been reported to be potentiated by
inhibitors ofNF-kB (Beg & Baltimore, 1996, Van Antwerp et ah, 1996, Wang et ah,
1996), supporting the hypothesis that gliotoxin does function to limit NF-kB
activation. Embryonic fibroblasts and macrophages from Rel-A deficient mice also
showed dramatic loss of viability when treated with TNF-a, leading to the
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suggestion that Rel-A regulates a protective mechanism against the cytotoxic effects
of TNF-a. Although the experiments presented here indicate that gliotoxin does not
inhibit the constitutive form ofNF-kB, at least at early time-points, it does inhibit the
activation of an inducible isoform of NF-kB, which most likely consists of
heterodimers containing the Rel-A/p65 protein and therefore could perform a similar
anti-apoptotic function in neutrophils and eosinophils. While TNF-a does not
produce significant cytotoxic effects in eosinophils, co-treatment with gliotoxin
caused these cells to become highly responsive to this cytokine, producing greatly
increased levels of apoptosis. This suggests that both of these inflammatory cell
types could be stimulated to undergo apoptosis and hence be cleared rapidly by
phagocytes at sites of inflammation if activation of the inducible NF-kB isoforms
were inhibited.
The mechanism by which NF-kB inhibition induces granulocyte apoptosis and
increases the cytotoxic response to TNF-a is currently unclear. Since gliotoxin and
TNF-a driven apoptosis are both inhibited by zVAD-fmk a cell permeable,
irreversible tripeptide inhibitor of caspases (Dolle, et al., 1994, Pronk et al., 1996),
NF-kB or an NF-kB regulated intermediate might influence granulocyte apoptosis at
a stage in the pathway between the TNF-a receptor and caspase activation.
However, the fact that a potentiated TNF-a effect can be achieved with the protein
synthesis inhibitor CHX (Figure 5.15), which is also blocked by zVAD-fmk,
suggests that NF-kB may upregulate the synthesis of a protective protein or proteins,
which inhibits activation of the caspase pathway in response to TNF-a.
The simplest conclusion from these observations is that one or more of the NF-kB-
dependent genes that are induced by TNF-a protect cells from apoptosis. Such a
scenario also helps explain why, in most cell types, TNF-a is not cytotoxic unless the
cells are simultaneously exposed to an inhibitor of RNA or protein synthesis, which
may block expression of protective NF-kb-dependent genes. The putative anti-
apoptotic genes that are activated by NF-kB in response to endogenous TNF-a
remain to be identified.
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NF-kB induces activation of genes for G-CSF, GM-CSF, TNF-a, NO synthase, and
c-myc (Baeuerle, 1991, Geller et al., 1993, Muller et al., 1993). Given that both
TNF-a and TGF-(3 (a reputed NF-kB inhibitor) synergistically downregulate the
production of c-Myc (Hori et al., 1994, Arsura et al., 1996), this is one protein which
may be involved. Hori et al. (1994) found that TNF-a used at concentrations greater
than 1 ng/ml reduced c-Myc expression by 30 min with maximal reduction at 1 h.
This would correlate with the onset of apoptosis in our studies (Figure 4. 17, 5.2 A,
5.3 B. In HL-60 cells, c-Myc is rapidly downregulated in apoptotic cells when TNF-
a is used as the inducing agent; apoptosis could also be induced by c-myc antisense
(Kumakura et al., 1996). Of interest is the short half-life of this protein (approx. 20
min) (Waters et al., 1991). Therefore the short time between signal and induction of
cell death (approx. 90 min in this system) could be mediated via the rapid removal of
a protective factor such as c-Myc. This will differ in other systems for example, in
activation-induced apoptotic cell death in T cells hybridomas, antisense c-myc
prevents apoptosis (Shi et al., 1992). Although the protein is present, there is little
expression of c-Myc in peripheral blood neutrophils (Cotter et al., 1994, Hannah,
personal communication).
NF-kB has been shown to interact directly with AP-1 subunits and to synergise with
a number of different transcriptional activator proteins including Spl, Ets, ATF-2/c-
Jun, and NF-kF6 (Stein et al., 1993a, b). This synergy is a consequence of the direct
interactions between NF-kB and these proteins and cooperative binding to adjacent
binding sites. The interactive transcription factor can be present constitutively or
coinduced with NF-kB. An example of the latter possibility is the recent finding that
several inducers ofNF-kB activate the c-Jun terminal protein kinase (JNK), which in
turn phosphorylates ATF-2 and c-Jun both ofwhich synergise with NF-kB (Gupta et
al., 1995, Lee et al., 1997a). C-Jun deficient mice die at mid to late gestation and
exhibit impaired hepatogenesis, altered fetal liver erythropoiesis and generalized
oedema; in the liver, apoptosis and necrosis of cells are apparent (Hilberg et al.,
1993). Interestingly, this pathology is similar to that of the RelA/p65 deficient
mouse (Beg et al., 1995). Therefore apoptosis induced by NF-kB inhibition may be
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induced by dysregulation of genes which are controlled by other transcription factors
due to loss of synergistic and other interactions. The results for the c-Jun-deficient
mouse suggest that this protein could also be important. As shown in Figure 1.2,
TNF-a will activate both NF-kB and AP-1.
A20 is a novel zinc finger protein originally identified as a TNF-a- and IL-1-
inducible gene product in endothelial cells (Dixit et al., 1990). It inhibits TNF-a-
induced apoptosis (Opipari et ah, 1992). Protection mediated by this protein is
specific for TNF-a-induced apoptosis but it also inhibits TNF-a-induced activation
of phospholipase A2 and activation ofNF-kB and AP-1 (Jaattela et ah, 1996). A20
expression is regulated by NF-kB (Krikos et ah, 1992) and interacts with TRAF1 and
TRAF 2, inhibiting the activation of NF-kB by TRAF2, TNF, CD40 TRADD and
IL-1 (Song et ah, 1996). The mechanism by which A20 exerts its protective effect is
unknown, but it does bind to several isoforms of the 14-3-3 proteins in vitro
(Vincenz & Dixit, 1996). Interestingly, 14-3-3 proteins have been shown to function
as regulators ofPKC (Aitken et ah, 1992). Activation of CD40, another TNFR, leads
to the induction of A20. The induction of transcripts occurs within 1 h, which
renders B cell lines resistant to apoptosis (Sarma et ah, 1995). However, A20 does
not rescue RelA null fibroblasts from the pro-apoptotic effects of TNF-a (Beg &
Baltimore, 1996), indicating that other NF-kB driven mechanisms are involved.
Another protein, C-IAP2 is up regulated following TNF-a treatment and protects
cells from apoptosis (Chu et ah, 1997). This protein is recruited to the TNF receptor
through TRAF proteins (Rothe et ah, 1995) and is an NF-kB inducible gene product
(Chu et ah, 1997). However, exogenous cIAP2 expression could not protect cells
from TNF-a-induced apoptosis even with activation ofNF-kB (Chu et ah, 1997).
Manganese superoxide dismutase (an antioxidant) suppresses TNF-a-induced
apoptosis and activation of NF-kB and AP-1 in human breast cancer MCF-7 cells
(Manna et ah, 1998). This protein provides partial protection against apoptosis when
expressed constitutively (Wong et ah, 1989). However a role for NF-kB in regulation
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of manganese superoxide dismutase gene expression has not yet been established
(Baichwal & Baeuerle, 1997).
The role of NF-kB as a promoter or attenuator of cell death may ultimately depend
on both the cell type and the nature of the apoptosis-inducing stimulus. In different
cell types, NF-kB could perform these opposing functions by activating distinct
patterns of genes in conjunction with cell-type-specific transcription factors
(Baichwal & Baeuerle, 1997), and its behaviour might vary with different stimuli.
The ability of gliotoxin to enhance the cytotoxic effects of TNF-a and itself produce
a rapid onset of apoptosis in inflammatory cells such as neutrophils and eosinophils
may suggest NF-kB inhibition as a logical therapeutic target in the treatment of
inflammatory conditions. In a rat model of lung inflammation, suppression of NF-
kB activity has already been shown to block the development of neutrophil lung
inflammation by inhibiting the synthesis of chemotaxins (Blackwell et al., 1996).
These results, together with results presented in this Chapter, suggest that NF-kB
inhibition may also be of benefit in enhancing the resolution of inflammation by




The safe removal of aged granulocytes from an inflammatory site by apoptosis is
now considered a central part of the mechanism underlying the processes of healing
and resolution, but the physiological mediators which control this response are
unknown. Many of the inflammatory mediators present at a site of tissue injury in
vivo, have previously been demonstrated to prolong the life of both neutrophils and
eosinophils in vitro. If this situation prevailed in an in vivo situation, the result
would be chronic inflammatory conditions as effete cells became fragile and necrotic
and histotoxic cell contents are released. This thesis examined the role of
inflammatory mediators of various different classes, in controlling apoptosis in both
neutrophils and eosinophils, with particular interest in those which could drive cell
death, with the long term aim of finding possible physiological factors that may be
involved in the natural process of clearance of these cells.
Generally, culture of these cells with most inflammatory mediators, including
chemokines, leukotrienes and prostaglandins either inhibited granulocyte apoptosis
or had no significant effect. However, prostaglandins of the J series produced
dramatic increases in apoptosis in both neutrophils and eosinophils. PGD2 is
produced in large quantities by mast cells, and is therefore a likely prostanoid to be
present at inflammatory sites in conditions such as asthma; it is also produced by
both neutrophils and eosinophils. Neutrophil apoptosis however, was not affected by
PGD?, but it produced large increases in the rate of eosinophil apoptosis. The
metabolites of PGD2 were potent inducers of cell death in both cell types, raising the
possibility that PGD2 may be differentially metabolised in neutrophils and
eosinophils. The PGD2 metabolites, A12-PGJ2 and 15-deoxy-A12,A14~PGJ2 are ligands
for peroxisome proliferator activated receptors (PPARs), and therefore these
receptors may be involved in the induction of granulocyte apoptosis. PPARs can
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antagonise transcription factors such as STATs, AP-1 and NF-kB, all of which are
involved in regulating various inflammatory mechanisms. This would therefore be
an attractive model to account for granulocyte apoptosis as a part of the processes
involved in resolution, since PPARs are known to be upregulated in activated
macrophages, and have been shown to inhibit genes controlled by NF-kB. Such
genes include many pro-inflammatory cytokines that are known to increases the
longevity of both neutrophils and eosinophils.
The pro-apoptotic effects of the cytokine TNF-a are apparent in neutrophils at early
timepoints, but there is no induction of cell death in eosinophils in response to this
cytokine. IL-10 and TGF-(3 are cytokines with known anti-inflammatory properties.
IL-10, however had no effect on the constitutive rate of apoptosis in either
neutrophils or eosinophils, but did significantly inhibit LPS-mediated neutrophil
survival. TGF-p significantly decreased constitutive apoptosis in both granulocytes,
but interestingly, it enhanced TNF-a-induced apoptosis at early timepoints.
As part of the examination of the mechanism of TGF-(3/TNF-a induction of
neutrophil apoptosis we examined the role of the transcription factor NF-kB in
process of granulocyte cell death. We show that there is both a constitutive and
inducible activation ofNF-kB in neutrophils, and that the inducible isoform appears
to be necessary for granulocyte survival. Treatment of cells with gliotoxin, which
specifically inhibited the inducible isoform at the timepoints examined by EMSAs
produced a profound increase in apoptosis in both neutrophils and eosinophils. Pro-
apoptotic effects were also observed with SN50, a cell-permeable peptide which is
known to inhibit NF-kB activation. Co-culture of both granulocytes with TNF-a and
gliotoxin caused dramatic increases in cell death, with almost 100% apoptosis
reached in 2 h in neutrophils and 4 h in eosinophils.
Interestingly, many of the inflammatory mediators and cytokines known to inhibit
granulocyte apoptosis have either been found to activate NF-kB, or are in part,
regulated by this transcription factor. One exception to this is glucocorticoids, which
we have shown to induce eosinophil apoptosis, while inhibiting neutrophil apoptosis.
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Glucocorticoids induce transcription of the IkBoc gene, resulting in an increased rate
of IkBoc protein synthesis, which inhibits NF-kB activation (Akira & Kishimoto,
1997). This mechanisms is similar to that suggested for TGF-(3, but dexamethasone
significantly inhibited TNF-a-induced apoptosis in neutrophils, suggesting another
mechanism is involved in these cells, particularly since many NF-kB inhibitors have
been shown to potentiate the cytotoxic effects of TNF-a.
One of the most powerful inhibitors of granulocyte apoptosis was found to be cAMP.
The direct effect of cAMP on NF-kB is unlikely to account for this anti-apoptotic
effect since direct stimulation of cells with dbcAMP causes only a modest increase in
NF-kB activity (Zhong et ah, 1997). However, other transcription factors such as
cAMP-responsive element binding protein (CREB) and the closely related factor
p300 which are activated by increases in cAMP can interact with p65/RelA and
potentiate its transactivating ability (Gerritsen et al., 1997, Perkins et al., 1997).
CBP/p300 can also form a molecular bridge between DNA-bound p65 and other
transcription factors such as ATF-2 or c-Jun and the basal transcriptional apparatus
(TFIIB), which may be required for full transcriptional activation. Therefore, it is
possible that secondary effects on NF-kB activation could be involved in the
inhibitory effects of cAMP on granulocyte apoptosis.
TNF-a, also inhibits neutrophil apoptosis if cultured for 20 h. We show that
neutrophils appear to be protected against the cytotoxic effects of this cytokine by a
process requiring synthesis of a protein(s), which is induced by the activation ofNF-
kB. While several proteins have been suggested to fulfil this role, none meets with
the requirements needed for total inhibition of TNF-a-induced cell death. The
kinetics of the response in neutrophils, in which almost all cells undergo apoptosis
within 2 h if cultured with both TNF-a and an inhibitor ofNF-kB suggest a protein
with a high turnover rate and a short half-life, which are both characteristics of the
protein c-Myc. This protein has several attributes that would fit the model: c-Myc is
present in small amounts in granulocytes and as granulocyte precursors mature and
differentiate, c-Myc levels fall. Decreases in c-Myc concentration have been
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correlated with the onset of apoptosis in some cells, and both TGF-J3 and TNF-a
reduce c-Myc levels and can act synergistically to induce this response. NF-kB
activation is involved in the regulation of c-Myc levels. In other cells, changes in c-
Myc concentrations have been shown to occur well within the timeframe of 90 min
as determined for the onset of apoptosis in experiments with gliotoxin and TNF-a.
NF-kB plays a role in other aspects of inflammation. The expression of leukocyte
adhesion molecules (ELAM-1, VCAM-1 and ICAM-1) on endothelial cells is
induced by TNF-a and other inflammatory cytokines and requires NF-kB (Eck et al.,
1993, Siebenlist et al., 1994). Sodium salicylate inhibits activation of NF-kB and
inhibits the expression of adhesion molecules and transendothelial migration of
neutrophils (Pierce et al., 1997). NF-kB inhibition also blocks the upregulation of
CDllb/CD18 on neutrophils (Zhou et al., 1996). Blocking the activation of NF-kB
in an in vivo rat model of lung inflammation suppresses neutrophil infiltration by
blocking the synthesis of neutrophil chemotaxins (Blackwell et al., 1996).
The results presented in this thesis suggest that while NF-kB is a potent stimulator of
the innate immune response, any mediator which can inhibit NF-kB is likely to have
a beneficial effect on the resolution phase of inflammation by inducing granulocyte
apoptosis and inhibiting the influx of inflammatory cells into the site. Logically this
could provide a useful target for therapeutic intervention in inflammatory conditions.
However, it should be remembered that in almost no case does a transcription factor
act alone to regulate its target genes. Promoters or enhancers typically depend on
multiple transcription factors for their activity. The particular NF-kB complex that
binds a given kB site may be selected from among several by physical interaction
with a transcription factor from an adjoining site (Siebenlist et al., 1994). Therefore
interactions between NF-kB and other transcription factors may potentiate either the
effects of NF-kB or affect activity of the other transcription factor. Therefore by
modulating the activities ofNF-kB, other genes, which are not normally regarded as
being under the control of this transcription factor, may be adversely affected. Very
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little is known of the interactions of various transcription factors and NF-kB or the
specific combinations of these factors with regard to specific genes.
The controversy over the role of NF-kB in apoptosis means that inhibition of this
transcription factor is unlikely to be a specific mechanism that induces cell death in
all cells. However, to be therapeutically useful, a degree of specificity would be
needed. More in vivo models of various inflammatory conditions would be useful to
investigate the efficacy of this approach and to examine the effects on other cell
types. If TGF-P and J series prostaglandins prove to be physiological inhibitors of
NF-kB in granulocytes, further work may elucidate novel strategies to interfere with
the activities of this transcription factor in a cell-specific manner. If they do not
block activation, and other pathways are involved in their pro-apoptotic activities,
further research may lead to the of design specific inducers of apoptosis in these cells
which would be of therapeutic benefit.
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